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Systemic Regulation of Cancer Metastasis 
Timothy James Zhong 
 
Cancer mortality is the second leading cause of death in the United States. It is estimated that 90% 
of these are attributed to stage IV metastatic disease, in which tumor cells have disseminated from 
the primary tumor to form clinically relevant macroscopic metastatic colonies in distant organs. 
While advances in early screening protocols, surgical intervention and treatment with 
chemotherapy, radiation therapy, immunotherapies, and targeted therapies have improved the 
management of primary tumors in earlystage cancer patients; cancers that have progressed to 
metastatic disease are often resistant to these strategies and generally represent a terminal illness. 
Furthermore, even aggressive treatment of some cancers, such as triple-negative breast cancer, can 
often leave behind significant residual cancer burden that can spontaneously relapse and culminate 
in metastatic disease, even years after initial treatments. Until advances throughout the last century, 
metastasis-associated cancer mortality was thought to be largely attributed to local complications 
due to widespread tumor burden, such as the physical crushing of vital organs and damage to blood 
circulation, neuron circuitry, and the gastrointestinal tract. And while these are often causes 
metastasis-associated mortality, studies have revealed that cancer metastasis is a systemic illness 
that dysregulates the host’s metabolism and immune system. 
 It is now well known that tumor cells themselves or through signaling with non-tumor cells 
– can release a milieu of soluble factors, exosomes, and metabolites that can systemically alter 
host metabolism, physiology, and immune regulation to promote metastasis and compromise 
natural homeostasis. These systemic alterations often culminate in a lethal condition known as 
 
 
cachexia, which is defined as: “a multifactorial syndrome characterized by an ongoing loss of 
skeletal muscle mass (with or without loss of fat mass) that cannot be fully reserved by 
conventional nutritional support and leads to progressive functional impairment”. Cancer-
associated cachexia develops in about 80% of metastatic cancer patients, depending on cancer 
type, has no approved efficacious treatments, and is associated with 20% of all cancer-related 
deaths due to severe loss muscle mass and function.  
Here, we show that the aberrant muscle-cell upregulation of the metal ion importer, ZIP14, 
expression and concomitant increase in intramuscular zinc is associated with the development of 
cachexia in Pan02 and FC1242 experimental metastasis models of pancreatic adenocarcinoma and 
a Bard1-deficient model of BRCA-like triple-negative breast cancer. Furthermore, we show that 
ZIP14 expression is highly upregulated human advanced pancreatic adenocarcinoma patients. 
These findings are consistent with our previous studies that show the ZIP14-zinc axis mediates the 
development of cachexia in metastatic models of breast, lung, and colon cancer and suggest that 
inhibition of ZIP14 function or zinc chelation strategies may provide a potential therapeutic option 
for the prevention or treatment of metastasis-induced cachexia.  
 In addition to systemic metabolic dysregulation, metastatic cancers also locally or 
systemically dysregulate immune responses and immune cell populations to promote tumor growth 
and help facilitate metastasis. As the tumor progresses and metastasizes, tumor cell- or tumor 
stroma-derived factors polarize many myeloid and lymphocyte cell populations into tumor-
promoting subsets that can suppress anti-tumor immune response through the production of 
immunosuppressive cytokines or expression of co-inhibitory molecules, remodel the extracellular 
matrix, induce angiogenesis, and promote the survival, proliferation, and motility of tumor cells. 
These tumor-associated factors can also dysregulate the hematopoiesis of immune cells, resulting 
 
 
in a systemic alteration of immune cell populations, such as peripheral expansion of 
immunosuppressive, immature myeloid-derived suppressor cells or T-regulatory cells.  While the 
functional roles and subsets of tumor-infiltrating myeloid and T lymphocytes have been 
extensively studied, the role and function of tumor-infiltrating B lymphocytes are less defined, 
especially in the metastatic context. Here, we show that a population of B220+ B cells is recruited 
to the invasive margin of lung metastases in triple-negative breast cancer patients and 4T1 and 
LM3 metastatic mouse models of triple-negative breast cancer. Furthermore, B220+ B cells 
isolated from the metastatic lungs of the 4T1 and LM3 triple-negative breast cancer models were 
found to enhance the invasion of lung metastasis-derived organoids in 3-dimensional co-culture 
and promote the migration of triple-negative breast cancer cell lines. We confirmed that 4T1 B 
cell-deficient mouse models exhibit impaired formation of lung metastases and a concomitant 
reduction in the proportion of cytokeratin-14+ invasive leader tumor cells and p-mTOR+ tumor 
cells per lung metastasis, suggesting that the B cell-associated invasion-promoting mechanism is 
mediated in part by p-mTOR. We further show that the lung metastases of triple-negative breast 
cancer patients with high tumor-infiltrating B cell density exhibit increased p-mTOR expression 
compared to patients with low tumor-infiltrating B cell density. Taken together, our findings 
provide evidence of a tumor invasion-promoting function for metastasis-infiltrating B cells in 
metastatic triple-negative breast cancer and suggest that further elucidation of the metastasis-
infiltrating B cell phenotype and the role of p-mTOR in the tumor cell-B cell invasion-promoting 
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1.1 Cancer Metastasis: history and epidemiology, biology, and clinical implications 
History and Epidemiology 
Unlike a majority of the diseases that humanity has encountered, succumbed to or 
overcame, cancer is a disease older than the human race and has always been prevalent in our 
history of medicine. The oldest known record of cancer is breast cancer (BC), described in the 
Edwin Smith Papyrus in 3000 BC as masses in the breast that are incurable.1 The subsequent Ebers 
Papyrus, written in 1500 BC, further describes other tumors of the skin, uterus, and gastrointestinal 
tract.1 The Greek physician Hippocrates (460-375 BC) is credited with coining the term “cancer”, 
after associating the moving invasive protrusions of tumor masses to the claws of a crab.1 
Throughout antiquity, various cultures attempted to treat these masses with cauterization, crude 
surgery, bloodletting, salts, herbal remedies, and heavy metal poisons, practices that were often 
fatal and remained unchanged for over 3000 years until the advent of modern medicine.1  
Although modern medicine has improved the survival rate of many cancer types, cancer 
remains the second leading cause of death in the USA.2 It is estimated that 1,898,160 new cancer 
cases will be diagnosed in 2021 in the USA, with 608,570 patients succumbing to the disease.2 
The overall mortality rate of cancer patients is dependent on type of cancer, incidence, stage of 
diagnosis, and efficacy of available treatments.2,3 For example, USA cancer mortality rates peaked 
in 1991 (215 cancer deaths per 100,000 cases) due to the smoking epidemic, which resulted in 
high incidences of lung cancer (until recently, the most common cancer), but a reduction in 
smoking habits have seen an improvement in both lung cancer mortality and overall cancer 
mortality.2,3 Furthermore, numerous treatment breakthroughs have significantly reduced mortality 
in specific cancers, such as melanoma.3 However, the progress for treating other cancers, such as 
BC, have slowed since the reduction in mortality due to implementation of early-screening 
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procedures.2,3 Nonetheless, regardless of cancer type and treatment, it is undeniable that metastatic 
disease remains the primary cause of cancer-related deaths.4 In the clinic, cancer diagnosis and 
progression is typically classified into five stages, 0, I, II, III, and IV (Table 1-1).5 Stage 0 is 
referred to as carcinoma in situ disease and generally describes non-malignant pre-cancerous 
lesions. Stage I represents localized cancer, in which the malignant tumor is small and localized in 
a single area without nodal or vascular spread. Stage II and III represent early and late 
locally/regional advanced cancer, in which tumor is large in size and has extensively invaded into 
regional tissues and lymph nodes.5 Solid tumors of stages I-III are generally operable, with the 
chances of complete resection decreasing with increasing stage.5 Stage IV metastatic disease, in 
which clinically detectable metastases have formed in distant organs, however, generally 
represents an incurable, manageable, and terminal disease.2,5 It is well understood that about 90% 
of all cancer-related mortality is attributed to development of stage IV metastatic disease.4 Indeed, 
the lethality of metastatic disease is reflected in the five-year survival rates for both high mortality 
cancers, such as pancreatic ductal adenocarcinoma (PDAC) (Stages I-III = 39-13%; Stage IV = 
3%) and lung cancer (Stages I-III = 59-32%; Stage IV = 6%) and lower mortality cancers, such as 
BC (Stages I-III = 99-86%; Stage IV = 28%) and colon cancer (Stages I-III = 91-72%; Stage IV = 




Table 1-1: Five-year relative survival rates (%) by cancer stage at diagnosis, US, 2010-2016 
Table showing the five-year relative survival rates of various cancer types from patient data from 
SEER 18 from 2010-2018. Survival rates are shown as a % of patients surviving for five years 
post-diagnosis and are stratified by all stages and stages at diagnosis: local (stage I), regional 
(stages II-III), and distant disease (stage IV). Rates are based on cases diagnosed from SEER 18 
locations from 2010-2016 and followed through 2017. Information source: Table 8, (American 





Similar to the progression of cancer through its clinically defined stages, cancer metastasis 
represents a multistage progression of biological processes, which are collectively termed the 
metastatic cascade and first proposed by Irwin Bross in 1975.4,6 The metastatic cascade describes 
the process of how malignant tumor cells 1) invade through the basement membrane of local tissue, 
2) disseminate from the primary tumor, 3) intravasate, travel, and survive through circulation, 4) 
extravasate into the tissue of a distant organ, and finally 5) their escape from dormancy as either 
single tumor cells or micrometastases to proliferate and form clinically detectable and relevant 
malignant macroscopic metastatic (macrometastases) colonies (Figure 1-1).4 The elucidation of 
the complex series of steps and mechanisms of the metastatic cascade is the result of many 
landmark experiments and observations by dedicated physicians and researchers.  
The term, “metastasis”, was first defined by the French physician, Joseph-Claude-
Anthelme Récamier in 1829.7 Récamier described the “transfer of cancer from one organ to 
another not directly connected to it” and hypothesized that invasion of tumor cells into circulation 
may be the route of disease spread.7 In 1858, Rudolf Virchow, a Polish pathologist, proposed that 
metastases are formed from malignant cells that disseminate from the primary tumor through 
mechanical factors.8 However, this was insufficient to determine the mechanism for how the 
disseminated cells seed into distant organs or explain how specific metastatic sites can vary from 






Figure 1-1: The metastatic cascade 
The formation of clinically relevant metastases in distant organs represent the endpoint of a 
multitude of biological processes collectively described as the metastatic cascade. The metastatic 
cascade starts with tumor cells from the primary tumor invading into local tissue, intravasating 
into circulation, translocating and surviving through circulation, and arresting and extravasating 
into the parenchyma of distant organs.  These tumor cells initially form small micrometastases that 
may remain indolent until they adapt organ-specific programs or modulate the host organ 
microenvironment to provide necessary survival and growth signals. Acquisition of these 
programs or signals then allow micrometastases to proliferate and form clinically detectable 
macroscopic metastases.  
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Upon the observation of BC patient autopsy records – which revealed that sites of 
metastasis were not random - Stephen Paget proposed the “seed and soil” hypothesis in 1889.9 The 
hypothesis states that metastatic colonization is organ specific and not random; and that metastatic 
“seeds” can only grow in congenial “soil”, in which the seed is the cancer cell and the soil is the 
microenvironment of the secondary organ.9 The hypothesis stresses that cancer cell-host organ 
microenvironment interaction is critical for the formation of metastases and metastases only form 
if both seed and soil are compatible.10 Indeed, many cancers exhibit organ-specific metastatic 
colonization. For example, colorectal cancer (CRC) and PDAC frequently metastasize to the liver, 
and lungs to a lesser extent, but rarely to bone, skin, or brain.11 However, BC metastasizes to the 
bone, lungs, liver, and brain; and prostate cancer metastasizes to the bone, but rarely to the lung 
and liver.11  
Paget’s theory was challenged in 1929 by James Ewing, who argued that metastatic 
dissemination occurs only by mechanical factors dependent on the anatomic structure of 
vasculature.10,11 An example of this is that in CRC and PDAC, the liver is the most common 
metastatic site because blood flow from the pancreas and gastrointestinal tract flows directly to the 
liver, resulting in the massive influx and deposition of tumor cells into the liver and leading to the 
formation of liver metastases.2 Indeed, extensive experimental pathological analysis by Dale Rex 
Coman revealed that metastases do derive from tumor cell arrest in capillary beds: a vascular-
mechanical phenomena.10 However, Balduin Lucke demonstrated through experimental 
intravenous injections of metastatic V2 rabbit carcinoma into either the portal vein/hepatic artery 
or systemic vein that metastatic growth was always higher in the liver compared to lung, and was 
independent of injection route.12  This suggested that while tumor cell arrest is a vascular event, 
metastatic growth rates are organ specific.12 Indeed, review of clinical data regarding metastatic 
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sites of various cancers by Sugarbaker in 1979 revealed that while common regional metastases 
can be derived by anatomical/mechanical factors, metastases to distant organs were site specific 
in many cancer types.10,13  
This was soon followed by Isiah Fidler’s landmark experiment, in which he grafted lung, 
ovary, and kidney tissues into syngeneic mice and injected highly metastatic B16-F10 melanoma 
cells intravenously into engrafted mice.10,14 While all three organs grafted successfully, Fidler 
observed that the B16 cells metastasized preferentially to the lungs and ovaries but not the kidneys, 
despite the fact that the anatomical vascularization between all engrafted organs were identical.14 
Fidler also analyzed the initial arrest of tumor cells at ten minutes, one hour, and one day post-
injection and revealed that there was no significant difference in the number of tumor cells that 
arrested between engrafted lungs and kidneys in any of these early timepoints.14 This study 
confirmed that while anatomical-mechanical factors do play a role in the initial arrest of tumor 
cells into distant organs, tumor cells indeed preferentially grow and metastasize in specific organs, 
thus validating Paget’s theory.14 A following study by Fidler demonstrated that isolating cancer 
cells that have metastasized in vivo and reimplanting them into mice increased the metastatic 
ability of the cells upon each successive cycle of isolation and re-engraftment.15 Moreover, the 
experiment showed that selected “highly metastatic” cancer cells (following multiple selection 
cycles) display higher rates of survival in distant organs when compared to the “lowly metastatic” 
parental line, further demonstrating that metastasis is a selective process and tumor cell-host organ 
interaction is critical for metastasis.15,16  
Fidler also revealed through intravenous injection of 125I-5-iodo-2′-deoxyuridine-labeled 
B16 melanoma cells into syngeneic mice that only about 1% of all injected tumor cells survived 
after 24 hours, with approximately 400 individual cells capable of developing into an average of 
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78 metastatic colonies.17 This demonstrated that while 1) metastasis is a highly inefficient process, 
with the vast majority tumor cells dying in circulation, and 2) few individual tumor cells from a 
tumor have the ability to metastasize; only a few tumor cells are necessary to form metastatic 
colonies.17 Moreover, subsequent studies found that tumor cells that metastasize to specific organs 
display unique gene expression alterations that favor metastasis to the distant organ, which is 
consistent with previous findings that highly metastasis tumor cells can be selected for by multiple 
cycles of engraftment, isolation of cells from metastases, and rengraftment.18 These studies reveal 
that successful metastasis is dependent on a tumor’s clonal population of tumor-initiating cells, 
their  seeding potential, and their ability to adopt organ-specific colonization programs.  
However, questions remain regarding the molecular mechanisms of how tumor cells can 
acquire motility and invasive properties. In 2002, upon observation of how an epithelial-
mesenchymal transition (EMT) reprograming of cells can confer upon epithelial cells the mobility 
of mesenchymal cells during development or wound healing; Thiery and Weinberg hypothesized 
that this EMT program could similarly allow cancer cells to acquire invasive properties.4,19,20 
Subsequent studies have shown that this EMT program is a partial alteration, in which epithelial 
tumor cells lose some of their epithelial traits, such as E-cadherin-mediated cell to cell adhesion, 
and acquire some mesenchymal traits, resulting in increased motility, invasiveness, and the ability 
to degrade extracellular matrix (ECM) components.4 Indeed, circulating tumor cells (CTCs) from 
BC patients were found to express both epithelial and mesenchymal markers, while primary tumor 
cells contained mostly epithelial markers, suggesting that partial EMT plays a role in the 
dissemination of tumor cells.21 Further studies have revealed that EMT is orchestrated by the 
master-regulator transcription factors, Snail, Slug, Twist, and Zeb1, and the expression of these 
can be induced by a variety of cytokines, growth factors, and signaling pathways, such as Wnt.4 
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Although formal proof that EMT is necessary or absolutely required to establish metastases is 
lacking, there is compelling evidence that EMT programs do promote metastatic potential in tumor 
cells when activated.  
Successful metastatic colonization is also dependent on the presence or development of a 
supportive microenvironment niche in the host organ. Tumor cells that have disseminated into a 
distant organ naturally find themselves in a novel microenvironment with differing stromal cells, 
immune cells, growth factors, and ECM composition compared to their primary site. Keith Luzzi 
demonstrated using intraportal injection of B16 melanoma cells that while 80% of injected cells 
survived injection and extravasated into the liver, 36% of these remained as individual cells.22 
Additionally, 1 in 40 extravasated cells formed micrometastases, with only 1% of all 
micrometatases progressing to form macrometatases.22 Interestingly, 95% of the individual 
surviving cells and several micrometastases were found to be in a state of non-proliferating 
dormancy and could persist as indolent cells for months and years, only to exit dormancy when 
favorable conditions are met.22 This would explain the phenomena of residual cancer burden 
(RCB), also known as minimal residual disease (MRD), and relapse, in which a small number of 
cancer cells that have either seeded to distant organs or remain in the primary location after 
successful surgical or anti-neoplastic treatment have removed the primary tumor.4 These dormant 
tumor cell(s) can eventually adapt organ-specific programs or modulate the host 
microenvironment, including mechanisms such as angiogenesis or immunomodulation, to exit 





 As stated previously, stage IV metastatic disease represents the terminal stage of cancer 
and the cause of 90% of all cancer-associated mortality.4 The deadly nature of metastases stems 
from their 1) local effects, such as organ failure due to gross metastatic burden, 2) distribution 
throughout multiple organs, 3) decreased sensitivity and increased resistance to radiation therapy 
(RT) and chemotherapy compared to the primary tumor, 4) dormancy programs allowing for tumor 
cells to escape detection and treatment by anti-neoplastic agents, and 5) systemic effects that 
compromise the host’s natural homeostasis (Figure 1-2). These systemic effects can result in 
dysregulated immune response and metabolism both promote tumor growth, survival, and invasion 
and render the host more susceptible to other co-morbidities and decreased tolerance to anti-
neoplastic agents.  
 
 
Figure 1-2: The effects of cancer metastasis 





The local effects of metastases-associated deaths are relatively straightforward and have 
been understood since antiquity. The growth of a malignant mass represents a physical barrier that 
interferes and damages the body’s anatomy. The unrestrained growth of a tumor mass within an 
organ will compromise the function of said organ and result in organ failure. Furthermore, the 
mass can restrict blood vessels and circulation, neuron circuitry, respiratory function, and digestive 
tract function. In this manner, metastases can cause death by physically interference of the host’s 
internal anatomical tissues and their functions. Therefore, the number of different and specific 
organ(s) bearing metastases can significantly impact patient survival and prognosis.23 For example, 
BC patients bearing brain and multi-site metastases have significantly lower survival compared to 
those with lung-only and liver-only metastases, with bone-only metastatic patients having the best 
prognosis.23 The local effects of metastasis are generally more lethal than that the primary tumor, 
because the primary tumor is generally localized to a singular location and in many early-stage 
cancers, can be surgically removed. However, metastatic disease is widespread, more difficult to 
detect, and often presents in vital and sensitive organs difficult to access through surgical means.  
 
Treatment resistance 
Since Emil Grubbé first pioneered RT treatment of cancer patients in 1933, it is estimated 
that over 50% of cancer patients receive RT during the course of their disease.24-26 However, while 
RT remains effective in treating primary tumors, it known that RT can also promote metastasis.24 
RT can cause tumor, immune, and stromal cells to secrete metastasis-promoting cytokines, growth 
factors, and ECM-remodeling proteins.24 Furthermore, distant tissues exposed to radiation through 
RT have been found to exhibit an increased propensity for metastatic colonization, which is 
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mediated by radiation-induced hypoxia, damage to tissue vasculature, and pro-tumor 
inflammation.24  Furthermore, RT treatment has also been shown to increase the number of CTCs, 
suggesting a role of RT in tumor cell dissemination from the primary tumor.24 Finally, prolonged 
RT acts as a selecting agent for radioresistant clones that display an increased metastatic potential, 
which can result in relapse that is resistant to RT.24  
Chemotherapy remains a mainstay of systemic anti-neoplastic treatment. Although their 
specific mechanisms differ, chemotherapeutic agents generally target various phases and 
mechanisms in the cell cycle to kill fast-dividing cells. While this is effective in killing rapidly 
proliferating tumor cells, dormant disseminated tumor cells in MRD can effectively bypass 
chemotherapeutic intervention by halting its cell cycle.27 Another major issue in chemotherapy is 
intrinsic or acquired drug resistance; and it is estimated that 90% of chemotherapy failure occurs 
during the invasion and metastasis stages of cancer.28 Furthermore, even successful treatment of 
the primary tumor by either RT or chemotherapy can result in later metastatic outgrowth that is 
resistant to the initial treatment. For example, while chemotherapy is able to manage early stage 
BC, treatment loses efficacy in the 30% of patients that progress to metastatic disease.29 Only 30-
70% of these patients respond to first line anthracycline or taxane chemotherapy and their median 
progression-free survival (mPFS) is limited to 6-10 months before onset of chemoresistance.29 
Patients resistant to first line treatment are then treated with capecitabine, but the response rates 
and mPFS drops significantly to 15-28% and < 6 months, respectively.29,30 Similar trends are 
observed in other cancers, such as locally advanced rectal cancer, in which combined 
chemoradiation therapy fails in the 25-40% of patients that develop distant metastases; and 
advanced ovarian cancer, in which 80% of patients that respond well to first line chemotherapy 
ultimately relapse, with only 15-35% of patients responding to second line therapy.31,32 This 
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suggests that tumor acquisition of drug resistance is a selective and progressive process. Indeed, 
studies have shown that drug resistance can be caused by a variety of intrinsic, such as tumor 
heterogeneity and selection of resistant variants, and multi-drug resistance (MDR) mechanisms 
(e.g. drug efflux, drug metabolism, and inhibition of apoptosis), and extrinsic factors, such as 
modulation of the tumor microenvironment (TME) and inducing non-cancer cells to release pro-
tumor survival factors.28,33  
It is well known that tumors masses are heterogeneous, and this intra-tumor heterogeneity 
contains a multitude of tumor cell variants with alterations in their genetic (e.g. mutations, gene 
amplifications, aneuploidy, and translocations), epigenetic (e.g. chromosomal and histone 
modifications, hyper/hypomethylation, and hyper/hypoacetylation), transcriptomic, and proteomic 
backgrounds.28 Moreover, tumor cells exhibit a high rate of genetic instability and aneuploidy, 
leading to high mutation and chromosomal rearrangement rates that can drive the development of 
novel drug-resistant variants.28,34 Because chemotherapy acts as a selecting agent for tumor cells 
that have acquired various mechanisms of chemoresistance, over the course of treatment, these 
resistant variants gradually become the predominant population and this ultimately results in 
treatment failure.  
In addition, because there is overlap between mechanisms conferring drug resistance and 
mechanisms involved in invasion and metastasis, such as EMT, drug resistant variants often have 
increased metastatic potential and thus their metastases are intrinsically resistant.33,35 One such 
mechanism is through upregulation of Twist, a transcription factor that promotes EMT and 
metastasis, which can also upregulate the expression of P-glycoprotein (P-gp).35,36 P-gp is an ATP-
dependent membrane efflux transporter that contributes to MDR by binding to a multitude of 
chemotherapeutic agents (e.g. taxol, doxorubicin, etoposide, and paclitaxel) and utilizes ATP to 
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release them into extracellular space.28,37,38 Other mechanisms linking metastasis and MDR have 
been observed in amplified drug metabolism and inhibition of apoptosis.32,39,40  Studies have also 
demonstrated that elevated glutathione S-transferase (GST) and glutathione (GSH), which confer 
MDR through detoxification of drugs (e.g. cyclophosphamide, adriamycin, and cisplatin) and 
ionizing molecules (e.g. reactive oxygen species), correlate directly with liver metastatic potential 
in B16 melanoma.35,39,41 Moreover, GST can indirectly inhibit drug-induced apoptosis pathways 
via inhibition of mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase 1 (JNK1), 
and apoptosis signal-regulating kinase 1 (ASK1).39,40 Furthermore, elevated expression of 
aldehyde dehydrogenase (ALDH), which detoxifies and confers resistance to a multitude of drugs 
(e.g. cyclophosphamide, cisplatin, doxorubicin, taxanes, and temozolomide), has also been shown 
to correlate with metastatic capability.42 Elevated ALDH expression has been shown in both 
clinical studies and multiple mouse cancer models, including BC, prostate cancer, ovarian cancer, 
and hepatic cancer, to play a functional role in metastasis.42 These studies, along with a multitude 
of others, demonstrate that metastasis and intrinsic tumor chemoresistance pathways are linked. 
 However, metastasis and chemoresistance are also linked via extrinsic factors as well. 
Similar to RT, chemotherapy is a systemic treatment that acts as a stress-inducer that promotes 
tissue damage, hypoxia, and dysregulated stromal and immune responses that can favor 
metastasis.33,43 Studies of prostate cancer show that chemotherapy induces stromal cells to secrete 
Wnt ligands, which then drives tumor cell EMT and metastasis.42 Studies in lung cancer show that 
chemotherapy induces cancer-associated fibroblasts (CAFs) to secrete growth factors, such as 
IGF-1, HGF-1, and SDF-1, which promote tumor cell survival, proliferation, and EMT.44 Our 
laboratory has also demonstrated that chemotherapy drugs (e.g. doxorubicin and 
cyclophosphamide) induce stromal cells to secrete TNF-α, which then induces BC cells to secrete 
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CXCL1. 45 CXCL1 then recruits neutrophils that secrete S100A8/9 cytokines that promote both 
primary tumor and metastatic BC cell survival and drug resistance through activation of ERK1/2 
pathways.45 Inhibition of this mechanism significantly reduces lung metastasis and increases the 
efficacy of chemotherapy.45 Other studies have also shown that chemotherapy can “prime” certain 
tissue microenvironments to be more permissible to tumor cell intra and extravasation, which 
supports metastatic colonization.33 These studies, along with others, demonstrate that 
chemotherapy treatment can promote metastasis by modulation of extrinsic factors, thus limiting 
the long-term efficacy of treatment. 
 In addition to RT and chemotherapy, targeted therapeutics are also utilized in the treatment 
of cancers, although their usage is highly dependent on cancer type and expression of drug target. 
While targeted therapeutics generally represent a more efficient option and are less harmful to the 
host compared to systemic chemotherapy, most treatments share similar challenges of acquired 
resistance and reduced efficacy in metastatic patients. An example is with kinase inhibitors, such 
as erlotinib and vemurafenib, which are used to treat EGFR-mutant lung cancer and BRAF-mutant 
melanoma patients, respectively. Initial treatment is usually successful with partial to full tumor 
regression, however the duration until acquisition of resistance, tumor progression, and metastasis 
is a low 6-12 months.46 Subsequent experimental studies using mouse and xenograft models 
revealed that while the tumor and TME regressed upon treatment, the treatment stimulated stressed 
melanoma and lung cancer cells, which ultimately promoted the proliferation, invasion, and 
metastasis of resistant tumor cells.46 Targeted endocrine therapy, such as tamoxifen, in estrogen 
receptor (ER)-positive BC is another example of acquisition of resistance in recurrence and 
metastasis.47 Studies show that around 33% of treated patients acquire resistance, many of them 
through mutations in the ER coding gene, ESR1.47 These ER-mutant tumor cells were found to be 
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significantly higher in metastases than in primary tumors, suggesting that acquisition of ER 
resistance is linked to metastasis.47 Taken altogether, these studies link metastasis to resistance to 
radio, chemo, and targeted therapeutic intervention, further underscoring the lethal nature of 
metastatic disease and the pressing need to discover novel targetable mechanisms for the treatment 
of metastatic patients.  
 
1.2 Metastasis and Immunotherapy – background, state of the field, new frontiers – 
B cells 
Background 
 Throughout the initiation and progression of both primary tumors and their metastases, 
tumor cells will interact with the host’s immune system. The growth, survival, and metastasis of 
tumor cells is intricated linked to tumor-immune crosstalk and the balance between anti-tumor and 
pro-tumor inflammation and immune cell phenotypes.48 It is well understood that cytotoxic CD8+ 
T lymphocytes (CTLs) and natural killer cells (NK) cells mediate anti-tumor immunity and 
depletion of these populations result in increased formation of metastasis in various mouse models 
of cancer.48-52 Conventionally, anti-tumor immune response requires tumor cells to express 
neoantigens/tumor-associated antigens (TAA), which are internalized by antigen-presenting cells 
(APCs), such as dendritic cells (DCs) or B cells, and displayed on their surface MHC-I or MHC-
II proteins. These APCs then migrate to the TME or draining lymph nodes through locally-released 
inflammatory cytokines and chemokines where they present the TAAs to CTLs. This primes the 
CTLs to secrete pro-inflammatory cytokines, recognize TAA-expressing tumor cells, and kill the 
malignant cells through release of perforin and granzyme B.48 There is extensive evidence that 
decreased tumor CTL infiltration is associated with poor prognosis in many cancer types, including 
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BC, ovarian, and CRC; and depletion of CTLs in mouse models of results in increased 
metastasis.49,50,53-56 NK cells target tumor cells deficient in MHC-I and studies in multiple mouse 
models of cancer show that NK cell depletion can increase metastasis.51,57,58 Myeloid cells, such 
as macrophages and neutrophils, can also mediate anti-tumor functions through phagocytosis and 
secretion of reactive oxygen species (ROS), although their phenotypes are often found to be altered 
to a tumor-promoting role.48  
Tumor cells must evade these anti-tumor response mechanisms to successfully grow and 
metastasize. One method is through establishment of an immunosuppressive TME through the 
release of tumor-derived cytokines, such as TGF-β or IL-10, which can trigger the differentiation 
of anti-tumor immune cells into a pro-tumor immune phenotype, such T-regulatory cells (Tregs), 
tumor-associated macrophages (TAMs), and tumor-associated neutrophils (TANs).59-62 These 
immunosuppressive immune cells secrete immunosuppressive cytokines and express T cell co-
inhibitory molecules to blunt CTL-mediated anti-tumor response.48 Tregs, TAMs, and TANs have 
all been demonstrated to promote metastasis in mouse models of BC through the suppression of 
anti-tumor immune responses.45,63,64 Furthermore, the secretion of tumor- or TME-derived 
cytokines, such as G-CSF, into systemic circulation alters the hematopoiesis and generation of 
myeloid cells in the bone marrow, resulting in both local and systemic accumulation of 
immunosuppressive TANs and immature myeloid-derived suppressor cells (MDSCs).48 This 
creates a systemic “myeloid-bias” skewing of immune homeostasis, which promotes the survival 
of tumor cells in circulation and promotes the formation of pre-metastatic niches in distant organs 
that promotes metastatic colonization. Immunosuppressive immune cells have also been shown to 
promote metastasis through secretion or expression of ECM remodeling proteins, such as matrix 
metalloproteinases, and angiogenesis-stimulating proteins, such as VEGF-A, which increase the 
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invasion and intra/extravasation of tumor cells, respectively.48 Moreover, ECM and vascular 
remodeling can result in a high-density, fibrotic TME and leaky vasculature, respective, which can 
impair the infiltrating of anti-tumor immune cell populations.48,65,66 Another method for tumor 
immune escape is for tumor cells and tumor-induced immunosuppressive immune cells to regulate 
their expression of inhibitory immunoreceptors (also known as immune checkpoints), such as PD-
L1, CTLA-4, LAG3, and TIM3.67,68 The binding of these immune checkpoint molecules to their 
cognate ligands, such as tumor PD-L1 to CTL PD-1, or T cell CTLA-4 to APC-CD80, will 
inactivate the CTL and revert it into an anergic state incapable of mediating anti-tumor 
response.48,67,68 
 
State of the Field 
 Since the discovery of immune checkpoints in cancer, there has been an extensive effort in 
the research and development of antibody-based immune checkpoint inhibitors (ICIs) to increase 
T cell-mediated anti-tumor response. This has led to the FDA approval of many ICI treatments, 
including those targeting CTLA-4 (ipilimumab), PD-1 (pembrolizumab and nivolumab), and PD-
L1 (atezolizumab, avelumab, and durvalumab).69 These ICI therapies have yielded positive 
indications in a wide range of cancers, including, but not limited to, metastatic melanoma, 
lymphomas, renal cancer, and lung cancer.69 However, the response and efficacy of ICIs are not 
universal, as ICIs have minimal efficacy in metastatic PDAC, metastatic castration-resistant 
prostate cancer, and metastatic triple-negative breast cancer (mTNBC).69,70 Indeed, similar to 
tumor acquisition of resistance to other treatment discussed previously, tumors undergoing ICI 
treatment can develop mechanisms to escape T cell-mediated targeting. These mechanisms can 
include alterations in antigen presentation pathways, reduced CTL proliferation and diversity, 
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downregulation of TAAs, increased immunosuppression in the TME, resistance to CTL effector 
molecules, and alterations in vasculature and ECM remodeling to reduce CTL infiltration into the 
TME.69  
Clinical studies in BC patients show that metastases exhibit reduced CTL infiltrate, reduced 
pro-inflammatory cytokines and increased immunosuppressive cytokines, and decreased antigen 
presentation when compared to matched primary tumors.71 This suggests that metastases are more 
immunologically inert and are more resistant to ICI.71 This difference could explain the reduced 
mPFS of Atezolizumab in mTNBC (mPFS=6.6 months) when compared to locally advanced 
TNBC (mPFS=9.6 months).70 The treatment efficacy of ICIs is not only dependent on whether the 
patient has developed metastases or not, but also on the number and sites of metastasis as well: 
atezolizumab: brain (mPFS=4.9 months), bone (mPFS=5.7 months), liver (mPFS=5.3 months), 
lung (mPFS=5.7 months); pembrolizumab: 0-3 sites (mPFS=8.0 months), >3 sites (mPFS=5.9 
months).70 Furthermore, atezolizumab efficacy is also dependent on its administration as a first or 
second-line treatment, as the overall response rate (ORR) in mTNBC falls from 24% as first-line 
treatment to 6% as second-line treatment.72 This suggests that resistance mechanisms acquired 
during first-line treatment using other drugs can also play a role in ICI resistance, further 
decreasing the benefit of ICIs in an advanced metastatic disease context. This demonstrates a need 
for the discovery of other immunotherapies for the management of metastatic disease.  
 Another T cell-based immunotherapy is chimeric antigen receptor T cell (CAR-T) therapy, 
in which  autologous T cells are taken from a patient, genetically engineered to express a synthetic 
T cell receptor (TCR) targeting a specific TAA, expanded in vitro, and injected back into the 
patient.73 However, while CAR-T therapy is FDA-approved and efficacious in managing 
hematological malignancies, such as leukemia and lymphomas, they illicit poorer responses in 
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solid tumors.74 This lack of efficacy can be due to the difficultly in identifying TAAs, impaired 
CTL trafficking, a heavily immunosuppressive TME, and the heterogenous nature of solid tumors 
and selection of variants not expressing the specifically targeted TAA.74  
 Other immunotherapies that target myeloid cells are also actively being explored, albeit to 
limited efficacy in clinical trials when compared to preclinical mouse models. For example, 
blockade of CSF1/CSFR1 or CCL2/CCR2, which mediate TAM differentiation and recruitment, 
respectively, in combination with ICI failed to show benefit over chemotherapy in clinical 
trials.75,76 Targeting of other macrophage targets, such as the SIRPα/CD47 phagocytosis-inhibition 
axis, have shown promising activity and response (36% complete response) in B cell malignancies 
in conjunction with anti-CD20 (rituximab).77 However, efficacy in solid tumors remains low.78,79 
Phase I studies of anti-CCL2 (carlumab) in multiple solid tumors, including BC, showed only short 
duration transient suppression of free CCL2 with only 4/44 patients achieving response. 
Furthermore, a Phase IIb clinical trial of carlumab in metastatic castration-resistant prostate cancer 
showed ineffective blockade of CCL2/CCR2 signaling and no single-agent anti-tumor activity. 
Subsequent studies reveal that a pertinent issue with targeting TAMs in solid tumors is that 
although they do contribute to maintaining an immunosuppressive TME, there are a plethora of 
other immune cells, such as Tregs and TANs, that are functionally redundant. Furthermore, 
targeting TAM differentiation or trafficking does not directly mediate anti-tumor killing and 
upregulation of redundant pathways or cessation of treatment will restore TME TAM populations 
and result in continuation of tumor progression. Studies using patient samples and TNBC mouse 
models also revealed that cessation of anti-CCL2 treatment promotes TNBC lung metastasis, 
which is mediated by accelerated angiogenesis through upregulation of IL-6 and VEGF-A.80 
Zoledronic acid, which is used to strengthen bones in early BC patients, plays a role in 
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reprogramming TAMs into anti-tumor M1 macrophages.81 However, despite initial promise in 
early hormone-responsive BC patients observed in the phase III ABCSG-12 and ZO-FAST clinical 
trials, results from other phase III AZURE and SUCCESS A clinical trials revealed no significant 
reduction in disease-free survival (DFS), overall survival (OS), or bone metastases.82,83  
 Similarly, immunotherapies targeting immunosuppressive MDSCs are also being tested in 
clinical studies, with limited results. Entinostat is a class I histone deacetylase inhibitor with a role 
in reducing MDSC populations through epigenetic reprogramming.84 However, entinostat failed 
to demonstrate increased mPFS in TNBC and ovarian cancer patients in the ENCORE 602 and 
ENCORE 603 clinical trials, respectively.84 A CXCR1/CXC2R2 inhibitor, SX-682, that blocks 
recruitment of CXCR2+ MDSCs has shown efficacy in combination with ICI in preclinical models, 
but is still currently undergoing phase I clinical trials.84 Ibrutinib, a bruton’s tyrosine kinase (BTK) 
inhibitor used in B cell malignancies that also targets BTK signaling-dependent macrophages and 
MDSCs, has also shown promising results in inhibiting tumor growth and metastasis in preclinical 
mouse models of BC and TNBC by converting MDSCs into DCs and enhancing CTL activity.85-
87 However, the phase III RESOLVE and phase Ib/II NCT02403271 clinical trials showed that 
ibrutinib in combination with chemotherapy or ICI yielded no improvement in mPFS or OS in 
metastatic PDAC patients, and poor ORR (3%) in advanced and metastatic HER2+ and TNBC 
patients, respectively.88 
  Taken together, while immunotherapeutic intervention remains a novel and promising field 
in the management of primary tumors and metastatic disease, there are many limitations to its 
efficacy, especially in a metastatic context. Given the lethality of stage IV metastatic disease and 
its augmented resistance to current RT, chemotherapy, targeted therapies, and immunotherapy 
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strategies, it is of vital important to elucidate novel metastasis-promoting mechanisms for potential 
targeting. 
 
New Frontier – B cells 
 While the role of tumor-infiltrating myeloid cells and T lymphocytes have been extensively 
explored, the role and function of tumor-infiltrating B lymphocytes (TIBs) are less defined. 
However, there is growing interest in the functional roles of TIBs, as studies have demonstrated 
the presence of TIBs in about 70% of solid primary tumors, including PDAC, CRC, melanomas, 
and BC.89,90 B cells are an integral part of the immune system. Although their canonical role is 
mediating humoral immunity through the production of antibodies, B cells also represent a 
heterogenous population that can mediate cellular immunity by secreting cytokines, performing 
effector functions, serving as professional APCs, acting as positive and negative regulators of 
myeloid and T cells, and maintenance of lymphoid tissues.91 
Mature B cells are divided into three primary subsets: B1 cells, which are distinct from 
conventional B2 cells and located in the peritoneum and pleural cavities, B2 follicular (FO) B 
cells, located and comprising about 95% of the B cell population in secondary lymphoid organs 
(SLOs) and B2 marginal zone (MZ) B cells, located in the spleen’s marginal zone.92 B1 and MZ 
B cells are activated in a T cell independent manner, in which non-protein or crosslinked antigens 
are recognized by multiple B cell receptors (BCRs), and subsequently proliferate and differentiate 
into short lived immunoglobulin (Ig) producing plasma cells (PCs). FO B cells are activated in a 
T cell dependent manner, in which an antigen recognized by the BCR is internalized, fragmented, 
and presented on the FO B cell’s MHC class II receptors to the TCRs of CD4+ T helper cells. Upon 
successful recognition and in conjunction with the co-stimulatory FO B cell CD40 binding to CD4+ 
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T cell CD40L, the CD4+ T cell then releases cytokines, IL-4 and IL-21, to activate and stimulate 
the FO B cell. The activated B cell then proliferates and differentiates into either short-lived PCs 
and effector B cells, or migrates to the germinal center (GC) of SLOs to become GC B cells. GC 
B cells undergo clonal expansion, somatic hypermutation, Ig class switching, and affinity selection 
to become either long-lived PCs with high affinity Ig secretion or memory cells.92  
Several mechanisms of B cell recruitment to TME have been reported. Activated stromal 
cells in the TME can induce tissue-specific expression of CCL21 and CXCL13, which can recruit 
TIBs through their cognate B cell receptors, CCR7 and CXCR5, respectively.89 Furthermore, 
tumor-associated blood vessels can also express CCL21; and tumor-associated TGF-β can also 
induce CD8+ T cells to secrete CXCL13.89 In solid tumors, TIBs have been found to be distributed 
as either singular cells at the invasive margin and the peritumoral stroma, or as aggregates within 
tertiary lymphoid structures (TLSs) or lymphocyte clusters (LCs).90,93 TLSs share morphological 
and phenotypical similarities to SLOs and contain their own B cell follicles and functional GCs 
that can produce memory B cells and long-lived PCs.94 Conventional SLO development requires 
hematopoietic lymphoid tissue inducer (LTi) cells that express membrane-bound lymphotoxinα1β2 
(LT) that binds to stromal tissue organizer cells to express adhesion molecules, such as ICAM1 
and VCAM1, and maintain a lymphoid-chemokine feedback axis. This axis produces CCL19, 
CCL21, and CXC13, which recruit and segregate B and T cells and induce the differentiation of 
high endothelial venules.94 While TLS formation is largely dependent on LT signaling, TLS can 
form without specific LTi cells as M1 macrophages and B and T cells can upregulate LT 
expression and drive TLS development upon CCL21 and CXCL13 signaling, respectively.94 In 
particular, LT-expressing B cells, through CXCL13 signaling and interactions that induce stromal 
25 
 
cell chemokine production, are critical to the formation and maintenance of B cell follicles in both 
SLOs and TLS.94  
Interestingly, the presence of TLSs have been demonstrated to correlate with good 
prognosis in cancer patients and anti-tumor function in mouse models.95-97 TLS-associated B cell 
(TLS-B) aggregates were found to be present in 37.69% of stage I-III BC patient primary tumors 
and correlated with increased distant disease-free survival (DDFS) (HR=0.251) and increased OS 
(HR=0.325) in hormone-negative patients.98 High primary tumor TLS-B cell density is also 
correlated with improved metastasis-free survival and mOS in melanoma, gastric cancer, ovarian 
cancer, non-small cell lung cancer, hepatocellular carcinoma, Merkel cell carcinoma, bladder 
cancer, and CRC.99-111 Furthermore, a recent clinical study revealed that elevated numbers of 
spatially dispersed LC-associated B cells (LC-B) in TNBC primary tumors correlate with good 
prognosis and increased recurrence/relapse-free survival (RFS) after initial treatment and 
mastectomy.93 
Contrary to the positive correlation with TLS and prognosis, studies have shown that non-
TLS TIBs have been associated with poor prognosis and tumor-promoting function. In PDAC 
patients, the prognostic value of TIBs is highly dependent on their spatial distribution as TLS-B 
or single TIBs.97 A high TLS-B to TIB ratio was found to correlate with increased CTL cell 
infiltration and increased patient mOS (mOS=30.9 months) compared to patients with a low TLS-
B to TIB ratio (mOS=14.1 months).97 Furthermore, depletion of TIBs in allograft Pan02 and LSL-
KrasG12D-Pdx1-Cre genetically-modified mouse models (GEMM) of PDAC with an anti-CD20 
antibody slightly reduced tumor size and increased CTL and NK cell infiltration, suggesting that 
singular TIBs have a pro-tumor function.97 Other studies report that allograft implantation of EL4 
thymoma, MC38 colon cancer, and B16 melanoma cell lines in syngeneic IgM-/- B cell-deficient 
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mice (B-deficient) resulted in no tumor growth, spontaneous tumor regression after 10 days post 
inoculation, and significantly slowed tumor growth, respectively, compared to immunocompetent 
B cell-proficient (B-proficient) mice.112  This increased resistance to tumor growth was attributed 
to elevated anti-tumor IFN-у and IL-12 cytokine concentrations and CTL response in B-deficient 
mice. Adoptive transfer of B cells from syngeneic mice into B-deficient mice lowered anti-tumor 
cytokine levels and CTL responses and restored tumor growth, indicating that B cells can inhibit 
anti-tumor responses in multiple histologically distinct murine tumor models.112  
B cells have been implicated in tumorigenesis as well. TIBs have been reported to be the 
dominant lymphocyte population in both pre-cancerous breast lesions and ductal carcinoma in situ, 
suggesting a potential role in tumorigenesis.113 Coussens and colleagues have demonstrated that 
activated B cell paracrine Ig deposition in premalignant lesions is necessary for innate immune 
cell infiltration, chronic inflammation, and the initiation of de novo carcinogenesis in the K14-
HPV16 mouse model of squamous cell carcinoma (SCC).114 Studies also show that B cell-
activated innate immune cells in premalignant lesions promote tumorigenesis by secretion of 
survival factors, tissue remodeling, and angiogenesis.115 Furthermore, HIF-1α was found to 
accumulate throughout PDAC development in both human PDAC tissue samples and the LSL-
KrasG12D-Pdx1-Cre GEMM.116 Deletion of HIF-1α increased PDAC CXCL13 secretion in early 
pancreatic neoplasia, which recruited TIBs and enhanced PDAC progression. Depletion of B cells 
reduced PDAC progression, further demonstrating the tumor-promoting role of TIBs.116  
B cell-mediated pro-tumor immunosuppression is primarily mediated through IL-10-
secreting B regulatory (Breg) cells. Studies demonstrate that Bregs are recruited to PDAC tumors 
by CXCL13-secreting CAFs. These Bregs promote PDAC tumor proliferation through secretion 
of IL-35 in K-Ras-driven GEMMs of PDAC.117 These IL-35+ Bregs were also identified as the 
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prominent TIBs in human pancreatic intraepithelial neoplasia and PDAC lesions and correlate with 
poor prognosis. Furthermore, adoptive transfer of IL-10-secreting Bregs from carcinogen-treated 
immunocompetent mice were found to restore carcinogen-induced SCC in T and B cell deficient 
Tnf-/-Rag2-/- mice.118 Another study showed that Bregs are increased in tongue SCC patient tumors 
and metastatic lymph nodes; and high Breg infiltrate was associated with poor patient prognosis.119 
Patient-derived tongue SCC cells were found to induce Breg differentiation in co-culture, which 
were able to induce CD4+ T cell conversion into immunosuppressive Tregs, further implicating 
the pro-tumor role of TIBs.119  
A clinical study in BC also revealed that that surgically resected invasive BC tumors were 
enriched for both immunosuppressive IL-10-secreting Bregs and Tregs compared to fibroadenoma 
and normal breast tissue and Breg infiltrate increased based on tumor grade, suggesting a 
correlation with Bregs and malignancy.120 The study further showed that PD-L1hi human TNBC 
MDA-MB-231 cells induced the differentiation of CD19+ B cells into Bregs in co-culture, which 
in turn, induced the differentiation of CD4+ T cells into immunosuppressive FoxP3+ Tregs.120 
Moreover, co-culturing T cells with CD19+ B cells from healthy individuals did not induce Treg 
differentiation, suggesting that specifically tumor-induced Bregs play a role in maintaining an 
immunosuppressive TME. Studies by Olkhanud et al further demonstrated that lung metastasis in 
the 4T1.2 orthotopic TNBC mouse model is dependent on the inhibition of NK cells by Tregs, and 
the induction of these Tregs were dependent on tumor-induced Bregs.57,121-123 The study showed 
that both 4T1 and 4T1.2 tumors and their conditioned medium were able to induce the formation 
of Bregs both in vitro and in vivo and that the these cancer-induced Bregs were capable of 
transforming CD4+ T cells into immunosuppressive FoxP3+ Tregs through Breg-secreted TGF-β 
in co-culture.123 Furthermore, both 4T1.2 tumor-bearing T and B cell-deficient NOD/SCID mice 
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or mice treated with either B cell and Treg depleting antibodies did not develop lung metastases. 
The ability to generate lung metastases in T and B cell deficient NOD/SCID mice was restored 
upon adoptive transfer of either Tregs or both Tregs and Bregs, but not with Bregs alone.123 This 
suggests that these Bregs promote metastasis strictly by inducing Treg formation and do not exhibit 
a direct tumor-promoting function by themselves.  
Studies by Zhang and colleagues further demonstrated the tumor-promoting function Bregs 
using B-deficient IgM μ−/− BALB/c mice.124 The study demonstrated that tumor growth is 
abrogated, and Treg expansion and function are impaired in B-deficient mice compared to B-
proficient Balb/c mice using the allograft EMT6 mouse BC model.124 Interestingly, adoptive 
transfer of IL-10- B cells restored Treg function and tumor growth in B cell deficient mice, 
suggesting that the B cell-mediated Treg promotion is independent of IL-10 secretion. High TIB 
counts were also found to be associated with increased intra-tumoral Treg proliferation and 
decreased NK and CD8+ T cell infiltration and anti-tumor function.124 However, a subsequent 
study showed that B cell depletion by anti-CD20 antibody treatment failed to fully reject EMT6 
tumor growth.125 Further analysis revealed that while CD20+ B cells were successfully depleted, a 
small population of CD20low CD19+ B cells remained and Treg populations were maintained.125 
When isolated from primary tumors, these CD20low CD19+ B cells had a greater inhibitory effect 
on CD4+ T cell function than those isolated from the spleen in vitro.125 This is consistent with the 
previously reported finding that CD20low Bregs are enriched following anti-CD20 antibody 
treatment, which enhanced 4T1.2 lung metastasis.126  
In addition to Bregs, other studies have shown that antibody-secreting PCs may also play 
a pro-tumor role. One mechanism is through the formation of immune complexes (ICs) in which 
multiple antigens bind to multiple aggregated antibodies to form their own antigenic molecule.127 
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High circulating IC concentrations have been found in both pre-malignant breast tissue and BC, 
and correlate with increased tumor growth and poor prognosis.127,128 Furthermore, a study using a 
transgenic RIP-Tag2 mouse model of PDAC found that injected non-specific antibodies 
extravasate and localize at leaky blood vessels in tumor-associated stroma.128,129 Ig and IC 
accumulation has been shown to promote ECM degradation, angiogenesis, and accumulation of 
myeloid cells from Fc receptor binding in the xenograft BC T-47D mouse model.130 This promoted 
tumor invasion and metastasis to the lungs and liver in in vivo experimental metastasis assays.130 
Utilization of B-deficient IgM μ−/− mice or B cell depleted mice via anti-IgM antibody 
administration reduced metastasis formation.130 Moreover, T and B cell-deficient SCID mice 
implanted with hybridoma cells producing anti-tumor Igs promoted the growth and metastasis of 
xenografted human SW620 colon cancer cells compared to non-tumor targeting Igs.130 Further 
analysis confirmed that the anti-tumor Ig cohort showed increased tumor stroma IgG deposition, 
reduced tumor necrosis, increased angiogenesis, and destabilized the ECM near the tumor. These 
reports are consistent with the study by Coussens and colleagues, which showed that transfer of B 
cells from HPV16 mice into T and B cell-deficient HVP16 increased IC deposition and chronic 
inflammation, leading to tumorigenesis in premalignant skin.114  
PC and pathogenic Ig accumulation have also been reported to promote metastasis outside 
of the tumor microenvironment as well.131 Gu and colleagues demonstrated that primary murine 
TNBC 4T1 and EMT6 orthotopically-implanted tumors induced the accumulation of PCs in 
tumor-draining lymph nodes as early as one week post implanation.131 These “tumor-educated” B 
cells secrete pathogenic IgGs against tumor extracellular HSPA4, which activates HSPA4-binding 
protein ITGB5 and the src/NF-κB pathway, resulting in tumor expression and secretion of CXCR4 
and PGE2, respectively. PGE2 then induces lymphoid stromal cell release of chemokine CXCL12, 
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which binds to tumor-expressed CXCR4 to induce tumor chemotaxis and the formation of lymph 
node metastases.131 Taken together, these studies show that Igs can be pathogenic and that tumor-
infiltrating PCs and Ig production and deposition in tumors or malignant tissues can promote 
tumorigenesis, tumor growth, and metastasis.  
Despite the studies and evidence covered here regarding the tumor-promoting roles of 
TIBs, the role of TIBs in cancer and especially metastatic disease remains underexplored compared 
to other immune cell populations. Furthermore, existing mechanisms of metastasis-promoting B 
cells are dependent on signaling to other immune or stromal populations and a direct tumor-
promoting mechanism only involving B cells and tumor cells remains unknown. However, because 
of recent findings revealing that TIBs can function in many diverse roles, which can be dependent 
on spatial localization, further studies are warranted on elucidating the association between B cell 
localization and function in the context of metastatic disease.  
 
1.3 Systemic Effects of Cancer Metastasis – Cachexia: background, biology 
Cachexia Background 
 Advances in the study of cancer have revealed that the lethality of cancer and metastasis 
goes beyond the physical and local effects of tumor burden.132 Tumor cell interactions and 
signaling with non-tumor cells can trigger the release of soluble factors, metabolites, and 
exosomes, which systemically alter host metabolism and physiology and contribute to patient 
mortality.133 One of the most profoundly lethal systemic effects associated with advanced and 
metastatic cancer patients is cachexia, derived from the Greek lexicon: kakos” and “hexis” - 
meaning bad and condition, respectively.134-136 The term cancer cachexia was first coined by 
English ophthalmologist John Zachariah Laurence in 1858 in referring to the body wasting 
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syndrome exhibited by cancer patients.134 Although the formal definition of cachexia has varied 
since, an international consensus in 2011 defined cancer cachexia as “a multifactorial syndrome 
defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot 
be fully reserved by conventional nutritional support and leads to progressive functional 
impairment”.137 The consensus of clinical diagnosis criteria for cancer cachexia was defined as a 
greater than 5% loss of body weight or a greater than 2% loss of body weight in patients that 
already exhibit weight loss or sarcopenia.137 Furthermore, cachexia was determined to be a 
progressive disease with multiple stages – pre-cachexia, cachexia, and refractory cachexia - and 
can be classified into each by the severity of body protein and weight loss.137  
The incidence of cachexia varies by cancer type, with the highest incidence of 87% among 
PDAC and gastric cancer patients and lower incidences of around 40% in BC, sarcomas, and 
leukemias.136 However, because obesity and weight gain is a risk factor for BC patients, cachexia 
diagnoses by weight loss alone may not accurately detect cachexia in many patients.135,138,139 
Regardless of cancer type, cachexia presents as a severe and debilitating body and muscle wasting 
syndrome characterized by dysregulated metabolism and systemic inflammation.134,135,137 The 
development of cachexia significantly reduces patient survival and is responsible for 
approximately 20% of all cancer-related mortality and up to 80% of all advanced PDAC-associated 
mortality.140-142 The primary cause of death from cachexia stems from the loss of muscle mass and 
function, the proper function of which are necessary for vital functions such as breathing, 
locomotion, ingestion of food, and pumping blood.143 Additionally, not only can chemotherapy 
exacerbate or worsen cachexia symptoms by inducing weight loss, inflammation, fatigue, and 
release of cachexia-promoting cytokines, but cachectic patients also exhibit a decreased tolerance 
to chemotherapeutic agents, thus limiting treatment options.144,145  
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Cachexia Biology  
It is important to recognize that weight loss from cachexia is distinct from age-related 
sarcopenia, anorexia/starvation, malabsorption, and hyperthyroidism.134,135,137 The distinction 
between weight loss in cancer cachexia and anorexia or sarcopenia is that weight loss from 
cachexia presents with a reduction in muscle mass caused by increase in resting energy 
expenditure, systemic inflammation, is independent of adipose tissue loss, and a decrease in 
muscle-protein synthesis coupled with an increase in energy and protein catabolism mediated by 
ubiquitin-proteosome degradation and autophagy pathways.133,141,146 Importantly, weight loss in 
cachectic patients cannot be reversed by nutritional support. Conversely, weight loss in anorexia 
or sarcopenia is reversible with nutritional support, and presents without inflammation, increase 
in protein catabolism, or increases in resting energy expenditure.147,148 
Metastasis and cachexia are intricately linked, as the aberrant metabolic and systemic 
reprogramming of host physiology necessary for metastasis ultimately culminates to the 
development of cachexia at the systemic level.149 Studies in mouse models of PDAC have shown 
that 1) complete surgical resection of the tumor can reverse cachexia and 2) experimental 
metastasis assays can induce cachexia in the absence of a primary tumor.150 These confirm that the 
induction and maintenance of cachexia is requires either a primary tumor or metastatic colonies. 
Furthermore, studies using parabiotic experiments to exchange blood flow between sarcoma 
tumor-bearing (Tb) and non tumor-bearing (nTb) rats revealed that nTb parabiotic rats also 
developed cachexia, indicating that a Tb host contains humoral cachexia-promoting circulating 
factors.151,152 Following studies utilizing both primary tumor and experimental metastasis mouse 
models of cachexia have revealed that cachexia-promoting factors are highly diverse and can 
originate from either tumor cells, non-tumor cells within the TME, or distant organs and these 
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factors can either interact with muscle cells directly or reprogram the metabolism of other organs 
and tissues to induce muscle atrophy.133,152,153 
Muscle mass loss in cachexia is internally mediated by increased muscle protein catabolism 
and reduced muscle protein synthesis, as cancer cells reprogram the host metabolism to increase 
their own nutrient uptake and proliferation.133,153 Cachexia muscle protein catabolism is driven by 
increased activity of muscle ubiquitin-proteosome degradation pathways, which is mediated by 
transcriptional upregulation of muscle atrophy-related E3 ubiquitin ligases, such as muscle-
specific RING finger protein 1 (MURF1 or TRIM63), muscle atrophy F-box protein (MAFBX or 
FBXO32), FBXO31, and FBXO30 (MUSA1).133,153  
Tumor and non-tumor cells in the TME secrete a multitude of soluble factors into 
circulation, including proinflammatory cytokines, such as TNF-α, IL-1β, IL-6, and IL-8, and 
immunosuppressive cytokines, such as TGF-β.133,153 The TGF-β family member, myostatin, is a 
known negative regulator of muscle growth and functions by activating muscle smad-2 to inhibit 
downstream proliferation-promoting Akt and mTORC1 pathways.154 TNF-α can activate 
downstream the NF-κB pathway in muscle cells to drive 1) upregulation of muscle atrophy-related 
E3 ubiquitin ligases to mediate muscle protein breakdown and 2) the posttranscriptional 
suppression of MyoD mRNA, which is responsible for muscle-cell differentiation.155,156 The 
proinflammatory cytokines, TNF-α, IL-1β, IL-6, and IL-8, also induce fatty acid oxidation in 
muscles cells, resulting in high levels of oxidative stress, which activates the p38-MAPK stress 
response pathway to impair myotube growth.157  
Similarly, extracellular vesicles (EVs) released from malignant cells can contain heat shock 
proteins HSP70 and HSP90 can activate toll-like receptor 4 (TLR4) on muscle cells, which also 
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activates the p38-MAPK pathway.158 Tumor-derived EVs containing microRNA-21 have also 
been shown to activate toll-like receptor 7 (TLR7) on myoblasts to promote myoblast apoptosis.159  
 Circulating factors can also indirectly mediate cachexia by altering the metabolism of other 
organs to increase resting energy expenditure. Tumor-derived factors, such as IL-6 and parathyroid 
hormone-related protein, can induce chronic inflammation within white adipose tissue (WAT).160 
This increases the expression of uncoupling protein 1 (UCP1) in WAT, which uncouples ATP 
synthesis and oxidative respiration to increase thermogenesis and the browning of WAT into beige 
adipose tissue.160 Beige adipose tissue exhibits increased lipolysis compared to WAT, which 
ultimately increases host resting energy expenditure and has been demonstrated in multiple mouse 
models of PDAC, lung, CRC, and hepatic cancer.160 Furthermore, tumor-derived IL-6 activates 
STAT3 in liver hepatocytes and lung tissue to drive production of pro-inflammatory acute phase 
response (APR) proteins, resulting in the massive synthesis of plasma proteins.152,153 To meet this 
high demand for amino acids needed for APR-induced protein synthesis, skeletal muscle proteins 
are catabolized, leading to muscle atrophy.153 These APR proteins also include ECM components, 
such as fibronectin and fibrinogen, the synthesis of which can induced by other tumor-derived 
factors (e.g. TNF-α, TGF-β and VEGFA), resulting in inflammation and fibrosis of liver and lung 
microenvironments that primes the organs for metastatic colonization.153 Taken together, these 
examples demonstrate that tumor-derived factors can alter the metabolism of distant organs to 
drive both cachexia and metastasis. Moreover, because metastatic tumor cells also secrete tumor-
derived factors and modulate their host organs, the progression of cancer into metastatic disease 
further accelerates the development and exacerbation of muscle atrophy and cachexia.  
However, despite the elucidation of many mechanisms that mediate cancer cachexia and 
over a hundred clinical trials targeting various mediators of cachexia, there currently remains no 
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approved or effective treatments for cachexia in cancer patients.161 The high prevalence, lethality, 
and lack of treatment for cachexia highlights a dire need for the discovery of targetable novel 
mediators for cancer cachexia and the in vivo targeting of these mediators in preclinical models. 
Furthermore, because of how cancer metastasis and cachexia are intricately linked in both 
mechanism and patient prognosis, these treatment targets should focus on mediators of cachexia 




















Chapter 2: Upregulation of ZIP14 and elevated Zinc levels in 
























2.1 Zinc and ZIP14: biological function and effects on cancer cachexia 
Biological function 
Zinc (Zn2+) is trace metal that plays a vital role in many biological processes. About 10% 
of all human proteins binds to Zn2+ and Zn2+ functions as a cofactor for more than 300 enzymes 
and 2000 transcription factors.162 However, serum and intracellular zinc concentrations must be 
strictly regulated, as excess zinc is toxic and zinc deficiency impairs host growth, immune 
response, metabolism, and can result in hypogonadism.162 Adult humans typically contain a total 
of 2-3g of zinc, 57% and 29% of which are located within skeletal muscle and bone, 
respectively.163 Extracellular zinc is found in serum, with 75-85% of serum zinc being bound to 
albumin.164 However, unlike other nutrients, humans do not have a reserve or storage organ for 
zinc. Therefore, zinc levels must be consistently replenished by nutritional intake and a carefully 
regulated homeostasis between extracellular and intracellular zinc levels must be maintained.165 In 
mammals, intra and extracellular zinc concentrations are regulated by two families of zinc 
transporters, the SLC30 (ZnT) exporter and SLC39 (ZIP) importer families, which decrease and 
increase intracellular zinc, respectively.162 The ZIP family encompasses 14 members: SLC39A1-
SLC39A14 (ZIP1-ZIP14) and are widely expressed in different tissues and cell types.  
  
Effects on cancer cachexia 
  Clinical studies have observed that serum zinc concentrations are reduced in multiple types 
of cancers, including those with high incidences of cachexia, such as PDAC, lung cancer, and 
CRC.166-168 In 2010, decreased serum zinc and aberrant systemic zinc redistribution were 
hypothesized to play a role in the development of cachexia, as 1) APR and dysregulated immune 
response often presented in cachectic patients and 2) cachectic patients and zinc deficient patients 
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both exhibit similar impaired growth, immune response, and metabolic functions.165 Because 
humans lack a functional zinc reserve, decreased serum zinc would suggest that extracellular zinc 
has been aberrantly distributed into specific tissues. Studies utilizing preclinical mouse models of 
fibrosarcoma and CRC have shown that tumor-bearing cachectic muscles exhibit significantly 
elevated zinc concentrations, suggesting that extracellular zinc is aberrantly imported into 
cachectic muscles.169,170 However, the link between aberrant muscle zinc concentration, muscle 
wasting and cachexia, and cancer and metastasis remained largely unknown, until recent findings 
from our laboratory.  
 Based on the these correlations, Acharyya et al investigated the mechanisms involving 
metastasis and zinc homeostasis in cachectic muscles using murine metastatic allograft models, 
4T1 (TNBC), C26m2 (CRC), and KP1 (lung cancer), a xenograft PC9-Brm3 (lung cancer) model, 
and the K-rasLSL-G12D/+, p53fl/fl, Ptenfl/fl, Lkb1fl/fl (lung cancer) GEMM.171 Allograft and xenograft 
models had their primary tumors surgically resected 2-3 weeks post-implantation to eliminate the 
effects and complications of a primary tumor, leaving only distant metastases. Therefore, these 
resected models specifically represent the interactions and effects between metastasis and 
cachexia. Metastasis was detected and confirmed by bioluminescent imaging using the in vivo 
imaging system (IVIS) and by histological analysis of metastatic organs. The development of 
cachexia was confirmed by 1) significant decrease in body mass throughout tumor progression, 2) 
morphometric analysis of tibialis anterior (TA) muscles, which revealed that Tb mouse muscle 
fiber cross-sectional area (CSA) was reduced compared to nTb mice, and 3) amplified transcription 
of muscle atrophy-related E3 ubiquitin ligases (Murf1, Mafbx, Fbxo31, and Musa1) in TA, 
diaphragm (DIA), extensor digitorum longus (EDL), soleus, gastrocnemius (GAST) quadriceps 
(QUAD), and cardiac muscles.171 
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 The Zip14 gene was found to be transcriptionally upregulated, even compared to other Zip 
family genes, by transcriptomic RNA-sequencing (RNA-seq) analysis of cachectic TA, DIA, EDL, 
GAST, QUAD, and cardiac muscles from 4T1, C27m2, PC9-Brm3, and K-rasLSL-G12D/+, p53fl/fl, 
Ptenfl/fl, Lkb1fl/fl models compared to those of healthy nTb mice.171 This suggests that Zip14 
expression is correlated with the expression of muscle atrophy-associated E3 ubiquitin ligases and 
cachexia development in multiple muscles groups associated with vital functions. Furthermore, 
Zip14 was not upregulated in the muscles of a non-metastatic GEMM of lung cancer and a non-
cachectic metastatic allograft lung cancer model, which suggests that the muscle upregulation  of 
Zip14 is specific to the context of metastasis-induced cachexia.171 These results were validated by 
immunohistochemical staining and analysis of ZIP14 expression in non-cachectic and cachectic 
muscle samples from human cancer patients. Blinded pathological analysis revealed high ZIP14-
specific staining in the atrophic muscle fibers 19 out of 43 cachectic cancer patients and 8 of out 
of 53 non-cachectic patients, with low or no signal in non-atrophic muscle fibers.171 This confirms 
that ZIP14 protein expression is elevated in atrophic muscles of advanced cancer patients.  
 The study revealed that induction of Zip14 expression during tumor progression and 
cachexia development was mediated by tumor-derived TGF-β and TNF-α cytokines though in 
vitro and in vivo functional assays. Treatment of human primary muscle cells and murine C2C12 
myoblasts with either recombinant TGF-β or TNF-α induced Zip14 expression while inhibition of 
respective downstream SMAD and NF-κB pathways with respective inhibitors blocked Zip14 
expression.171 Furthermore, elevated serum and TME levels of TGF-β and TNF-α have been 
reported in both human patients and mouse models and treatment of 4T1 and C26m2 mouse 
models with either TGF-β or TNF-α neutralizing antibodies significantly reduced muscle 
expression of Zip14.171  
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 To determine the role of Zip14 expression in metastasis-induced cachexia, Acharyya et al 
generated Zip14 germline deletion and muscle-specific conditional knockdown of Zip14 mouse 
models. These displayed no defect in tumor growth or metastasis compared to wild-type control, 
but both germline Zip14-null and muscle-specific Zip14 knockdown models demonstrated a 
significant rescue of body weight loss and muscle atrophy compared to wild-type controls.171 
These results suggest that muscle Zip14 expression is required for the development of metastasis-
induced cachexia.  
 Furthermore, the study revealed that ZIP14 mediates metastasis-induced cachexia through 
its canonical function as a zinc importer. Inductively coupled-plasma mass spectrometry (ICP-
MS) confirmed an increased in muscle-zinc concentrations and a concomitant reduction in serum 
zinc concentrations in cachectic 4T1 and C26m2 mouse models. Conversely, tumor-bearing 
germline Zip14-null mice exhibited no difference in muscle-zinc levels compared to non tumor-
bearing mice. Furthermore, zinc supplementation exacerbated body weight loss and muscle 
atrophy in wild-type, but not Zip14-null mice without any alterations in tumor growth in either 
model. Subsequent in vitro experiments revealed that accumulation of zinc in Zip14-expressing 
myoblasts and myotubules resulted in loss of MyoD and Mef2c expression, which resulted in the 
blockade of myotube differentiation, and loss of myosin heavy chain (MyHC), respectively.171 
Taken together, these findings demonstrate that metastatic cancer-secreted TGF-β and TNF-α 
induce aberrant muscle expression of Zip14, which increases intracellular zinc that leads to muscle 
atrophy and the development of cachexia in mouse models of lung, breast, and lung cancer. 
 
2.2 Generation and validation of experimental metastasis mouse models of 
pancreatic adenocarcinoma cachexia 
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PDAC patients exhibit one of the highest mortality rates among cancers, with an overall 
five-year survival rate of 9% that drops to 2% for metastatic patients.172,173 A major factor 
contributing to its lethality is that PDAC has the highest incidence of cachexia among cancers, 
with approximately 87% of diagnosed patients developing cachexia over the course of disease 
progression.136 Furthermore, most PDAC patients are diagnosed when the cancer has already 
progressed to locally advanced stage III or stage IV metastatic disease, which limits opportunities 
for surgical resection, which is the only curative option for PDAC.174-177 The high incidence of 
cachexia and its significant impact on patient mortality underscores the importance of elucidating 
the mechanisms of PDAC-induced cachexia to uncover potential targets for therapeutic 
intervention.  
To determine the mechanisms mediating PDAC-induced cachexia, we generated two 
experimental metastasis models of PDAC that utilize the murine PDAC cell lines: Pan02 and 
FC1242. These cell lines were selected to model metastatic human PDAC based on the following 
criteria: 1) the ability of metastasize and induce cachexia, and 2) different mutational landscapes 
to rule out cell line- or mutation- specific effects. The Pan02 cell line is a metastatic SMAD4null 
murine PDAC cell line derived from a 3-methylcholanthrene carcinogen-induced primary 
pancreatic tumor that developed in a C57BL/6 background mouse.178,179 The FC1242 cell line was 
derived from a primary pancreatic tumor that developed in a LSL-KrasG12D; LSL-Trp53R172H; Pdx1-
Cre GEMM with a C57BL/6 background.178 We generated experimental metastasis models 
through intracardiac injection of 1 x 105 murine Pan02 and FC1242 into arterial circulation in male 
8- to 9- week old athymic nude and syngeneic C57BL/6 mice, respectively (Figure 2-1A). The 
Pan02 and FC1242 experimental metastasis models gradually developed metastasis and cachexia, 
which were confirmed by histological analysis and measurements of weight loss, hind-limb grip 
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strength, muscle fiber CSA, and muscle expression of muscle atrophy-associated E3 ubiquitin 
ligases (Figure 2-1B-H). Both Pan02 and FC1242 experimental metastasis models exhibit a 
significant loss in body weight and reduction of hind limb functional grip strength by endpoint, 
along with the development of lung and liver metastases, when compared to age-matched healthy 
control mice (Figure 2-1B-E). The loss of muscle function demonstrated by reduction of hind limb 
grip strength was found to be associated with a decrease in muscle fiber size, which was quantified 
by morphometric analysis of muscle fiber CSA (Figure 2-1F, G). Pan02 and FC1242 experimental 
metastasis model GAST muscles displayed histological features of muscle atrophy, reduced size, 
and contained a lower percentage of muscle fibers with larger CSA and a higher percentage of 
muscle fibers with smaller CSA when compared to healthy control mice (Figure 2-1F, G). 
Furthermore, cachectic GAST muscles from Pan02 and FC1242 experimental metastasis models 
exhibited elevated expression of Murf1, Mafbx, Fbxo31, and Musa1 muscle atrophy-associated E3 
ubiquitin ligases (Figure 2-1H) compared to healthy control mice. Taken together, these results 
suggest that the Pan02 and FC1242 PDAC experimental metastasis models develop metastatic 









Figure 2-1: Cachexia development in Pan02 and FC1242 experimental metastasis models of 
pancreatic ductal adenocarcinoma (PDAC)  
(A) Schematic depicting the intra-cardiac injection of 1 x 105 Pan02 or FC1242 cells into the 
arterial circulation of mice and subsequent development of metastasis. (B) Body weight 
measurements of Pan02 and FC1242 experimental metastasis models (Tb, blue lines) compared to 
non tumor-bearing control mice (Con, gray lines). (C) Measurements of hind-limb grip strength in 
Pan02 and FC1242 experimental metastasis models (Tb, blue bars) compared to control (Con, gray 
bars) mice before tumor-cell injection (initial) and at endpoint (final). Data is normalized to the 
mean of initial values of each group. (D) Representative images of hematoxylin and eosin- (H&E) 
stained liver tissue sections from the FC1242 experimental metastasis model compared to control 
mice. Scale bars represent 100 µm. (E) Representative images of H&E-stained lung tissue sections 
from Pan02 and FC1242 experimental metastasis models compared to control mice. Scale bars 
represent 100 µm. (F) Representative images of H&E-stained gastrocnemius muscle cross-
sections from Pan02 and FC1242 experimental metastasis models compared to control mice. Scale 
bars represent 25 µm. (G) Quantitation of gastrocnemius muscle fiber cross-sectional area (CSA) 
from Pan02 and FC1242 experimental metastasis models compared to control mice. Morphometric 
analysis is shown as the distribution frequency of muscle fibers stratified by CSA ranges. (H) 
Results from real-time quantitative reverse transcription PCR (RT-qPCR) analysis of muscle 
atrophy markers Trim63 (Murf1), Fbxo32 (Mafbx), Fbxo31, and Fbxo30 (Musa1) in the 
gastrocnemius muscles from Pan02 (top) and FC1242 (bottom) experimental metastasis models 
compared to control mice. n = 3–5 mice/group. Data are expressed as mean + standard error of the 
mean (SEM). p-values were determined by the two-tailed, unpaired Student’s t-test. n.s., Not 
significant; Con, control; Tb, tumor-bearing. 
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2.3 Cachectic gastrocnemius muscles exhibit upregulated ZIP14 expression and 
elevated intramuscular zinc concentration in Pan02 and FC1242 experimental 
metastasis models of pancreatic adenocarcinoma  
 Continuing our studies that demonstrated that muscle upregulation of Zip14 expression and 
elevated intramuscular zinc concentration mediate cachexia in metastatic mouse models of colon, 
breast, and lung cancer,171 we analyzed the role of the Zip14-zinc axis in the cachectic muscles 
from Pan02 and FC1242 experimental metastasis models. Quantitative RT-qPCR and immunoblot 
analysis revealed that the cachectic GAST muscles of Pan02 and FC1242 experimental metastasis 
models had significantly upregulated expression and protein levels of Zip14 when compared to 
nTb control mice (Figure 2-2A, B). These results are consistent with our previous findings.171 
 Because ZIP14 is a broad-spectrum importer for not only zinc, but iron (Fe2+) and 
manganese (Mn2+) as well, we analyzed the intramuscular levels of these metal ions along with 
copper (Cu2+) as a negative control in GAST muscles by ICP-MS.180 The results revealed that zinc 
ion levels were elevated in the cachectic GAST muscles of Pan02 and FC1242 experimental 
models compared to control mice (Figure 2-2C). A small increase manganese levels was detected 
in the Pan02, but not the FC1242, experimental metastasis model and there were no significant 
alterations in manganese or copper levels in either model (Figure 2-2C). This suggests that 
upregulated Zip14 in the cachectic GAST muscles functions primarily in its zinc import role. 
Concomitant with elevated Zip14 expression and intramuscular zinc concentration, cachectic 
GAST muscles also exhibited significantly upregulated expression of zinc-inducible and zinc-
binding metallothionein (Mt) proteins 1 (Mt1) and 2 (Mt2) (Figure 2-2D).181,182 Mt proteins contain 
cysteine-rich metal-binding domains and are markers for aberrantly elevated intracellular zinc 
concentrations.181,182 Taken together, these findings demonstrate that cachectic muscles of Pan02 
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and FC1242 experimental metastasis models harbor concomitant elevated Zip14 expression, 




















Figure 2-2: Zip14 is induced and associated with elevated zinc levels in the cachectic muscles 
of experimental metastasis models of pancreatic adenocarcinoma (PDAC) 
(A) Results from RT-qPCR analysis of Zip14 expression in the gastrocnemius (Gast.) muscles 
from Pan02 (left) and FC1242 (right) experimental metastasis models (Tb, blue bars) compared to 
control mice (Con, gray bars) and Pan02 and FC1242 cell lines (Tum, white bars). (B) Immunoblot 
analysis probing for ZIP14 in gastrocnemius (Gast.) muscle-cell lysate from Pan02 (left) and 
FC1242 (right) experimental metastasis models compared to control mice. GAPDH was used as 
an internal control. Data is representative of three independent experiments. (C) Results from 
metal ion analysis of zinc (Zn2+), iron (Fe2+), manganese (Mn2+), and copper (Cu2+) in 
gastrocnemius muscles from Pan02 (top) and FC1242 (bottom) experimental metastasis models 
compared to control mice at endpoint. Data is expresed as micrograms (mg) of metal ions per gram 
(g) of muscle dry weight. (D) Results from RT-qPCR analysis of Mt1 and Mt2 expression in the 
gastrocnemius muscles from Pan02 (top) and FC1242 (bottom) experimental metastasis models 
(Tb, blue bars) compared to control mice (Con, gray bars) at endpoint. n = 3–5 mice/group. Data 
are represented as the mean + SEM. p-values for RT-qPCR analysis were determined by using the 
two-tailed, unpaired Student’s t-test. p-values for metal ion analysis were determined by using the 
Mann–Whitney test. Con, control; Tb, Tumor-bearing; Tum, tumor cell lines; Gast., 
Gastrocnemius muscle. 
 
2.4 Clinical validation of elevated ZIP14 expression in cachectic pectoralis muscles 
from advanced pancreatic adenocarcinoma patients  
 To clinically validate our experimental findings that associate the Zip14-zinc axis with 
metastatic PDAC-induced cachexia, we performed immunohistochemical staining and analysis of 
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ZIP14 expression in pectoralis muscle sections from human cachectic and non-cachectic advanced 
PDAC patients (Figure 2-3A, B). Blinded pathological analysis revealed significantly more ZIP14-
positive staining in the atrophic pectoralis muscle fibers from cachectic PDAC patients (75%) 
compared to the muscle fibers of non-cachectic PDAC patients (42.9%) (Figure 2-3B). 
Furthermore, ZIP14-positive staining was restricted to and observed specifically in the atrophic 
muscle fibers from cachectic PDAC patients (Figure 2-4A). These results are consistent with our 
experimental results that show that cachectic muscles from Pan02 and FC1242 experimental 






Figure 2-3: Clinical validation of elevated ZIP14 expression in cachectic pectoralis muscles 
from patients with metastatic pancreatic adenocarcinoma (PDAC) 
(A) Representative images of human pectoralis muscle cross-sections from non-cachectic (left, n 
= 7) and cachectic (right, n = 12) PDAC patients immunostained with antibodies against human 
ZIP14. A representative atrophic fiber is marked by the yellow dotted line. Additional atrophic 
fibers in the field of view are marked with black arrows. Scale bars represent 50 µm. (B) Blinded 
pathological analysis and scoring of ZIP14-stained pectoralis muscle sections from human non-
cachectic and cachectic PDAC patients as ZIP14-positive (ZIP14 (+), blue bars) or ZIP14-negative 
(ZIP14 (-), gray bars). Data are shown as a percentage of total samples. The p-value was calculated 
using Pearson’s chi-square test on scored sample counts (p = 0.0005). 
 
2.5 Zip14 expression is upregulated in the cachectic diaphragm muscles of Pan02 
and FC1242 experimental metastasis models and cachectic human pancreatic 
adenocarcinoma patients  
 To confirm the systemic upregulation Zip14 in skeletal muscles during the development of 
cachexia, we analyzed DIA muscles for the upregulation of muscle atrophy markers, Zip14, and 
Mt expression in the Pan02 and FC1242 experimental metastasis models. DIA muscles are skeletal 
muscles that are intricately and functionally linked to respiration and compromised DIA muscle 
function can result in respiratory failure and poor survival in cachectic cancer patients.183,184 
Histological analysis of H&E-stained DIA muscle sections from Pan02 and FC1242 experimental 
metastasis models revealed significant reduction in muscle fiber size when compared to control 
mice (Figure 2-4A). The presence of muscle atrophy was further confirmed by RT-qPCR, which 
revealed that the DIA muscles from Pan02 and FC1242 experimental metastasis models exhibited 
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significant upregulated expression of Murf1, Mafbx, Fbxo31, and Musa1 muscle atrophy-
associated E3 ubiquitin ligases compared to control mice (Figure 2-4B). Furthermore, similar to 
GAST muscles, Zip14 and zinc-inducible Mt1 and Mt2 expression were found to be significantly 
upregulated in the cachectic DIA muscles of Pan02 and FC1242 experimental metastasis models 
compared to control mice (Figure 2-4C).  
 To clinically validate these experimental findings, we performed immunohistochemical 
staining and analysis of ZIP14 expression in DIA muscle sections from human cachectic and non-
cachectic advanced PDAC patients (Figure 2-4D). Blinded pathological analysis revealed 
significantly more ZIP14-positive staining in the atrophic DIA muscle fibers from cachectic PDAC 
patients (100%) compared to the muscle fibers of non-cachectic PDAC patients (23.19%) (Figure 
2-4E). Taken together, the elevated expression of muscle atrophy-associated E3 ubiquitin ligases, 
Zip14 and Mt1 and Mt2 in both GAST and DIA muscles of Pan02 and FC1242 experimental 
metastasis models, along with strong ZIP14-positive staining in both GAST and DIA muscles of 
cachectic advanced PDAC patients suggests that the aberrant Zip14-zinc axis is systemically 







Figure 2-4. ZIP14 expression in diaphragm muscles from pancreatic adenocarcinoma 
(PDAC) experimental metastasis mouse models and human patients 
(A) Representative images of diaphragm muscle cross-sections stained with H&E from Pan02 
and FC1242 experimental metastasis mice compared to control mice. Scale bars represent 25 
µm. (B) Results from RT-qPCR analysis of Trim63 (Murf1), Fbxo32 (Mafbx), Fbxo31, and 
Fbxo30 (Musa1) in the diaphragm muscles from Pan02 (top) and FC1242 (bottom) experimental 
metastasis models (Tb, blue bars) compared to control mice (Con, gray bars). (C) Results from 
RT-qPCR analysis of Zip14, Mt1, and Mt2 in the diaphragm muscles from Pan02 (top) and 
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FC1242 (bottom) experimental metastasis models compared to control mice. (D) Representative 
images human diaphragm muscle cross-sections immunostained with antibodies against human 
ZIP14 from non-cachectic (top, n = 13) and cachectic (bottom, n = 10) advanced PDAC patients. 
A representative atrophic fiber is marked by the yellow dotted line. Additional atrophic fibers 
visualized in the field are marked with arrows. Scale bars represent 25 µm. (E) Blinded scoring 
of ZIP14-stained human diaphragm muscle sections as ZIP14-positive (ZIP14 (+), blue bars) or 
ZIP14-negative (ZIP14 (-), gray bars) from non-cachectic and cachectic advanced PDAC 
patients. n = 3–6 mice/group. Data for RT-qPCR analysis are represented as the mean + SEM. 
Data for ZIP14 pathological scoring are shown as a percentage of total samples. p-values for RT-
qPCR analysis were determined using the two-tailed, unpaired Student’s t-test. p-values for 
ZIP14 pathological scoring were determined using the Pearson’s chi-square test (p < 0.0001). 
Con: Control; Tb: Tumor-bearing. 
 
2.6 Discussion 
 Analogous to our lab’s previous work on metastatic BC-, CRC-, and lung cancer-induced 
cachexia,185 here, we show that aberrant muscle-cell upregulation of the zinc importer, Zip14, 
correlates with 1) increased intramuscular zinc levels, 2) elevated zinc-inducible Mt expression, 
and 3) elevated expression of muscle atrophy-associated E3 ubiquitin ligases in the cachectic 
GAST and DIA muscles from two independent experimental metastasis models of PDAC. 
Furthermore, we show that pectoralis and DIA muscles from cachectic human advanced PDAC 
patients have exhibit elevated ZIP14 expression when compared to non-cachectic patients. 
Future studies are warranted to determine at what timepoint during PDAC progression and 
cachexia development is Zip14 expression induced in muscle cells and to determine and 
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subsequently validate if a clinical association exists between patient PDAC stage and ZIP14 
induction in patient muscle cells. Our previous work had also revealed that tumor-associated 
TNF-α and TGF-β cytokines can upregulate ZIP14 expression in muscle cells and myoblasts.171 
It is known that TNF-α and TGF-β are present in the conditioned media of PDAC cell lines and 
in the serum of PDAC patients.178,186-189 Therefore, further in vivo studies are needed to 
determine if pharmacologic blockade of either TNF-α or TGF-β signaling in muscle cells can 
reduce Zip14 expression and inhibit or slow the development of PDAC-induced cachexia. The 
identification of TNF-α, TGF-β, and other potential factors that mediate muscle upregulation of 
ZIP14 in PDAC can have critical clinical implications as they can be used as 1) biomarkers to 
determine cachexia development and 2) potential druggable targets to manage cachexia 
development in PDAC patients.  
 In addition to targeting mediators of Zip14 expression, directly targeting and inhibiting 
ZIP14 function or metal chelation therapy to reduce intramuscular zinc levels could be tested as 
a therapeutic strategy to treat PDAC-induced cachexia. A recent study had demonstrated that 
treatment of human PDAC cell lines with TPEN (N, N, N”,N’-Tetrakis (2-pyridylmethyl)-
ethylenediamine), a membrane-permeable intracellular zinc chelator, induced tumor cell death by 
reducing GSH levels, increasing oxidative stress, and promoting mitochondrial dysfunction.190 
Furthermore, zinc chelator-induced tumor cell death has also been reported in leukemia, BC, 
osteosarcoma, and prostate cancer cell lines in vitro, although in vivo zinc chelation assays in 
PDAC mouse models have yet to be performed.191-196 Taken together, our previous studies,185 
and these current findings provide a strong rationale for testing the efficacy of ZIP14 inhibition 




Chapter 3: Aberrant Zip14 expression in muscle is associated with 























3.1 Cachexia and BRCA-mutant breast cancer 
 Until recently, BC patients have been associated with lower incidences of cachexia.136 
However, computed tomography (CT) analysis of body composition of BC patients have revealed 
that cachexia-associated weight loss and muscle wasting is often masked by BC-associated obesity 
and gain of excess adipose tissue.197-200 Because cachexia is typically diagnosed using loss of body 
weight, the prevalence of cachexia in BC patients  is often underdiagnosed in the clinic. Building 
upon our previous studies that show that the 4T1 mouse model of TNBC develops cachexia during 
metastatic progression,171 here we report the reduction of muscle mass, development of cachexia, 
and presence of the ZIP14-zinc axis in a novel Bard1-deficient orthotopic metastatic model of 
murine Brca-like TNBC. 
 Female individuals harboring loss of function mutations in their breast cancer susceptibility 
proteins 1 and 2 (BRCA1/2) and the “BRCA-like” BRCA1-associated RING domain 1 (BARD1) 
protein are predisposed a 65% risk of developing BC by 70 years of age and represent 20% of all 
hereditary/familial BC cases.201 BRCA-mutations are present in about 30% of TNBC patients and 
about 80% of BRCA-mutant BCs are TNBCs.202,203 Furthermore, BRCA-mutant BC patients are 
associated with increased tumor size, histological grade, and poorer ten-year survival rate (66%) 
when compared to non-BRCA-mutant BC patients (81%).204 Functionally, BRCA1 and BARD1 
dimerize into a heterodimer, which is a critical regulator of DNA homologous recombination and 
double stranded-break repair pathways.205,206 Therefore, BRCA- or BRCA-like mutant carriers, who 
only carry one functional copy of the BRCA or BARD1 gene, respectively, that undergo loss of 
heterozygosity through acquired loss of function mutations in their functional BRCA/BARD gene 
copy exhibit impaired DNA repair pathways and are more susceptible to acquisition of mutations 
that lead to the onset of BC. 
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 Initial attempts to generate heterozygous or homozygous BRCAnull GEMMs of BRCA-
mutant BC were unsuccessful due to the lack of tumor development in the former and embryonic 
lethality in the latter models.207 A breakthrough was achieved by the Baer lab, in which 
homozygous conditional mammary epithelium knockout Bard1flex1/flex1, Wapcre+ mice were 
generated by crossing mice with loxP sites flanking exon 1 of Bard1 (Bard1flex1/flex1) with knockin 
mice expressing cre recombinase under the mammary epithelium-specific Wap promoter 
(Wapcre+).208,209 These Bard1flex1/flex1, Wapcre+ mice exhibit no developmental defects and develop 
spontaneous mammary carcinomas with a latency of about 473 days that histologically recapitulate 
human BRCA-mutant/BRCA-like basal TNBC.208,209  
 
3.2 Generation and validation of a Bard1-deficient orthotopic mouse model of 
BRCA-mutant triple-negative breast cancer cachexia 
To determine the mechanisms mediating BRCA-like TNBC-induced cachexia, we 
generated a metastatic orthotopic model of Bard1-deficient murine TNBC by injecting 5 x 105 
Bard1-deficient tumor cells, isolated from the primary mammary carcinomas of Bard1flex1/flex1, 
Wapcre+ mice, into the fourth mammary fat pad of 8- to 9- week old syngeneic female B6129SF1/J 
mice (Figure 3-1A). These mice developed primary mammary carcinomas that metastasized to the 
lungs along with concomitant reduction of body weight and loss of muscle mass and function, 
measured by hind-limb grip strength prior to tumor cell injection and at endpoint, compared to 
healthy control mice (Figure 3-1B-D). Pathological analysis of GAST muscles showed histological 
signs of muscle atrophy in the GAST muscles from orthotopic Bard1-deficient metastatic TNBC 
models compared to control mice (Figure 3-1E). Subsequent measurements of GAST muscle fiber 
CSA revealed that orthotopic Bard1-deficient metastatic TNBC models had a larger percentage of 
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muscle fibers with smaller CSA and smaller percentage of muscle fibers with larger CSA 
compared to healthy control mice (Figure 3-1F). To further confirm the presence of muscle atrophy 
and cachexia, RT-qPCR revealed that GAST, DIA, TA, and heart muscles from orthotopic Bard1-
deficient metastatic TNBC models exhibited elevated expression of Murf1, Mafbx, Fbxo31, and 
Musa1 muscle atrophy-associated E3 ubiquitin ligases when compared to healthy control mice 
(Figure 3-1G). Taken together, these results suggest that orthotopic Bard1-deficient metastatic 








Figure 3-1: Cachexia development in a Bard1-deficient mouse model of Brca-like triple-
negative breast cancer (TNBC) 
 (A) Schematic depicting the orthotopic injection of 5 x 105 Bard1-deficient TNBC cells 
into the left fourth mammary fat pad of 8- to 9- week old female syngeneic B6129SF1/J mice. (B) 
Measurements and analysis of body weight of healthy non tumor-bearing control (Con, grey lines) 
mice compared to tumor-bearing (Tb, blue lines) Bard1-deficient TNBC models post tumor cell 
injection. (C) Measurements of hind-limb grip strength in orthotopic Bard1-deficient metastatic 
TNBC models (Tb, blue bars) compared to control mice (Con, gray bars) before tumor-cell 
injection (initial) and at endpoint (final). Data is normalized to the mean of initial values of each 
group. (D) Representative images of hematoxylin and eosin- (H&E) stained lung tissue sections 
from orthotopic Bard1-deficient metastatic TNBC models compared to control mice. Scale bars 
represent 100 µm. (E) Representative images of H&E-stained gastrocnemius muscle cross-
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sections from Bard1-deficient TNBC mice compared to control mice. Scale bars represent 50 µm. 
(F) Quantitation of gastrocnemius muscle fiber cross-sectional area (CSA) from orthotopic Bard1-
deficient metastatic TNBC models compared to control mice. Morphometric analysis is shown as 
the distribution frequency of muscle fibers by CSA. (G) Results from real-time quantitative reverse 
transcription PCR (RT-qPCR) analysis of muscle atrophy markers Trim63 (Murf1), Fbxo32 
(Mafbx), Fbxo31, and Fbxo30 (Musa1) in the gastrocnemius muscles from orthotopic Bard1-
deficient metastatic TNBC models compared to control mice. n = 5 mice/group. Data are expressed 
as mean + standard error of the mean (SEM). p-values were determined by the two-tailed, unpaired 
Student’s t test. Con, control; Tb, tumor-bearing; n.s., not significant. 
 
3.3 The zinc-importer gene, Zip14, and zinc-inducible genes, Mt1 and Mt2, are 
systemically upregulated in multiple cachectic muscle groups in the Bard1-deficient 
mouse model of Brca-like triple-negative breast cancer  
 Our previous studies have revealed that aberrant upregulation of Zip14 expression in 
muscle cells and intramuscular zinc concentrations are associated with and mediate metastasis-
induced cachexia in metastatic mouse models of PDAC, BC, colon, and lung cancer.171,185  To 
determine whether development of cachexia in the orthotopic Bard1-deficient metastatic TNBC 
model is associated with upregulated Zip14 and zinc concentration in cachectic muscles, we 
performed RT-qPCR in the cachectic GAST muscles for Zip14, and zinc-inducible Mt1 and Mt2 
genes from orthotopic Bard1-deficient metastatic TNBC models and healthy control mice. In line 
with our previous studies, we found that Zip14, Mt1, and Mt2 were all upregulated in the cachectic 
GAST muscles of orthotopic Bard1-deficient metastatic TNBC models and compared to control 
mice (Figure 3-2). To confirm the systemic presence of the aberrantly upregulated Zip14 and Mt 
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expression, we repeated the RT-qPCR on DIA, TA, and heart muscles and found that these genes 
were similarly upregulated in these muscle groups from orthotopic Bard1-deficient metastatic 




Figure 3.2: Zip14 and zinc-inducible genes, Mt1 and Mt2, expression are upregulated in the 
cachectic gastrocnemius muscles in the Bard1-deficient mouse model of Brca-like triple-
negative breast cancer (TNBC) 
Results from RT-qPCR analysis of Zip14, Mt1, and Mt2, expression in the gastrocnemius muscles 
from orthotopic Bard1-deficient metastatic TNBC models (Tb, blue bars) compared to control 
mice (Con, gray bars) The mouse Gapdh gene was utilized as an internal control. n = 5 mice/group. 
Data are expressed as mean + standard error of the mean (SEM). p-values were determined by the 






Figure 3-3: Zip14 and zinc-inducible genes, Mt1 and Mt2, expression are upregulated in 
diaphragm, tibialis anterior, and heart muscles in the Bard1-deficient mouse model of Brca-
like triple-negative breast cancer (TNBC) 
Results from RT-qPCR analysis of Zip14, Mt1, and Mt2, expression in the diaphragm, tibilalis 
anterior, and heart muscles from orthotopic Bard1-deficient metastatic TNBC models (Tb, blue 
bars) compared to control mice (Con, gray bars) The mouse Gapdh gene was utilized as an internal 
control. n = 5 mice/group. Data are expressed as mean + standard error of the mean (SEM). p-
values were determined by the two-tailed, unpaired Student’s t-test. Con, Control; Tb, tumor-
bearing. 
 
3.4 Upregulation of Zip14 is associated with elevated zinc concentration in cachectic 




 To determine if elevated muscle cell Zip14 expression is associated with a concomitant 
increase of intracellular metal ion concentrations, we performed ICP-MS for Zn2+, Fe2+, Mn2+ and 
Cu2+ on muscle cell lysate taken from the GAST and DIA muscles from orthotopic Bard1-deficient 
metastatic TNBC models and healthy control mice. The results revealed that the cachectic GAST 
and DIA muscles from orthotopic Bard1-deficient metastatic TNBC models had elevated Zn2+ and 
Fe2+ concentrations compared to control mice (Figure 3-4). Furthermore, Mn2+ and Cu2+ 
concentrations were found to be increased only in GAST, but not DIA muscles. These results 
suggest that elevated ZIP14 expression in cachectic GAST and DIA muscles of orthotopic Bard1-
deficient metastatic TNBC mice functions in its canonical role as a Zn2+ importer and possibly as 
a Fe2+ importer as well. The lack of increased Mn2+ and Cu2+ concentrations in cachectic DIA 
muscles suggests that these two metal ions may be imported via a different metal ion importer and 




Figure 3-4: Intramuscular zinc and iron levels are elevated in the cachectic gastrocnemius 
and diaphragm muscles from the Bard1-deficient mouse model of Brca-like triple-negative 
breast cancer (TNBC) 
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Results from metal ion analysis by ICP-MS of zinc (Zn2+), iron (Fe2+), manganese (Mn2+), and 
copper (Cu2+) on gastrocnemius and diaphragm muscles from orthotopic Bard1-deficient 
metastatic TNBC models (Tb, blue bars) compared to control (Con, grey bars) mice at endpoint. 
Results are shown as micrograms (mg) of metal ions per gram (g) of muscle dry weight. n = 7 
mice for gastrocnemius muscles. n = 7 Con mice and n = 6 Tb mice for diaphragm muscles. Data 
are expressed as mean + standard error of the mean (SEM). p-values were determined by the two-
tailed, unpaired Student’s t-test. Con, Control; Tb, tumor-bearing; n.s., not significant. 
 
3.5 Elevated Zip14 expression is associated with increased SMAD2 signaling in the 
cachectic gastrocnemius muscles from the Bard1-deficient mouse model of Brca-like 
triple-negative breast cancer  
Our previous studies in metastatic mouse models of BC, colon, and lung cancer revealed 
that tumor-associated TGF-β signaling induces muscle cell expression of Zip14 through the 
activation of the NF-κB pathway via phosphorylation of downstream SMAD2 proteins.171  To 
determine if the SMAD2 pathway is activated concomitant with elevated Zip14 expression in the 
cachectic muscles of orthotopic Bard1-deficient metastatic TNBC models, we performed an 
immunoblot analysis for phospho-SMAD2, SMAD2, and skeletal actin. Immunoblot analysis 
confirmed that elevated Zip14 occurs concomitant with elevated SMAD2 phosphorylation in the 
cachectic GAST muscles of orthotopic Bard1-deficient metastatic TNBC models when compared 
to control mice (Figure 3-5). Taken together, this suggests that TGF-β mediated SMAD2 
phosphorylation is associated with elevated Zip14 expression and increased intramuscular zinc 





Figure 3-5: Protein levels of phospho-SMAD2 are elevated in the cachectic gastrocnemius 
muscles from the Bard1-deficient mouse model of Brca-like triple-negative breast cancer 
(TNBC) 
Immunoblot analysis probing for phospho-SMAD2, SMAD2, and skeletal actin (Skel. actin) in 
gastrocnemius muscle-cell lysate from orthotopic Bard1-deficient metastatic TNBC models (Tb, 
right) compared to control (Con, left) mice. Skel. actin was used as an internal control. Data is 
representative of three independent experiments. Con, Control; Tb, tumor-bearing. 
 
3.6 Discussion 
 Continuing our studies that show that an aberrant Zip14/zinc axis is associated with 
metastatic PDAC, BC, colon, and lung cancer-induced cachexia;171,185 here, we report and 
characterize the development of cachexia a novel orthotopic metastasis mouse model of Brca-like 
TNBC that similarly develops cachexia along with concomitant presence of a Zip14/zinc axis in 
cachectic muscles. The orthotopic implantation of Bard1-deficient TNBC cells into the mammary 
glands of syngeneic mice resulted in the growth of mammary tumors that histologically 
recapitulate human BRCA-mutant TNBC and spontaneously metastasizes to the lungs along with 
the progressive development of muscle atrophy and cachexia. Although it remains to be 
determined if BRCA-mutant BC patients exhibit elevated risk of cachexia, the orthotopic Bard1-
deficient metastatic TNBC mouse model represents a useful preclinical model to elucidate the 
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mechanisms mediating metastasis and cachexia development in BRCA-mutant TNBC. 
Furthermore, CT-imaging can be utilized to determine the prevalence of cachexia in BRCA-mutant 
BC patients.  
 In addition to studies on cachexia, the orthotopic Bard1-deficient metastatic TNBC mouse 
model also represents a useful preclinical model to study the mechanisms of poly (ADP-ribose) 
polymerase (PARP) inhibitors in BRCA-mutant BC.210 Because BRCA-mutant BCs have impaired 
DNA homologous recombination and double stranded-break repair mechanisms and PARP 
functions in DNA damage sensing and single-stand DNA repair, PARP inhibitors in BRCA-mutant 
BCs cripple the tumor cell’s ability to efficiently execute high fidelity DNA repair, leading to 
accumulation of DNA damage and cell death.202 PARP inhibitors are currently approved for 
treatment of BRCA1/2-mutant BCs. Furthermore, there are ongoing clinical trials elucidating the 
efficacy of PARP inhibitors on patients with sporadic TNBC with “BRCA-like” similarities to 
BRCA-mutant BCs, and the Bard1-mutant mouse model can help facilitate the testing of PARP 
inhibitor efficacy in TNBC patients with BRCA-like mutations.211,212 In addition, it was been 
reported that PARP activation in the muscles of mouse models of lung cancer-induced cachexia 
may promote cachexia as deletion of PARP1/2 results in the rescue of body weight loss and reduces 
muscle expression of muscle proteolysis genes.213 Future studies are needed to elucidate the effects 
of PARP inhibitors on BRCA-like BC-associated cachexia. 
 Here, we report that the systemic upregulation of Zip14 expression in multiple muscle 
groups and concomitant increase in intramuscular zinc are associated with the development of 
cachexia in the orthotopic Bard1-deficient metastatic mouse model. Unexpectedly, we also found 
that intramuscular iron levels were also increased along with marginal increases of manganese and 
copper, which were not found in our previous studies associating the Zip14/zinc axis in mouse 
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models of PDAC, BC, colon, and lung cancer. Regardless, taken together, our study findings 
suggest that treatment with ZIP14 inhibitors and metal chelation therapy to lower intramuscular 
zinc and other metal ions should be tested in preclinical cancer-induced cachexia models. Future 
studies are warranted to evaluate if these strategies can reduce cachexia, rescue muscle mass and 
function, and extend survival in the orthotopic Bard1-deficient metastatic mouse model.  
 In addition to targeting Zip14 expression and intramuscular zinc, it is also essential to 
identify factors that induce Zip14 expression in the cachectic muscles of the orthotopic Bard1-
deficient metastatic TNBC mouse model. We had previously shown in vitro that tumor-associated 
TGF-β induces Zip14 expression in muscle cells and myoblasts through phosphorylation of 
SMAD2 and that in vivo treatment of cachectic mouse models of BC and colon cancer with a TGF- 
β inhibitor reduced muscle atrophy and intramuscular SMAD2 phosphorylation and Zip14 
expression.185 Here, we report similar elevated SMAD2 phosphorylation in the cachectic muscles 
of the orthotopic Bard1-deficient metastatic TNBC mouse model. Although our findings do not 
confirm that a TGF- β/phospho-SMAD2 mechanism induces Zip14 expression cachexia, TGF- β 
inhibitors should be tested in the orthotopic Bard1-deficient metastatic TNBC mouse model to 
evaluate if the treatment could reduce SMAD2 phosphorylation, Zip14 expression, and muscle 
atrophy. Taken together, future studies are needed to determine targetable factors that induce 
intramuscular Zip14 expression and to test the efficacy of ZIP14 inhibitors and metal ion chelation 
strategies to reduce muscle atrophy and cachexia in the orthotopic Bard1-deficient metastatic 






Chapter 4: Tumor-infiltrating B cells promote the invasion of lung 
metastases in triple-negative breast cancer mouse models though 























Triple-negative breast cancer and metastasis 
 In the USA, BC is the most frequently diagnosed cancer and it is estimated that 284,200 
new cases will be diagnosed along with 44,130 deaths in 2021.2,173 Although 6% of BC patients 
are diagnosed with stage IV metastatic disease due to routine early screening protocols, it is 
estimated that 30% of patients diagnosed with early-stage BC eventually develop distant 
metastases, even years after successful mastectomy or treatment of the primary tumor.214,215 BC is 
well documented as a heterogenous disease that is characterized into four major subtypes based on 
estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor 2 (HER2) 
expression: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+/-), HER2-
enriched (ER-, PR-, HER2+), and TNBC (ER-, PR-, HER2-).215 
In particular, TNBC, which accounts for about 20% of all BC cases, presents with higher 
tumor grade, lymph node positivity, mitotic count, and greater metastatic potential, which all 
culminates in poorer prognosis and increased mortality compared to other subtypes (TNBC: 42%; 
other subtypes: 28%).216-218 Furthermore, TNBC is associated with elevated risk of visceral 
metastases (lung and brain), which have higher mortality rates compared to bone metastases.217-219 
Lung and brain metastases comprise 32% and 9% of total TNBC metastases compared to a range 
of 21-25.5% and 4-8% in non-TNBC subtypes, respectively.219 Because TNBCs lacks 
overexpression of ER, PR, and HER2, treatments used in other BC subtypes that target these 
receptors cannot be used to treat TNBC patients. While chemotherapy remains a mainstay of 
TNBC treatments, TNBC exhibits higher chemoresistance compared to other BC subtypes, 
resulting in a mOS of 13.3 months.220 Furthermore, clinical studies report that about 50% of early-
stage or localized TNBC patients treated successfully with mastectomy exhibit significant RCB 
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(RCB-II or RCB-III), which correspond with 55% and 23% 10-year relapse-free survival rates, 
respectively.221,222 Likewise, TNBC patients also have elevated distant recurrence rates (6.7-
10.5%) compared to overall BC patients (2.1-6.4%).223 Taken together, TNBC exhibit an elevated 
risk of developing metastatic disease compared to other BC subtypes, which underscores the 
importance of elucidating the various mechanisms promoting TNBC metastasis to identify 
potential targets for the treatment of or prevention of mTNBC.  
 
Spatial localization of non-tumor cells in the tumor microenvironment is associated 
with anti- or pro-tumor function 
The TME is a complex and heterogenous microenvironment comprised of a multitude of 
non-tumor stromal and immune cells, including myeloid and lymphocyte populations. Simply 
evaluating the average densities of immune cell infiltrates in tumor tissues may overlook the 
significance of spatial heterogeneity and mask the effects of spatial distribution of specific immune 
populations.224 Moreover, many clinical studies utilize tissue microarrays, which only represent a 
small area of a tumor and may not be representative of the entire tumor overall.93 However, there 
is growing interest in the field of immune cell topography and spatial localization in the TME and 
studies have shown that the density and spatial localization of stromal or immune cells as 
intratumoral, stromal, or at the invasive margin, in BC can be utilized as biomarkers with positive 
or negative prognostic value.225-228 Pollard et al, revealed that that tumor-associated macrophages 
localized at the invasive margin can enhance the motility of lung metastasis by secreting epidermal 
growth factor (EGF) in the PyMT GEMM of BC.225,226 Another study in BC patients revealed that 
high stromal macrophage density was associated with larger tumor size and higher mitotic count 
when compared to intratumoral macrophages; while intratumoral macrophages, and not stromal 
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macrophages, were directly and significantly correlated with microvessel density.229 In addition, 
Gao et al, demonstrated that fibroblasts isolated specifically from the invasive margin of human 
BC patients significantly increased EMT and motility of human luminal and TNBC cell lines when 
compared to fibroblasts isolated from intratumoral or distal normal tissue zones.227  
Spatial localization of CD8+ TILs have also been shown to influence clinical outcome. In 
BC patients, high TIL density at the invasive margin is associated with smaller tumor sizes post 
chemotherapy and high intratumoral TILs are associated with improved prognosis and mOS.230,231 
Conversely, breast tumors with TILs absent from the stromal and intratumoral locations and 
restricted only to the invasive margin or peritumoral areas are associated with a more 
immunosuppressive and fibrotic TME and poor prognosis.230 Furthermore, breast tumors with 
TILs absent from the intratumoral region and restricted only to stromal compartments are 
associated with high infiltration of pro-tumorigenic neutrophils, an immunosuppressive TME, and 
worse prognosis.230  
A recent study analyzed the association between TIBs in TNBC primary tumors and RFS 
revealed that the density of CD20+ B cells in the stroma between tumor cell nests does not 
significantly correlate with RFS.93 The study also revealed that increased abundance of spatially 
dispersed TIBs and LC-Bs within the tumor nests of TNBC primary tumors were associated with 
improved RFS, suggesting that TIBs within tumor nests are functionally distinct from TIBs in the 
stroma between tumor cell nests. Taken together, these findings reveal that the spatial localization 
of non-tumor cells in the TME can exhibit differing and unique functions associated with their 
particular region. Although there is growing interest in elucidating the link between spatial 
localization, function, and effects on patient prognosis of non-tumor cells in primary tumors, there 
remains a lack of similar studies focusing on the metastatic context. 
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4.2 B220+ B cells are recruited to the invasive margin of lung metastases in mouse 
models and patients with triple-negative breast cancer  
 To determine the spatial localization of various immune cell populations in TNBC lung 
metastases, we generated allograft orthotopic and experimental metastasis models of TNBC using 
the murine TNBC cells lines: 4T1 and LM3. The two cells lines were specifically selected based 
off of three criteria: 1) a highly aggressive basal TNBC subtype with 2) the ability to accurately 
model, recapitulate, and spontaneously metastasize to the same sites (with the highest metastatic 
potential to the lung) as human TNBC patients when implanted into an immunocompetent host, 
and 3) distinct mutational landscapes between the cell lines to eliminate mutation- or cell line-
specific phenotypes.232-234 To generate 4T1 and LM3 orthotopic and experimental metastasis 
models, we injected 5x105 4T1 or 1x106 LM3 cells into the left mammary fat pad or 1x105 4T1 or  
LM3 cells into the tail vein of 6- to 8-week old female syngeneic BALB/cJ mice, respectively 
(Figure 4-1A, B). Both 4T1 and LM3 orthotopic metastasis models developed primary TNBCs 
that spontaneously metastasized to the lungs and the experimental metastasis models developed 








Figure 4-1: B cells localize at the invasive margin of lung metastases in triple-negative breast 
cancer models and patients. 
(A) 4T1 and LM3 orthotopic metastasis models were generated by orthotopic injection of 5x105 
4T1 and 1x106 LM3 cells into the left fourth mammary fat pad of 6- to 8-week old female 
syngeneic BALB/cJ background mice. 4T1 and LM3 orthotopic metastasis models developed 
mammary tumors that spontaneously metastasized to the lungs. (B) 4T1 and LM3 experimental 
metastasis models were generated by intravenous injection of 1x105 4T1 or LM3 cells into the tail 
vein of 6- to 8-week old female syngeneic BALB/cJ background mice. 4T1 and LM3 experimental 
metastasis models developed lung metastases. (C) Representative images of metastatic lung 
sections from 4T1 experimental metastasis models immunostained using antibodies against B220 
for B cells (left) and S100A9 for neutrophils (right). Black arrows mark representative B220+ B 
cells located at the invasive margin of lung metastasis. Scale bar represents 50μm. (D) 
Representative images of metastatic lung sections from 4T1 orthotopic metastasis (top) and 
experimental (bottom) metastasis models immunostained using antibodies against B220 for B cells 
(green), CD3 for T cells (red), and IBA1 for macrophages (far red). Scale Bars represent 100μm. 
(E-H) Representative images of metastatic lung sections from 4T1 and LM3 orthotopic (E) and 
experimental (G) metastasis models immunostained using antibodies against B220 for B cells. 
Scale bars represents 50μm. Bar graphs represent metastasis-infiltrating B cells by localization, 
either at the invasive margin or interior of lung metastases, and calculated as a proportion of total 
metastasis-infiltrating B cells in 4T1 and LM3 orthotopic (F) and experimental (H) metastasis 
model lungs. n = 7 mice for 4T1 orthotopic metastasis models. n = 4 mice for LM3 orthotopic 
metastasis models. n = 3 mice for 4T1 and LM3 experimental metastasis models. (I, J) 
Representative images of metastatic lung sections from human TNBC patients with confirmed 
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lung metastases and immunostained using antibodies against CD20 and shown as high (left) and 
low (right) density. Scale bars represent 100µm. Bars graphs representing tumor-infiltrating 
CD20+ B cells (TIBs) by localization, either at the invasive margin or interior of lung metastases, 
and calculated as a proportion of total CD20+ TIBs. 
n = 7 human TNBC patients. In all panels, data is expressed as mean + the standard error of the 
mean. p-values were determined by the two-tailed, unpaired Student’s t-test. TIB, tumor-
infiltrating B cell. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 
 
 To determine the spatial localization of metastasis-infiltrating immune cell populations, we 
first stained metastatic lungs from 4T1 experimental metastasis models for B220+ B cells and 
S100A9+ neutrophils (Figure 4-1C). Our results revealed an interesting discrepancy in the pattern 
and localization between B220+ B cells and S100A9+ neutrophils. The metastasis-infiltrating 
neutrophils were found to be evenly distributed throughout the metastases, but the localization of 
metastasis-infiltrating B cells appeared to be mostly restricted to the invasive margin of lung 
metastases (Figure 4-1C). To identify the spatial localization patterns of other metastasis-
infiltrating immune cells, we performed multiplex immunofluorescence staining for B220+ B cells, 
CD3+ T cells, and Iba1+ macrophages on metastatic lungs from both 4T1 orthotopic and 
experimental metastasis models (Figure 4-1D). Interestingly, we observed that metastasis-
infiltrating B220+ B cells remained localized to the invasive margin of lung metastases in both 
orthotopic and experimental metastasis models, while T cells and macrophages were eventually 
distributed throughout the lung metastases similarly to neutrophils. Further immunohistochemical 
staining for B220+ B cells in the metastatic lungs of 4T1 and LM3 orthotopic metastasis and 
subsequent quantitative analysis of B cell spatial localization as either interior or invasive margin 
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confirmed that 88.9-91.1% of all metastasis-infiltrating B220+ B cells were localized at the 
invasive margin of TNBC lung metastases (Figure 4-1E, F). The quantitative analysis further 
revealed that the metastasis-infiltrating B cells were distributed as single TIBs and not aggregated 
or organized into TLSs.  
 It is well documented that primary tumors can modulate the stromal or immune 
microenvironment of distant organs to establish “premetastatic niches” that can promote metastatic 
colonization through the release of soluble factors and exosomes.235 To determine whether the 
recruitment of localization of B220+ B cells to the invasive margin of TNBC lung metastases is 
mediated by the presence of a primary tumor, we repeated our B220+ immunohistochemistry 
staining on 4T1 and LM3 experimental metastasis models (Figure 4-1G). Quantitative analysis of 
spatial localization further confirmed that 67.2-76.3% of metastasis-infiltrating B220+ B cells were 
localized at the invasive margin of TNBC lung metastases (Figure 4-1H). Although the proportion 
of B cells at the invasive margin is lower in experimental metastasis models compared to 
orthotopic metastasis models, the trend of preferential invasive margin localization remains 
unaltered. This suggests that lung metastases are inherently capable of mediating the invasive 
margin localization of recruited metastasis-infiltrating B cells independently of a primary tumor. 
 It is important to translate findings from preclinical mouse models into human patients to 
clinically validate that the murine phenotype accurately recapitulates that of the human disease. 
To this end, we analyzed the spatial localization of metastasis-infiltrating CD20+ B cells in CD20-
immunostained metastatic lung sections from human TNBC patients (Figure 4-1I). Spatial 
localization analysis revealed that 64.1% of metastasis-infiltrating CD20+ B cells were localized 
at the invasive margin of human TNBC patient lung metastases (Figure 4-1J). Taken together, 
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these findings suggests that B cells recruited to lung metastases are preferentially localized at the 
invasive margin in multiple mouse models of TNBC and human mTNBC patients.  
 
4.3 Confirmation of metastasis-infiltrating B220+ B cell identity 
 Although B220 is generally regarded as a murine pan-B cell marker, there is evidence that 
shows it can be aberrantly expressed on populations of plasmacytoid dendritic cells (pDCs) in 
mouse models of BC and human BC patients.236,237 To confirm whether metastasis-infiltrating 
B220+ B cells are bona-fide B cells or aberrant B220+ pDCs, we performed an 
immunofluorescence co-stain for B220 and PAX-5 on metastatic lung sections from 4T1 and LM3 
orthotopic and experimental metastasis models (Figure 2A, C). PAX-5 is a transcriptional factor 
that functions on as a master regulator of commitment to B cell lineage, development, and 
maintenance of B cell identity.238 Although PAX-5 expression, along with B220 and CD20, is 
repressed upon B cell differentiation into antibody-secreting PCs, PAX-5 is exclusively expressed 
in and is determinative of B cell identity.238 Quantitative analysis of metastasis-infiltrating B220+ 
B cells as either PAX-5+ or PAX5- confirmed that about 80-92% of B220+ B cells are bona-fide 
PAX-5+ B cells over all 4T1 and LM3 orthotopic and experimental metastasis models (Figure 2B, 
D). These data validates that the majority of metastasis-infiltrating B220+ B cells are 





Figure 4.2: Confirmation of the identity of metastasis-infiltrating B cells by PAX-5 and B220 
dual staining 
(A-D) Representative images of lung sections from 4T1 and LM3 orthotopic (A) and experimental 
(C) metastasis models immunostained using antibodies against B220 (green) and PAX-5 (red). 
Cell nuclei are stained with DAPI. Scale bars represent 30μm. Bar graphs represent the quantitation 
and scoring of B220+ metastasis-infiltrating B cells, either as PAX-5+ or PAX-5-, as a proportion 
of total metastasis-infiltrating B cells in the lungs of 4T1 and LM3 orthoptic (B) and experimental 
(D) metastasis models. n = 4 mice for 4T1 and LM3 orthotopic models. n = 3 mice for 4T1 and 
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LM3 experimental metastasis models. In all panels, data is expressed as mean + the standard error 
of the mean. p-values were determined by the two-tailed, unpaired Student’s t-test. **** p<0.0001 
 
4.4 B220+ B cells isolated from the lungs or peripheral blood of triple-negative 
breast cancer mouse models promote the invasion of lung metastasis-derived 
organoids 
 Previous studies have suggested that spatial localization in the TME can affect cell function 
and that TIBs distributed as single cells and not in a TLS are associated with pro-tumor 
functions.90,225-227 This suggests that the single cell metastasis-infiltrating B220+ B cells localized 
at the invasive margin of TNBC lung metastases may exhibit tumor-promoting functions. 
Localization at the invasive margin is significant because it contains a distinct population of motile 
and migrating tumor cells that actively invade into the host tissue.239  
To determine whether metastasis-infiltrating B cells can directly affect tumor cells, we 
designed a 3-dimensional (3D) organotypic co-culture invasion assay using 4T1 and LM3 lung 
metastasis-derived organoids and B220+ B cells isolated from the metastatic lungs of 4T1 and LM3 
orthotopic metastasis mouse models. 4T1 and LM3 lung metastasis-derived organoids were 
generated by subjecting respective lungs with macroscopic metastatic nodules to limited 
mechanical and enzymatic dissociation into microscopic cell clusters, which are then embedded 
into a matrigel matrix and passaged until only lung metastasis-tumor organoids remained (Figure 
4-3A). The advantage of using lung metastasis-derived organoids is that they better recapitulate 
the 3D in vivo pathophysiological growth and invasion of lung metastases and their interactions 
with the microenvironment compared to traditional 2D cell cultures.240 Furthermore, because these 
organoids were derived from lung metastases, they have undergone “metastatic selection” and 
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have acquired intrinsic metastasis-specific alterations that are not present in their parental cell 
lines.15,16 These 4T1 and LM3 lung metastasis-derived organoids were co-cultured with 1x104 
B220+ B cells isolated from the metastatic lungs of respective 4T1 and LM3 orthotopic metastasis 
models (Figure 4-3B, C). Both monoculture control and co-cultured organoids were imaged at 0, 
48, and 96 hours post embedding and the fold change in each organoid’s form factor over time 
was calculated as a measurement of invasion into the Matrigel matrix.241  
The results revealed a striking phenotype, in which the 4T1 and LM3 lung metastasis-
derived organoids co-cultured with respective metastatic lung-isolated B220+ B cells displayed a 
significant increase in form factor fold change and invasion from 48 to 96 hours post embedding 
compared to monocultured control organoids (Figures 4-3B, C, F, G). Visually, co-cultured lung-
metastasis-derived organoids displayed increased elliptical architecture along with longer and 
more invasive protrusions (Figures 4-3B, C). Interestingly 4T1 and LM3 lung metastasis-derived 
organoids co-cultured with B220+ B cells isolated from the peripheral blood of 4T1 and LM3 
orthotopic metastasis models also exhibited an increase in form factor and invasion from 48 to 96 
hours post-embedding compared to monocultured organoids (Figure 4-3D, E, H, I). These data 
suggest that peripheral B cells that are recruited into the TME of lung metastases can be educated 
and programmed by tumor cells into a tumor invasion-promoting phenotype. Moreover, because 
our co-cultured system only contained lung metastasis tumor cells and isolated B cells, the results 
suggest that this tumor invasion-promoting mechanism does not require other intermediate cells 
types or signaling found in the TME, and that tumor-educated B cells can independently and 











Figure 4-3: Lung and blood B220+ B cells from TNBC tumor-bearing mice enhance the 
invasion of lung metastasis-derived organoids  
(A) Schematic depicting the generation of lung metastasis-derived organoids, the co-culture 
process, and the 3D invasion assay workflow.  Lung metastasis-derived organoids were generated 
by harvesting lungs with macroscopic metastatic lesions from 4T1 and LM3 orthotopic metastasis 
models and subjecting them to mechanical and enzymatic dissociation before embedding into a 
Matrigel matrix. B220+ B cells were isolated from the metastatic lungs of 4T1 and LM3 orthotopic 
metastasis models using flow cytometry and added into the Matrigel matrix for co-culture with 
lung metastasis-derived organoids. Organoids were imaged at 0, 48, and 96 hours. (B-E) 
Representative images taken at 48 (left) and 96 (right) hours post-plating of 4T1 (B, D) and LM3 
(C, E) lung metastasis-derived organoids as organoids alone (top) or co-cultured (bottom) with 
B220+ B cells isolated from the lungs (B, C) or peripheral blood (D, E) of 4T1 (B, D) or LM3 (C, 
E) orthotopic metastasis models. Scale bars represent 50μm. (F-I) Violin plots depicting the 
invasion of 4T1 (F, H) and LM3 (G, I) lung metastasis-derived organoids as organoids alone and 
co-cultured with B220+ B cells isolated from the lungs (F, G) or peripheral blood (H, I) of 4T1 
(F, H) and LM3 (G, I) orthotopic metastasis models. Invasion is calculated as a measure of fold 
change of organoid form factor from 48 to 96 hours. n = a minimum of 9 wells for 4T1 organoid 
alone controls. n = 3 mice for 4T1 orthotopic metastasis model lung-isolated B220+ B cells. n = 1 
mouse for LM3 orthotopic model lung-isolated B cells. n = 3 mice for 4T1 and LM3 orthotopic 
metastasis models blood-isolated B220+ B cells.  n = 2-3 wells were plated for each co-culture of 
organoids and isolated B220+ B cells. Data is shown as the median with the violin depicting all 




4.5 B220+ B cells isolated from the lungs of triple-negative breast cancer mouse 
models promotes the migration of TNBC cell lines 
 In addition to invasion, invasive leader tumor cells at invading fronts also undergo 
collective migration through the ECM and host tissue.242 To determine whether B220+ B cells can 
promote tumor cell migration, we performed a transwell migration assay using the 4T1 cell line to 
compare the migratory ability of tumor cells co-cultured with B220+ B cells to tumor cells alone. 
Tumor cells were serum-starved in serum-low media overnight and co-cultured tumor cells were 
co-cultured with 5x104 B220+ B cells, isolated from 4T1 orthotopic metastasis models, suspended 
in a 0.4μm membrane transwell insert that restricts cell crossing, but not the exchange of soluble 
secreted factors. Transwell inserts were removed and Celltracker green-labeled tumor cells were 
resuspended in serum-low media in 3μm membrane transwell inserts and placed into wells 
containing growth medium to facilitate tumor cell migration to the basal side of the membrane 
(Figure 3D). Imaging and quantitative analysis of total fully migrated tumor cells on the basal 
membrane showed that significantly more tumor cells co-cultured with B220+ B cells had fully 
migrated to through the limited-permeability membrane compared to non co-cultured tumor cells 
(Figure 3E, F). These data further show that B220+ B cells isolated from TNBC tumor-bearing 
mice not only promote the invasion, but also migration of tumor cells in vitro. Interestingly, the 
assay results suggests that the signaling mechanism mediating the invasion and migration of tumor 
cells relies on secreted factors, due to the transwell insert keeping the tumor cells and B cells 
physically apart during the co-culture process. Further studies are needed to identify the tumor and 







Figure 4-4: Lung B220+ B cells isolated triple-negative breast cancer mouse models promotes 
the migration of TNBC cell lines 
(A) Schematic of transwell migration assay workflow. 4T1 tumor cells were serum-starved 
overnight in serum-low media without (top) or with (bottom) B220+ B cells sorted from the lungs 
of 4T1 orthotopic metastasis models in a transwell insert with a semi-permeable 0.4μm membrane 
containing B cell media. Inserts were removed and tumor cells were labeled with Celltracker Green 
at 5μM for 30min, trypsinized, and resuspended in a transwell insert containing serum-low 
medium with a 3μm limited-permeability membrane. Transwells were placed into wells containing 
growth medium and incubated for 5 hours to allow tumor cells migrate through the limited 
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permeability membrane. Membrane were fixed paraformaldehyde, cells on the apical side were 
scraped off, and the membrane were excised and mounted with DAPI-containing mounting 
medium onto slides with basal-side up. Total migrated tumor cells on the basal side were imaged 
and counted for each transwell membrane. (B) Representative images of a 10x magnification field 
of view of fully migrated 4T1 tumor cells on the basal side of the membrane from 4T1 cells alone 
(left) and co-cultured (right) with B220+ B cells isolated from the lungs of 4T1 orthotopic 
metastasis models. Images are representative of total fully migrated 4T1 tumor cell counts on each 
membrane. Scale bars represent 50μm. (C) Bar graphs representing the total number of fully 
migrated 4T1 tumor cells on the basal side of the membrane from 4T1 cells alone and co-cultured 
with B220+ B cells isolated from the lungs of 4T1 orthotopic metastasis models. n = 4 tumor cell-
alone controls. n = 3 mice for 4T1 orthotopic metastasis model lung-isolated B220+ B cells. n = 1-
3 wells per mouse for co-cultured 4T1 cells. Data is expressed as mean + the standard error of the 
mean and p-values were determined by the two-tailed, unpaired Student’s t-test. ** p<0.01 
 
4.6 B cell-deficient mice show reduced invasive fronts and micrometastases during 
early metastatic disease 
 We further analyzed B220-stained lung sections from the 4T1 orthotopic metastasis model 
for association between the 1) the density of metastasis-infiltrating B cells per surface area of each 
metastasis and 2) number of tumor cells per metastasis and the respective proportion of metastasis-
infiltrating B cells. Quantitative histological analysis revealed that micrometastases (1-50 tumor 
cells) and medium-metastases (51-100 tumor cells) contained increased proportions of B cells to 









Figure 4-5: B cell density is elevated in smaller metastases compared to larger metastases 
(A) Dot plot depicting the density of lung metastasis-infiltrating B220+ B cells per metastasis 
surface area to the surface area of matching metastases. (B) Bar graphs depicting metastasis-
infiltrating B cells as a proportion of total tumor cells from micro- (1-50 tumor cells), medium- 
(51-100 tumor cells), and macrometastases (>100 tumor cells) from 4T1 orthotopic metastasis 
models. (C) Representative images of lung sections containing micro (left), medium (center), and 
macrometastases (right) from 4T1 orthotopic metastasis models taken at 3 weeks post tumor cell 
injection and immunostained using antibodies against B220 (green). Cell nuclei are stained with 
DAPI (blue). The edge of lung metastases are outlined by the dotted white line. Scale bars represent 
50μm. n = 6 for B 4T1 orthotopic metastasis models. p-values were determined by the two-tailed, 
unpaired Student’s t-test. n.s. not significant, ** p<0.01, **** p<0.0001 
 
 To evaluate the effects of metastasis-infiltrating B cells on early lung metastasis 
development and to validate our in vitro findings in vivo, we generated 4T1 orthotopic metastasis 
models using syngeneic immunocompetent B cell-proficient (B-proficient) BALB/cJ and B cell-
deficient Igh-Jtm1Cgn (B-deficient) BALB/c background mice (Figure 4-6A). These mice were 
harvested at the early metastatic timepoint of 15 days, which is when metastatic nodules first begin 
forming in the lungs of the 4T1 orthotopic metastasis model (Figure 4-6A). Routine tumor 
measurements determined that there was no significant difference in the growth of primary tumors 
between B-proficient and B-deficient 4T1 orthotopic metastasis models during at 15 days post 
tumor cell injection (Figure 4-6B). Interestingly, initial H&E stains of metastatic lungs sections 
suggested that B-deficient mice may exhibit reduced formation of lung metastases (Figure 4-6C). 
To confirm that the lack of B cells impairs the ability of 4T1 tumors to form lung metastases 
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through a reduction in the invasive ability of tumor cells in B-deficient mice, we stained five lung 
sections taken at >20μm intervals from B-proficient and B-deficient orthotopic metastasis models 
for cytokeratin-14 (K14) (Figure 4-6F). Studies from the Ewald lab reported that K14 is a marker 
for invasive leader cells located at the invasive fronts of BC primary tumors, lung metastases, and 
organoids.239 Quantification of the average number of metastatic nodules per lung from 5 lung 
sections sectioned at >20μm intervals from each mouse showed that B-deficient 4T1 orthotopic 
metastasis models had significantly reduced lung metastases, suggesting that the lack of B cells 
impaired metastatic colonization of the lung (Figure 4-6D). In line with our previous findings that 
metastasis-infiltrating B cell proportions were higher in smaller micrometastases, we stratified 
each lung metastasis from B-proficient and B-deficient 4T1 orthotopic metastasis models into 
micro, medium-, and macrometastases and found that B-deficient mice had a significantly lower 
number of micrometastases compared to larger metastases (Figure 4-6E).  
 Based on our data that showed that B cells can promote the invasion and migration of tumor 
cells in vitro, we analyzed the proportion of K14+ tumor cells to total tumor cells in each lung 
metastasis as a measurement of the number of invasive leader cells and invasive fronts. In line 
with our in vitro assay results, we found that the lung metastases from B-deficient mice had 
significantly reduced proportions of K14+ tumor cells, which is indicative of a reduction in the 
number of invasive leader cells and invasive fronts (Figure 4-6F, G). Taken together, our in vivo 
data suggests that B cells promote the development of invasive fronts and invasive leaders cells in 







Figure 4-6: B cell-deficient mice show reduced invasive fronts and micrometastases in early 
orthotopic metastatic disease 
(A) Schematic depicting the generation of 4T1 orthotopic early metastasis models through 
injection of 5x105 4T1 tumor cells into the fourth mammary gland of 6- to 8-week old female 
syngeneic BALB/cJ (B-proficient, top) and B cell-deficient Igh-Jtm1Cgn (B-deficient, bottom) 
mice with a BALB/c background. Mice were sacrificed and lungs were collected at the early 
metastatic timepoint of 15 days post injection. (B) Tumor growth in B-proficient and B deficient 
4T1 orthotopic early metastasis models. (C) Representative images of lung sections from 4T1 B-
proficient (left) and B-deficient (right) orthotopic early metastasis models taken at 15 days post 
tumor-cell injection and stained with hematoxylin and eosin (H&E). Scale bars represents 50μm. 
(D) Bar graphs depicting the average number of lung metastases per lung from 5 lung sections 
sectioned at >20μm intervals from B-proficient and B-deficient 4T1 orthotopic early metastasis 
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models. (E) Bar graphs depicting the average number of lung micro- (1-50 tumor cells), 
medium- (51-100 tumor cells), and macrometastases (>100 tumor cells) per lung from 5 lung 
sections sectioned at >20μm intervals from B-proficient and B-deficient 4T1 orthotopic early 
metastasis models. (G, H) Representative images of lung sections from B-proficient (left) and B-
deficient (right) 4T1 orthotopic early metastasis models taken at 15 days post tumor-cell 
injection and immunostained using antibodies against K14 for invasive margin tumor cells (G). 
Scale bars represent 50µm. Bar graphs depicting the number of K14+ invasive margin tumor 
cells as a proportion of total tumor cells from each lung metastasis from B-proficient and B-
deficient 4T1 orthotopic metastasis models (H). n = 6-7 mice for B-proficient 4T1 orthotopic 
metastasis models. n = 4 mice for B-deficient 4T1 orthotopic metastasis models. n.s. not 
significant, * p<0.05, ** p<0.01 
 
4.7 B cells are associated with upregulated tumor cell expression of phosphorylated-
mTOR (Ser2448) 
 To determine upregulated invasion-associated pathways, we performed 
immunohistochemical staining of metastatic lungs sections from 4T1 B-proficient and B-
deficient orthotopic early metastasis models for markers of growth and invasion pathways. 
Among these pathways, quantitative analysis revealed that that the lung metastases from B-
deficient mice had significantly reduced proportions of p-mTOR+ tumor cells compared to B-
proficient mice (Figure 4-7A, B). p-mTOR is constitutively activated and through activation of 
downstream pathways, has been shown to promote the invasion of TNBC cells; and its 
expression is associated with tumor cells at invasive fronts and is elevated in metastases when 
compared to primary tumors.243-248 To further clinically validate these findings, we stained 
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human TNBC patients, with high or low TIB density determined in a blinded pathological 
analysis by an independent pathologist, for p-mTOR (Figure 4-7C). Scoring of lung metastases 
for high or low p-mTOR expression revealed that TNBC patient lung metastases with high TIBs 
were significantly correlated with high p-mTOR-tumor cell expression compared to TNBC 
patients with low TIBs (Figure 4-7D). Taken altogether, our in vivo and clinical data suggests 
that B cells promote the phosphorylation and activation of mTOR at Ser2448 to promote the 




Figure 4-7: B cells are associated with upregulated tumor cell expression of 
phosphorylated-mTOR 
(A, B) Representative images (A) of lung sections from B-proficient (left) and B-deficient (right) 
4T1 orthotopic early metastasis models taken at 15 days post tumor-cell injection and 
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immunostained using antibodies against p-mTOR (Ser2448). Scale bars represent 50µm. Bar 
graphs (B) depicting the number of p-mTOR+ tumor cells as a proportion of total tumor cells 
from each lung metastasis from B-proficient and B-deficient 4T1 orthotopic early metastasis 
models. n = 7 mice for B-proficient 4T1 orthotopic metastasis models. n = 4 mice for B-deficient 
4T1 orthotopic metastasis models. (C-D) Representative images (C) of lung sections with high 
(left) and low (right) tumor-infiltrating B cell (TIB) density from human triple-negative breast 
cancer patients immunostained with antibodies against p-mTOR (Ser2448). Scale bars represent 
100µm. Bar graphs (D) depicting blinded scoring of p-mTOR (Ser2448)-stained lung metastases 
as high or low p-mTOR expression from TIB high and low human triple-negative breast cancer 
patients. n = 8 TIB high triple-negative breast cancer patients. n = 7 TIB low triple-negative 
breast cancer patients. In panel D, data is expressed as the number of triple-negative breast 
cancer patients and the p-value was determined using Pearson’s chi-squared test. In panel B, data 
is expressed as mean + the standard error of the mean and p-values were determined by the two-
tailed, unpaired Student’s t-test. * p<0.05  
 
4.8 Discussion 
The challenges of managing TNBC lies in the lack of effective targeted treatments and the 
reduction of efficacy in available immunotherapies in metastatic disease. The limited efficacy of 
treatments for mTNBC suggests that the discovery of novel tumor-promoting mechanisms and 
revaluation of overlooked cell types is urgently needed. Although B cells have generally been 
overlooked in tumor immunology due to their canonically accepted role in pro-inflammatory anti-
tumor function as APCs or antigen-secreting PCs, there is growing evidence that B cells can 
function in tumor-promoting roles as well. The discovery of Bregs in the 1970’s, which mediate 
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the immunosuppression of anti-tumor responses and T cell function, revealed that specific B cell 
subsets can function in tumor-promoting roles.249,250 Although studies elucidating the tumor-
promoting roles of B cells remain marginal compared to those on myeloid or T cells, there is 
growing evidence that  prognostic impact and anti- or pro- tumor function of B cells can be 
dependent on 1) spatial distribution (TLS-B, LC-B, or TIBs) and localization, 2) B cell subtype, 
such as Bregs and PCs, and 3) their polarization and function.  
 
The mTOR pathway 
The elucidation of the mammalian target of rapamycin (mTOR) was the culmination of 
over three decades of research. In 1964, Ayerst Research Laboratories discovered and isolated an 
anti-fungal macrolide antibiotic from the soil bacterium, Strepomyces hygroscopicus, and named 
it “rapamycin” after the island where the bacterium was discovered: Rapa Nui, or Easter Island.251 
Initial studies on rapamycin revealed several indications against tumors and roles in 
immunosuppression, although it’s specific mechanism of action remained unknown. In 1990 and 
1994, it was finally revealed that rapamycin forms a complex with prolyl-isomerase FKBP12, 
which then binds to mTOR to inhibit G1 cell-cycle progression and proliferation.252,253 Subsequent 
studies on mTOR have further revealed its role as a critical node that integrates with many major 
and minor signaling pathways to function as a master regulator of cell growth and metabolism.254  
mTOR is characterized as a 289-kDa serine/threonine protein kinase belonging to the PI3K 
protein kinase (PIKK) family and is the catalytic subunit of mTOR complexes 1 and 2 
(mTORC1/2) through binding with regulatory-associated protein of mTOR (RAPTOR) and 
rapamycin-insensitive companion of mTOR (RICTOR) scaffolding proteins, respectively.254 
mTORC1 functions as a regulator that integrates upstream signaling, nutritional, and stress 
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information to promote downstream biosynthesis, cell metabolism and catabolism, autophagy, and 
cell growth through phosphorylation of downstream effectors, such as ribosomal p70 S6 kinase 
(p70S6K) and eukaryotic translation initiation factor 4E (4E-BP1). Phosphorylation by mTORC1 
at Thr389 activates p70S6K, which then upregulates protein and nucleotide synthesis. 
Phosphorylation inhibits 4E-BP1, which is a negative regulator of 5’ cap-dependent mRNA 
translation, to promote protein synthesis. Specifically, extracellular positive upstream regulators 
of mTORC1 signaling include ample supplies of oxygen, amino acids, lipids, and 
growth/mitogen/cytokine factor signaling (such as TGF-β, TNF-α, insulin, and IGF) which 
activates RAS/ERK, PI3K, AKT, and IKKβ signaling pathways that inhibit TSC, a negative 
regulator “brake” for mTORC1 activity, through phosphorylation of its TSC2 subunit. TSC 
functions as a GTPase-activating protein that inhibits Rag and Rheb GTPase G proteins by 
catalyzing their active GTP-bound states to inactive GDP-bound states. Activated GTP-bound 
RAG conditionally recruits and anchors mTORC1 to lysosomes in the presence of abundant 
intracellular amino acids, glucose, and other nutrients. Activated GTP-bound Rheb then 
conditionally activates the RAG-bound mTORC1 upon inhibition of TSC from upstream signaling 
pathways. Conversely, nutrient deprivation, energetic stress, hypoxia, and the p53/PTEN-mediated 
DNA damage pathways activate TSC to inhibit mTORC1 activity.254 
mTORC2 integrates upstream information from signaling pathways to control downstream 
cytoskeleton remodeling and cell survival and proliferation through activation and 
phosphorylation of AKT, protein kinase  C α, focal adhesion proteins and small GTPase Rho and 
Rac proteins.254,255 mTORC2 is primarily activated by growth factor and insulin signaling through 
Ras, AKT, and PI3K signaling pathways and inhibited in the absence of insulin. Furthermore, 
activated mTORC1 forms a negative-feedback loop to downregulate the insulin/PI3K/AKT 
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pathway to inhibit mTORC2. Interestingly, mTORC1 is strongly inhibited even by acute 
rapamycin treatment while inhibition of mTORC2 requires prolonged chronic rapamycin 
treatment.254 
mTOR, as a serine/threonine kinase, contains a multitude of phosphorylation sites that 
promotes its activation: mTOCR1 only (Ser1415, Ser2159, Thr2164, and Thr2446); mTORC1/2 
(Ser1261, Ser2448, and Ser2481).256 Specifically, phosphorylation of mTOR Ser2448 (from here 
on, abbreviated as p-mTOR) renders mTOR constitutively active and is implicated in a multitude 
of diseases. p-mTOR phosphorylation is mediated by a positive feedback loop in which activated 
mTOR phosphorylates and activates S70S6K, which then phosphorylates mTOR at Ser2448.257 
Therefore, p-mTOR functions as a positive feedback loop upon initial activation of mTOR. 
 
p-mTOR in triple-negative breast cancer and invasion 
Because of its integration with cellular pathways that are often mutated or dysregulated in 
cancer cells and its central role in regulating cellular metabolism, cytoskeleton remodeling, 
growth, survival, and proliferation, mTOR activity is frequently upregulated, phosphorylated, and 
has a broad range of implications in many cancer types, including TNBC. Interestingly, p-mTOR 
expression was found to be not only upregulated in cancer tissues, but invading leader cells (lung 
cancer, CRC and PDAC) and metastases (renal cell carcinoma and hepatocellular carcinoma) had 
the higher p-mTOR expression compared to primary tumors, suggesting that p-mTOR and it’s 
downstream pathways play an important functional role in metastasis and invasion.244 Clinical 
studies on human BC patients have revealed that AKT,  mTOR, p-mTOR, and downstream p-
p70S6K and p-4E-BP1 pathways are aberrantly activated upon transition from normal breast 
epithelium to ductal carcinoma in situ and invasive BC.258,259 Furthermore the studies found that 
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72% of TNBC tumors were p-mTOR+ and patients with p-mTOR+ or mTOR overexpression BC, 
including TNBC, had significantly worse overall and recurrence-free survival (RFS).258,260 
Interestingly, p-mTOR, p-p70S6K, and p-4E-BP1 were found to be associated with HER2-positive 
BCs and in vitro transwell studies have shown that overexpressing HER2 in HER- BC cell lines, 
435.eB (TNBC) and MCF7.eB (luminal), had higher p-mTOR and p-4E-BP1 expression and 
increased invasion compared to their parental HER2- cell lines, MDA-MB-435 and MCF7.243 
Another clinical study revealed the high mTOR and p-mTOR expression is significantly associated 
with TNBCs compared to other BC subtypes.261 Furthermore, another study revealed through 
active kinase and pharmacological profiling that mTOR inhibitors demonstrated elevated efficacy 
in inhibiting the proliferation of TNBC cell lines and tumor growth in TNBC mouse models.262  
 Indeed, studies have uncovered numerous mechanisms on how mTORC1 activity and 
downstream mediators can promote cell migration and invasion. Rapamycin treatment was found 
to inhibit the migration of IGF-stimulated TNBC MDA-MB-468 cell lines (along with other cancer 
cell lines) through inhibition of mTORC1 mediated phosphorylation of p70S6K and 4E-BP1.263 
Additional studies showed that activated mTOR, p60S6K, and AKT are localized to the actin arc 
at the leading edge of actively migrating Swiss 3T3 cells and treatment with rapamycin blocked 
actin arc formation.255 Furthermore, mTORC1 activation was found to induce the expression of 
FSCN1, an actin-bundling protein that promotes migration and metastasis in cancers, in CRC HT-
29 cells and treatment of HT-29 cells with mTOR inhibitors, everolimus or rapamycin, inhibited 
mTORC1 activation, suppressed FSCN1 expression, and reduced tumor cell motility and 
proliferation.264,265 Another study revealed that TGF-β/SMAD signaling-induced mTOR 
activation and phosphorylation of p70S6K and 4E-BP1 mediates EMT and increased cell size in 
the NMugMG murine mammary epithelial cell line.266 p70S6K has also been shown to promote 
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phosphorylation of focal adhesion proteins, such as FAK, and remodeling of F-actin for the 
formation of lamellipodia to facilitate invasion of multiple cancer cell lines.267 
 Another potential mechanism of mTOR-mediated promotion of TNBC invasion is through 
hypoxia-inducible factor 1 (HIF1α). Although HIF1α expression can be induced independently 
from mTORC1 activity, active mTORC1 is sufficient to activate HIF1α, a transcription factor, 
through suppression of 4E-BP1 activity, which activates 5’ cap-dependent mRNA translation of 
the 5’ untranslated region of HI1Fα mRNA.245 HIF1α is found to be hyperactivated in multiple 
basal-like tumors, including TNBC with the highest expression in invasive leader cells, and is 
associated with poor prognosis, reduced RFS, EMT (transcriptional control of E-cadherin, SNAIL, 
ZEB1, and TWIST), angiogenesis (upregulation of VEGFA) radio and chemotherapy resistance, 
increased invasion (transcriptional activation of CSRP2, an invadopodia actin bundling protein 
that induces the formation of invadopodia), and metastasis.245-248 In addition to cell-intrinsic 
promotion of motility, activation of mTOR and downstream effectors, including HIF1α) has also 
been shown to promote the expression of ECM remodeling proteins, such as MMP-2/9 and uPA, 
which function in breaking down ECM components to help facilitate cell invasion through the 
ECM.255 A recent study also revealed that treatment of TNBC MDA-MB-231 and MCF7 cell lines 
with Berbamine downregulated the PI3K/AKT/mTOR pathway and reduced tumor cell invasion 
in vitro.268 Another study showed that knockdown of TSC in the TSCKO MMTV-PyMT GEMM 
of BC hyperactivated mTORC1, which induced AKT signaling and resulted in accelerated tumor 
growth, and lung metastasis in vivo and increased in vitro invasion using transwell invasion 
assays.269  
Although less studied than mTORC1, mTORC2 has also been shown to promote cell 
migration and invasion through regulation of downstream Rho/Rac-GTPases that in turn, regulate 
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actin cytoskeleton restructuring. Knockdown of mTOR or RICTOR in HEK293 or 3T3 fibroblast 
cells was found to inhibit the polymerization of actin, the formation of lamellipodia, and cell 
spreading and migration.270 Furthermore, inhibition of RICTOR in several BC and TNBC cell 
lines, MDA-MB-231, MDA-MB-468, BT549 and MCF7, inhibited TGF-β-mediated mTOR-
RICTOR-ILK (integrin linked kinase) function and blocked EMT and invasion.271 Taken together, 
these studies indicate that activated mTOR or p-mTOR and downstream effectors are integrally 
linked to tumor cell motility and invasion.263   
 
Key findings 
 Here, we present evidence in both human mTNBC patients and multiple murine TNBC 
orthotopic and experimental metastasis that there is a population of B220+ B cells that are recruited 
specifically to the invasive margin of TNBC lung metastases. Furthermore, we show that lung B 
cells from TNBC mouse models directly promote the invasion and migration of TNBC lung 
metastasis-derived organoids and cell lines, respectively, in co-culture. Interestingly, because 
peripheral B cells from TNBC mouse models also enhanced lung metastasis-organoid invasion in 
co-culture and that B cells kept in proximity, but not directly touching, to tumor cells still enhanced 
tumor cell migration, the data suggests that B cells can be “educated” via a paracrine signaling 
mechanism by tumor cells to promote tumor cell motility through secreted factors. It is important 
to distinguish that promotion of invasion within a 3D microenvironment, such as a Matrigel matrix, 
could also be caused by ECM degradation and remodeling, as has been shown with tumor-
associated myeloid cells.81 However, the transwell migration assay did not utilize an ECM matrix 
to evaluate migration, which suggests that the B cell-secreted factor that promotes tumor cell 
invasion and migration directly affects the tumor cell itself and not it’s microenvironment. 
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Furthermore, we validated in vivo that B-deficient mice exhibit impaired formation of lung 
metastasis along with a concomitant reduction in the number of K14+ invasive leader tumor cells 
and p-mTOR+ tumor cells in their lung metastases during early metastatic progression. This 
suggests that a B cell-derived factor induces the phosphorylation of p-mTOR at Ser2448, which 
can promote tumor cell invasion through downstream pathways and that while B cell-mediated 
invasion promotion through p-mTOR may not be required for the formation of lung metastasis, 
the mechanism does play a role in promoting the invasion and development of TNBC lung 
metastases during early metastatic colonization. This data is consistent with studies showing that 
1) mTOR/p-mTOR expression is highest in invading leader tumor cells and metastases244, 2) 
patients with p-mTOR+ TNBC have significantly poorer RFS258,260, and 3) that the mTOR/p-
mTOR pathways can promote invasion through a variety of downstream mechanisms, such as 
induction of EMT266 and action/cytoskeleton remodeling and formation of lamellipodia and 
invadopodia.246,255 
 Interestingly, metastasis-infiltrating B cell density was found to highest in smaller 
micrometastases, which correlated with the observation that the reduction of lung metastases in B-
deficient was primarily in micrometastases. Because mTOR lies at the nexus of many metabolic, 
nutrition, and growth factor signaling pathways and the phosphorylation of mTOR at Ser2448 is 
mediated in a positive feedback loop from downstream p70S6K, it is possible the B-cell mediated 
p-mTOR and downstream invasion-promoting mechanisms may be redundant with other non-
tumor cells in the TME. In this scenario, B cells are not required for the formation of lung 
metastases, but instead provide additional tumor-promoting support to micrometastases through 
p-mTOR until other tumor-promoting cells are recruited into the TME with functionally redundant 
roles in mTOR phosphorylation and invasion-promotion. Indeed, while there are many B cell-
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secreted factors that can activate mTOR (IL-2272, IL-4273, IL-6274, IL-12275, TGF-β276, and TNF-
α277), these factors can also be secreted by other cell types in the TME. Additionally, mTOR can 
also be activated by a host of other non B cell-secreted factors (IL-1278, IL-13279, IL-27280, IGF-
1263,281, VEGF282, and PDGF283). Regardless, taken together, our findings suggest that the putative 
p-mTOR-mediated invasion-promotion of tumor cells by B cells on small micrometastases may 
present a novel therapeutic option for advanced or mTNBC patients and TNBC patients with RCB. 
Therapeutic blockade of either B cell recruitment into the TME or mTOR/p-mTOR could delay or 
prevent small micrometastases in patients with RCB from relapsing. 
 
Study limitations 
There are several limitations to our findings. The first is the phenotyping of metastasis-
infiltrating tumor-educated B cells. Another is elucidating the signaling mechanism mediating 
tumor cell-B cell crosstalk and coupling the paracrine signaling axis to p-mTOR and downstream 
mediators of invasion. Furthermore, in vitro and in vivo functional assays using mTOR inhibitors 
or knockdown of mTOR-associated components will need to be performed to validate the role of 
p-mTOR in mediating invasion and lung metastasis. The strategy and experimental designs for 
addressing these limitations are described in the following sections. 
However, there is a study that, at a glance, may contradict our findings. Wortman and 
colleagues recently revealed in a retrospective clinical study that increased number of spatially 
dispersed CD20+ B cells as either single TIBs or LC-Bs within tumor nests in primary tumors are 
associated with improved RFS and good prognosis in TNBC patients.93 This suggests that TIBs in 
primary TNBC tumors function in an anti-tumor role. However, the study has several limitations 
as well. Firstly, they did not assess the phenotype or function of these TIBs. Second, the study 
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analyzed a small cohort of 36 TNBC patients with differing disease characteristics and non-
uniform treatment regiments.93 Therefore, their findings that associate pre-treatment TIBs to post-
treatment RFS can be confounded by these factors. There are also many other factors that de-
couple their findings from our study. Firstly, Wortman and colleagues did not analyze TIBs at the 
invasive margin between the primary tumor and breast tissue. Although they did differentiate 
stromal TIBs from tumor nest TIBs, these TIBs are still intratumoral TIBs and not located at the 
invasive margin between the primary tumor and breast tissue. Given that spatial localization can 
determine the function and phenotype of immune cells and that p-mTOR expression is higher in 
tumor cells at the invasive margin, it is plausible that the invasive margin-localized TIBs in our 
study are functionally distinct from the TIBs analyzed.244 Furthermore, tumor cells between 
primary tumors and their metastases are distinct, as tumor cells need to adopt organ-specific 
programs to form metastatic colonies.18 These organ-specific programs could alter the intrinsic 
properties of metastasized tumor cells, which can affect their interaction and signaling with 
immune cells. Indeed, there are studies showing that immune populations, signaling pathways, and 
TME composition between matched BC primary tumors and their metastases are distinct from one 
another.71,284,285 Furthermore, we show that lung metastases can recruit B cells to their invasive 
margin independent of a primary tumor and that 4T1 B-deficient models exhibit no differences in 
primary tumor growth but impaired development of lung metastases compared B-proficient 
models. Taken together, these differences suggests that the anti-tumor TIBs proposed by Wortman 
and colleagues are functionally different from the invasion-promoting, invasive margin-localized, 
metastasis-infiltrating B cells we report in our study. One limitation to this conclusion is that we 
also report that B cells can be educated in co-culture with 4T1 cells lines to promote migration. 
However, an explanation for this discrepancy is that our co-culture assay only utilized tumor cells 
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and B cells and was devoid of other heterogenous interactions with other cell types and signaling 
pathways that may be found in the TME of primary tumors, which are distinct from metastasis-
associated TME, that may polarize B cells toward an anti-tumor function. Taken altogether, despite 
somewhat conflicting results from Wortmann and colleagues, there are many discrepancies and 
differences between their study parameters and ours, which suggests that their results need to be 
considered as separate and distinct entities that are taken in a different context.  
 
Future perspectives: Elucidating the invasion-promoting B cell-tumor cell-p-mTOR 
axis 
Further studies are needed to dissect the precise signaling mechanisms between tumor cell-
B cell crosstalk and to evaluate the efficacy of inhibitors on this invasion-promoting mechanism. 
To determine whether B cell-secreted factors activate and phosphorylate mTOR in tumor cells to 
promote invasion, RT-qPCR and immunoblots are needed to confirm the upregulated tumor cell-
phosphorylation of mTOR at Ser2448 in tumor cell-B cell co-culture. Furthermore, mTOR 
inhibitors, such as rapamycin or everolimus, can be added into tumor cell-B cell coculture to test 
if inhibition of mTOR blocks B cell-mediated tumor cell invasion promotion. To identify candidate 
B cell-secreted factors mediating mTOR activation in tumor cells, proteomic strategies, such as 
mass spectrometry, ELISA, or protein microarrays, can be utilized to test the conditioned media 
taken from tumor cells co-cultured with B cells for B cell-secreted factors known to activate or 
phosphorylate mTOR. Following this, specific inhibitors targeting candidate B cell-secreted 
factors can be evaluated and screened for using the co-culture invasion assay system. However, if 
B cell-mediated tumor cell-mTOR activation is functionally redundant to other signaling pathways 
mediated by other cell types, then it may be more strategically feasible to direct efforts into 
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inhibiting tumor-mTOR/p-mTOR or downstream targets, such as p70S6K, AKT, and HIF1α, 
mediators of EMT, and mediators of actin/cytoskeleton remodeling. The expression and function 
of these downstream targets can be evaluated through RT-qPCR or immunoblotting of tumor cells 
co-cultured with B cells and with or without treatment by mTOR inhibitors. Mediators of the B 
cell-tumor cell-mTOR invasion promoting pathway can then be validated in vivo by treating 4T1 
orthotopic early metastasis models with inhibitors targeting mTOR/p-mTOR or upstream and 
downstream effectors. 
Preclinical BC mouse models have demonstrated the efficacy of targeting 
mTOR/mTORC1/2 in a metastatic and invasion context. One study revealed that conditional 
knockout or suppression of RICTOR in HER2+ BC models using RICTORFL/FL MMTV-NIC mice 
or orthotopic and experimental metastasis models using MDA-MB-361 expressing RICTOR 
shRNA exhibited reduced lung metastasis through loss of RICTOR-dependent RAC1-mediated 
invasion.286 Other studies show that treatment of seven TNBC patient-derived xenograft mouse 
models with rapamycin resulted in 77-99% reduction in tumor growth, and inhibiting mTOR/p-
mTOR in multiple BC and TNBC cell lines and mouse models through either rapamycin alone or 
combined with MLN8237 (Aurora-A inhibitor, upstream of mTOR signaling) reduced tumor cell 
proliferation and migration in vitro and reduced tumor growth in vivo. 287,288 Although these studies 
showed there was no complete tumor regression nor analyzed the effects of mTOR inhibition on 
metastasis287,288, another study revealed that treatment of TNBC xenograft MDA-MB-231 LM2 
experimental metastasis models with everolimus significantly reduced lung metastasis.289  
There are a limited number of studies targeting mTOR using the 4T1 TNBC orthotopic 
metastasis model. One of these demonstrated that additional treatment of doxorubicin-treated 4T1 
TNBC orthotopic metastasis models with metformin further reduced tumor growth compared to 
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doxorubicin alone through inhibition of the AKT/STAT3/mTOR pathway.290 However, the study 
did not analyze the effects of metformin-associated inhibition of mTOR on lung metastasis. A 
recent study revealed that 4T1 lung metastases have elevated expression of mTORC1 compared 
to matched primary tumors and targeting mTORC1 expression via inhibiting upstream the serine 
biosynthesis pathway through targeting MCT2 (pyruvate uptake) and silencing PHGDH reduced 
primary tumor growth and the development of lung metastasis.291 The study did not analyze 
mediators of invasion downstream of mTORC1, however, it does provide an example of a 
redundant pathway in which 4T1 cells can activate mTOR to promote lung metastasis. 
Interestingly, there is one study that showed that treatment of 4T1 orthotopic metastasis models 
after surgical resection with rapamycin increased lung metastasis through rapamycin-induced 
expansion of immunosuppressive Tregs.292 However, it should also be noted that acute rapamycin 
treatment does not affect mTORC2, which studies show can also mediate tumor invasion, and 
further testing with pan-mTORC1/2 inhibitors, such as AZD2014, should be utilized. Furthermore, 
there are other studies that show that 1) combination treatment using the PI3K/mTOR inhibitor, 
gedatolisib, with ICIs significantly reduced tumor growth and increased tumor-infiltrating CTLs 
in luminal/triple-negative-like PyMT BC orthotopic mouse models; and 2) combination treatment 
using the mTORC1/2 inhibitor, AZD2014, with ICIs reduced tumor-infiltrating Tregs and reduced 
tumor growth and improved survival in MC38 and CT-26 mouse models of colon cancer.293 These 
studies suggest that mTOR-inhibition-induced immunosuppression can be abrogated with the 
application of combination treatment.293  
However, another complication to mTOR inhibition is the acquisition of resistance. Mateo 
and colleagues showed that prolonged inhibition of mTOR in BC MCF7 and TNBC HCC1937 
cell lines and 4T1 orthotopic models with everolimus induced a feedback mechanism that 
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upregulated the expression of EVI1 and SOX9.289  This resulted in the upregulation of upstream 
promoters of mTOR activity, RAPTOR and RHEB, and FSCN1, a downstream mTOR-associated 
mediator of actin remodeling associated with invasion and metastasis, and no reduction in lung 
metastasis.289 Furthermore, depletion of EVI1, SOX9, or FSCN1 in 4T1 or MDA-MB-231 LM2 
was found to significantly impair the formation lung metastasis in vivo.289 Other mechanisms of 
mTOR inhibitor resistance include the emergence and selection for clonal populations that have 
acquired mutations in mTOR kinase domains or mTOR-associated FKBP12.294 This suggests that 
in addition to mTOR-induced immunosuppression; acquisition of resistance is another 
complication associated with monotreatment with mTOR inhibitors. However, mTOR inhibition 
used in a neoadjuvant setting to delay or prevent relapse from RCB may still prove to be 
efficacious. Furthermore, third generation mTOR inhibitors, such as rapalink-1, a conjugate drug 
of two mTOR inhibitors, rapamycin and MLN0128, have been shown to overcome mTOR 
resistance mutations in mTOR-resistant MCF-7 BC cell lines treated with first and second 
generation mTOR inhibitors.294 Additional studies have shown that rapalink-1 is well tolerated and 
demonstrates enhanced in vitro and in vivo tumor-suppressive effects on multiple sunitinib-(a 
receptor tyrosine kinase inhibitor) resistant cell lines and mouse models of renal cell carcinoma 
compared to temosirolimus.295 Taken together, these studies suggest that mTOR inhibition, in 
combination with other anti-tumor agents or usage of improved third generation mTOR inhibitors, 
can be utilized in preclinical mouse models of TNBC to investigate the invasion-promoting 
mechanisms of the B cell-tumor cell-p-mTOR reported here and to evaluate their efficacy in a 
neoadjuvant setting to delay relapse from RCB in surgically-resected models.  
 
Future perspectives: Targeting mTOR or B cells in breast cancer patients 
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Currently, only everolimus, a second generation mTOR kinase inhibitor, is approved in 
combination with exemestane, an aromatase inhibitor, for the treatment BC patients, albeit for 
advanced HR+ HER2- BC patients. 296,297 The combination treatment was found to extend mPFS 
and mOS to 6.9 months and 10.6 months compared to 2.8 months and 4.1 months, respectively, 
with placebo and exemestane treatment.296,297 The phase II clinical trial, NCT01127763, found that 
everolimus in combination with carboplatin in TNBC resulted in a clinical benefit rate of 36% 
with mPFS and OS of 3 months and 16.6 months.298 However, another mTOR inhibitor, 
temsirolimus, exhibited no response from TNBC patients in the phase II clinical 
trial,NCT01111825.299 Other clinical trials are currently testing other mTOR inhibitors, such as 
AZD2014300,301 and PQR309302, which could be additional promising agents to test in our models. 
Interestingly, studies have shown that monotherapy with mTOR inhibitors resulted in acquisition 
of resistance and no clinical benefit through elevated phosphorylated-AKT due to a negative 
feedback loop, thusly necessitating that mTOR inhibitors be combined with other 
chemotherapeutic agents.303 This is consistent with our findings that B cell-deficient mice, while 
exhibiting reduced p-mTOR expression and invasive leader cells in their lung metastases, were 
still able to develop lung metastasis. However, while mTOR inhibitiors may not be efficacious as 
monotherapies, they may be still provide clinical benefit when combined with other anti-cancer 
agents and our findings suggest that inhibition of mTOR may be useful in a neoadjuvant setting to 
treat TNBC patients with RCB to prevent or delay relapse. This strategy can be tested in preclinical 
TNBC orthotopic mouse models through timed surgical resection of the primary tumor and 




Another therapeutic strategy may be to target metastasis-infiltrating B cells. Although B-
deficient mice show impaired formation of TNBC lung metastasis, it may not be viable to deplete 
all B cell subsets when evaluating therapeutic options as they can deplete anti-tumor B cells in 
addition to tumor-promoting B cell subsets. Furthermore, studies have shown that treatment of 
preclinical BC EMT6 and 4T1.2 mouse models with an anti-CD20 antibody depleted most B cell 
populations, but enriched for CD20low and CD19+ Bregs, which resulted in increased Treg and 
enhanced tumor growth and lung metastasis.125,126 Currently, there are no approved B cell 
immunotherapies for the treatment of TNBC patients. The BTK inhibitor, Ibruitinib, which targets 
B cell BCR signaling and inhibits MDSC formation, had shown promising results in preclinical 
mouse models of TNBC, but poor ORR (3%) in mTNBC patients.85-88 These findings suggest that 
specific depletion of tumor-promoting B cell subsets may be a superior strategy compared to pan-
B cell depletion.  
 
Future perspectives: Elucidating the phenotype of tumor-infiltrating B cells 
However, there are significant challenges in elucidating the specific subset of metastasis-
infiltrating, tumor-educated B cells. Some studies have shown that co-culturing B cells with PD-
L1hi human TNBC MDA-MB-231 or murine TNBC 4T1 and 4T1.2 cell lines induced Breg 
differentiation.120,123 However, these Bregs were found to function in an immunosuppressive role 
through secretion of IL-10 and induction of Treg differentiation.123 Furthermore, contradictory 
results from recent single-cell RNA sequencing and antigen receptor profiling of TIBs cells in 
TNBC patient tumors revealed that TNBC TIBs were predominantly mature and memory B cell 
subsets, with a lack of any significant IL10+ Breg populations.304 However, these studies were 
primarily conducted in either in vitro cell culture (former) or using primary tumor samples (latter) 
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and not using metastasis-derived cells or in a metastatic context. Further studies are needed to 
identify the phenotype or subtype of invasion-promoting metastasis-infiltrating B cells.  
 There are several challenges to anticipate when phenotyping these metastasis-infiltrating 
B cells. Firstly, if proximity and spatial localization is critical for this specific B cell phenotype, 
then flow cytometry on whole metastatic lungs may not be sensitive enough to detect such a small 
population – as non tumor-infiltrating B cells in the lungs may be the predominant population. 
Flow cytometry also would be unable to determine spatial localization and additional tissue 
preparation steps may be needed to enrich for lung metastases. One such technique would be laser 
capture microdissection techniques to isolate lung metastases, however there may issues with 
epitope degradation using fixed tissues.305 In addition, the B cells may lose their tumor-educated 
phenotype if removed from the proximity of lung metastases. Therefore, our ex vivo 3D organoid 
co-culture system may represent a useful model for the phenotyping of metastasis-infiltrating B 
cells. Taken together, our findings show that further elucidation of the phenotype of metastasis-
infiltrating B cells and targeting mTOR/p-mTOR and its downstream invasion-promoting 
pathways may provide efficacious therapeutic targets for the treatment of mTNBC patients and 



































Stage IV metastatic cancers generally represent an incurable and terminal illness that is causative 
of about 90% of all cancer-associated mortality.4 As a cancer progresses toward and develops 
metastatic disease, interactions between tumor cells and non-tumor cells causes the release of 
soluble factors, exosomes, and metabolites that systemically and detrimentally alter host 
physiology, metabolism, and immune regulation.133 This physiological reprogramming often 
culminates in cachexia and aberrant tumor-promoting immune cell phenotypes.153 
 Our studies on metastatic PDAC- and BRCA-like TNBC-associated cachexia demonstrates 
that upregulation of muscle-cell ZIP14 expression along with concomitant increase in 
intramuscular zinc ion levels is directly correlated to the development of cachexia. This data is 
consistent with our previous findings that the ZIP14-zinc axis mediates cachexia development in 
metastatic mouse models of breast, lung, and colon cancer.171 The previous study also showed that 
muscle-cell expression of ZIP14 is induced by tumor-associated TGF-β and TNF-α.171 Taken 
together, these findings suggest that targeting either upstream mediators of muscle-cell ZIP14 
expression or ZIP14 blockade and zinc chelation strategies should be tested in preclinical 
metastatic mouse models of cachexia to determine potential strategies to prevent or treat cancer-
associated cachexia. 
 Our studies also revealed that B220+ B cells are preferentially recruited to the invasive 
margin of lung metastases from human mTNBC patients and 4T1 and LM3 metastatic mouse 
models of TNBC. We further demonstrate that B220+ B cells taken from the lungs and blood of 
mTNBC mouse models enhance the invasion of lung metastasis-derived organoids when co-
cultured together. Furthermore, B220+ B cells isolated from the lungs of mTNBC mouse models 
promoted the migration of TNBC cell lines. These findings suggest that B cell can be educated by 
crosstalk with TNBC tumor cells into a phenotype that directly promotes the tumor cell invasion 
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and migration. We validated these findings in vivo by showing that B-deficient mice exhibited 
impaired formation of lung metastases concomitant with a reduced proportion of K14+ invasive 
leader tumor cells and reduced proportion of p-mTOR+ tumor cells in their lung metastases. We 
further show that the lung metastases of triple-negative breast cancer patients with high tumor-
infiltrating B cell density exhibit increased p-mTOR expression compared to patients with low 
tumor-infiltrating B cell density. These findings suggest that B cells may induce the 
phosphorylation of mTOR in tumor cells to promote invasion. Interestingly B cell density was 
found to be highest in micrometastases, which correlated with in vivo analysis that showed that the 
reduction of lung metastases in B-deficient mice was predominantly in the number of 
micrometastases. Taken altogether, these findings suggest that further studies are needed to dissect 
the B cell-tumor cell-p-mTOR invasion-promoting signaling axis and to determine the specific 
phenotype of these metastasis-infiltrating tumor-associated B cells to identify potential therapeutic 













Materials and Methods 
Chapter 2 
Cell lines 
The Pan02 mouse pancreatic adenocarcinoma cell line was derived from a 3-
methylcholanthrene carcinogen-induced pancreatic tumor that developed in a C57CL/6 mouse and 
was purchased from the National Cancer Institute Cell Repository, MD, USA. The FC1242 mouse 
pancreatic adenocarcinoma cell line was derived from a pancreatic tumor that developed from a 
Kras+/LSL-G12D, Trp53+LSL-R172H, Pdx1Cre GEMM in the Tuveson laboratory (Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY, USA). The FC1242 cell line was procured from the Miller 
laboratory (New York University, New York, NY, USA). Pan02 and FC1242 cell lines were 
cultured in DMEM supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO, USA), and 
1% penicillin/streptomycin (Life Technologies, Carlsbad, CA, USA) and grown in a 37⁰C 
humidified incubator with 5% CO2. 
Mouse studies 
All mouse studies, experiments, and protocols were approved by The Columbia University 
Institutional Animal Care and Use Committee (IACUC) and are compliant with ethical guidelines 
and regulations from the Institute of Comparative Medicine (ICM) at Columbia University Irving 
Medical Center (CUIMC) with the IACUC-approved protocol: AAAR6450. All mice were housed 
in CUIMC’s pathogen-free barrier facility and fed on Labdiet 5053 (standard diet). Male, 8- to 9-
week old C57BL/6 and athymic nude mice were purchased from Jackson laboratory (Bar Harbor, 
ME, USA) and Envigo (Somerset, NJ, USA), respectively. C57BL/6 and athymic nude mice were 
injected with 1 x 105 murine FC1242 and Pan02 pancreatic adenocarcinoma cells, respectively, 
into arterial circulation via intra-cardiac injection. Cachexia development was assessed by mouse 
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body condition, monitored using a body-condition scoring system as previously described,306 and 
by routine measurements of body weight, hind-limb grip strength, histological and morphometric 
analysis of muscle sections, and analysis of muscle atrophy-associated molecular markers. 
Measurement of body weight and hind-limb grip strength 
 Measurements of body weight from healthy control mice and Pan02 and FC1242 
experimental metastasis models were performed weekly using a bench-top digital balance. All 
body weight measurements were normalized to the body weight on the day of tumor cell injection 
(day 0 post injection). Measurements of hind-limb grip strength were taken weekly using a grip 
strength meter (Columbus Instruments, Columbia, OH, USA). A minimum of five measurements 
were performed per mouse weekly and the mean values were calculated. The percent grip strength 
was normalized to the mean initial grip strength values (100%) on the day of tumor cell injection.   
Tissue Collection 
 Gastrocnemius and diaphragm muscles were harvested and fixed in 4% paraformaldehyde 
for 24 hours at 4⁰C or snap frozen in liquid nitrogen at stored at -80⁰C for histological analysis and 
molecular analysis, respectively. Liver and lung tissues were harvested and fixed in 4% 
paraformaldehyde for 24 hours at 4⁰C. All paraformaldehyde-fixed tissues were washed in PBS 
for an hour and stored in 70% ethanol until further histological processing and analysis. 
Histological analysis of metastases and muscle fibers 
 For histological analysis, paraformaldehyde-fixed paraffin-embedded gastrocnemius, 
diaphragm, liver, and lung tissues were sectioned at 5µm-thickness onto positive-charged slides 
and stained with hematoxylin and eosin (H&E). H&E-stained gastrocnemius and diaphragm tissue 
sections were visualized and imaged using an Eclipse Ni-U microscope (Nikon Corporation, 
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Tokyo, Japan). H&E-stained liver and lung tissue sections were visualized and imaged under a 
DM5500B microscope (Leica Microsystems, Wetzlar, Germany).  
Analysis of muscle cross-sectional area 
 Random two or three fields per H&E-stained paraformaldehyde-fixed paraffin-embedded 
5µm-thick cross-sections of gastrocnemius muscles were imaged at 20x magnification using a 
DM5500B microscope (Leica Microsystems, Wetzlar, Germany). Muscle fiber cross-sectional 
area was quantified using the drawing module in ImageJ (ImageJ software, Version 1.52h, 
National Institutes of Health, Bethesda, MD, USA) to trace individual muscle fiber boundaries. 
Muscle fiber cross-sectional areas from tumor-bearing and control mice were stratified by cross-
sectional area ranges of various sizes and the percentage of fibers in each range were calculated. 
The means of cross-sectional areas for each range were determined from replicate muscle samples.  
RT-qPCR analysis of gene expression 
 Snap frozen gastrocnemius and diaphragm muscles were minced into ~1-2mm pieces and 
15mg, representative of each sample, were taken from each muscle for total RNA extraction using 
Trizol (Life Technologies, Carlsbad, CA, USA). Muscle samples were lysed using 5mm steel 
beads (Qiagen, Hilden, Germany) and the TissueLyser II (Qiagen, Hilden, Germany) instrument. 
Samples were centrifuged at 18,000 x g for 5 min and the supernatant was isolated and processed 
using the RNeasy Mini Kit (Qiagen, Hilden, Germany) with DNase treatment while in-column, 
accounting to manufacturer’s instructions. The total purified RNA in each sample was quantified 
using a Nanodrop spectrophotometer (Thermo Fisher Scientific, Walthom, MA, USA) and 500ng 
of RNA was reverse transcribed into cDNA using the cDNA Synthesis Kit (Applied Biosystems, 
Thermo Fisher Scientific, Walthom, MA, USA). RT-qPCR was performed using 10ng of cDNA 
from each sample mixed with gene-specific primers and SYBR Green PCR master mix (Applied 
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Biosystems, Thermo Fisher Scientific, Walthom, MA, USA). Primers for Gapdh were used as an 
internal control. RT-qPCR data were analyzed on an Applied Biosystems 7500 Real Time PCR 
system (Applied Biosystems, Thermo Fisher Scientific, Walthom, MA, USA) and the fold change 
in gene expression was determined using the 2-∆DDCt method.307 RT-qPCR primer sequences used 
in this study are shown in Table S1.  
 
Table S1: Primers used for qRT-PCR analysis 
Table S1: Sequences of primers used in the study for gene expression analysis of murine Zip14, 
Trim63/MuRF1, MAFBx/Fbxo32, Fbxo31, Musa1/Fbxo30, Mt1, Mt2 and Gapdh   
 





Forward primer (5’ – 3’) 
 



































 15-20mg of each gastrocnemius muscle were sent to the Veterinary Diagnostic Laboratory 
at Michigan State University, MI, USA, for metal ion analysis. Tissues were dried overnight at 
75⁰C, digested overnight in 10x volume relative to muscle dry weight of nitric acid, and diluted in 
a 100-fold volume of water. Inductively-coupled plasma mass spectrometry (ICP-MS) (Agilent, 
Santa Clara, CA, USA) was performed for muscle sample metal ion analysis. Intramuscular metal 
ion concentration was determined using a four-point linear curve of analyte-standard response 
ratio.  
Immunohistochemical staining of ZIP14 in human muscle sections 
 Human muscle tissue sections were obtained from autopsy cases from the University of 
Nebraska Medical Center (UNMC) with approval from the Institutional Review Board (IRB). In 
brief, formalin-fixed paraffin-embedded pectoralis and diaphragm muscles from non-cachectic 
and cachectic metastatic pancreatic adenocarcinoma patients were sectioned at 5µm-thickness onto 
positive-charged glass slides. Slides were incubated at 60⁰C for an hour and rehydrated using 
Histo-clear (National Diagnostics, Atlanta, GA, USA) and a series of ethanol gradients. 
Endogenous peroxide was blocked in 1% hydrogen peroxide for 10 min at room temperature. 
Antigen retrieval was performed using citrate buffer, pH 6.0 (Vector laboratories, Burlingame, 
CA, USA) in a steamer apparatus for 30 min. All remaining incubation steps were performed at 
room temperature with three PBS washes between each incubation step. Endogenous avidin and 
biotin were blocked using avidin and biotin blocking reagents (Vector laboratories, Burlingame, 
CA, USA), respectively for 15 min each. Tissues were then blocked with PBS containing 2% BSA 
and 10% goat serum for 30 min and then incubated with rabbit polyclonal antibody against human 
ZIP14 (developed in our laboratory as referenced171) at 1:1000 dilution within blocking buffer. 
Tissues were then incubated in biotinylated goat anti-rabbit IgG secondary antibody (Vector 
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laboratories, Burlingame, CA, USA) at 1:250 dilution within blocking buffer. The ABC and DAB 
kits (Vector laboratories, Burlingame, CA, USA) were used for signal amplification and detection, 
respectively, according to manufacturer’s instructions. Tissues were then counterstained with 
hematoxylin (Richard-Allan Scientific, Kalamazoo, MI, USA), dehydrated, and cover slides were 
mounted using Cytoseal XYL (Richard-Allan Scientific, Kalamazoo, MI, USA) for histological 
analysis. ZIP14-stained pectoralis and diaphragm muscles from non cachectic and cachectic 
adenocarcinoma patients were scored as ZIP14-positive or -negative in a blinded pathological 
analysis.  
Muscle sample immunoblot analysis 
 15 mg of snap frozen gastrocnemius muscles from FC1242 and Pan02 experimental 
metastasis models and healthy control mice were homogenized in 250µL of lysis buffer containing 
150mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, and 0.1% SDS in 50mM Tris pH8.0 
supplemented with protease inhibitor (Roche, Mannheim, Germany) and phosphate inhibitor 
(Thermo Scientific, Waltham, MA, USA). Muscle samples were lysed using the TissueLyser II 
(Qiagen, Hilden, Germany) for two three minute cycles and supernatants were isolated after 
centrifugation at 15,000 x g for 15 min. The BCA protein assay (Pierce, Thermo Fisher Scientific, 
Carlsbad, CA, USA) was performed on supernatants to determine protein concentration. Proteins 
were run on an SDS-PAGE gel, transferred onto a nitrocellulose membrane, and blocked for an 
hour with 5% non-fat milk in 25mmol/L Tris-HCl pH7.4 supplemented with 150mmol/L NaCl 
and 0.1% Tween20 (TBS-T). Membranes were incubated with rabbit antibody against ZIP14  
(developed in our laboratory as referenced171) at 1:500 dilution, followed by goat anti-rabbit IgG 
secondary antibody and HRP-conjugated donkey anti-goat IgG tertiary antibody (Sigma, St. Louis, 
MO, USA). Membranes were also incubated with rabbit antibody against GAPDH (Cell Signaling 
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Technologies, Beverly, MA, USA) as a loading control, followed by HRP-conjugated goat anti-
rabbit IgG secondary antibody (Sigma, St. Louis, MO, USA). Membranes were developed using 
the ECL substrate (Bio-rad, Hercules, CA, USA) and visualized using the Bio-Rad ChemiDoc 
Imaging System (Rio-Rad, Heracules, CA, USA).  
Statistical Analysis 
Statistical analysis for body weight, hind-limb grip strength, muscle fiber cross-sectional areas, 
and gene expression were performed using the unpaired, two-tailed Student’s t-test using the 
GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA) software. Statistical analysis for 
ZIP14-stained human pectoralis and diaphragm muscle sections was performed using the 
Pearson’s chi-square test. All values are shown as the mean + standard error of the mean (SEM). 
p-values of < 0.05 are considered to be statistically significant.  
Human Specimens 
 Human patient pancreatic adenocarcinoma, metastatic lesions, pectoralis and diaphragm 
muscles, and unaffected samples from descendants previously diagnosed with pancreatic 
adenocarcinoma were obtained prospectively from the UNMC Tissue Bank through the Rapid 
Autopsy Program (RAP) for Pancreas. The RAP at the UNMC operates with IRB compliance and 
the approval code: UNMC IRB 091-01, which requires donor and next-of-kin consent for the 
collection and usage of patient samples in research. The UNMC RAP is not classified as Human 
Subjects Research and is exempt under 45 CFR 46.101(b)(4) from 45 CFR part 46 requirements. 
Clinical data for each donor were obtained from multiple sources, including OneChat and the 
UNMC Pathology autopsy report, which contains patient height, weight, and observable donor 
characteristics. All patient sample and clinicopathological data were deidentified prior to 
distribution and listed in Table S2.  
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 Pancreas, duodenal, spleen, liver, and diaphragm samples from non cancer patients were 
obtained through collaboration with Live On Nebraska. All patient samples and data were 
deidentified prior to distribution to UNMC and were stored under the auspices of the RAP. Limited 
deidentified patient clinical information was provided and listed in Table S2.  
 All organs and tissues were harvested within 3 hours postmortem and either flash frozen 
or fixed in formalin immediately to ensure retention of specimen quality. 5µm-thick sections were 
cut from formalin-fixed paraffin-embedded tissue onto positive charged slides for distribution. 
 
Table S2: Rapid Autopsy Program (RAP) de-identified human patient information 
A 








 Cachexia (1) 
Presence of 
cachexia: 1 and 
absence: 0 
105 89 F 26 IV IV  0 
107 83 F 269 IV IV  1 (minimal) 
108 78 M 762 IIA IV  1 
109 64 M 405 IV IV  1 
110 36 M 138 IV IV  1 
111 43 M 326 IV IV  0 
112 84 F 21 IV IV  0 
113 58 F 878 IV IV  1 
115 80 M 63 IV IV  0 
116 80 F 497 IV IV  1 
117 68 M 316 III IV  1 
118 72 M 38 IV IV  0 
119 85 F 183 IV IV  1 
120 69 M 507 III IV  1 
121 75 F 235 III IV  0 
123 74 M 90 IV IV  0 
124 53 F 421 IV IV  1 
125 49 F 27 IV IV  1 






RAP Non-cancer controls 
RAP 
NORS 





1 59 M 194 93 
3 58 F 164 99 
13 61 M 170 89 
21 53 M 180 110 
23 39 M 172 121 
24 48 F 165 66 
25 36 F 156 70 
28 57 F 155 66 
32 48 M 163 67 
 
Table S2A-B: Limited de-identified human patient information. (A) Rapid Autopsy Program 
(RAP) #105-126: cachectic and non-cachectic pancreatic adenocarcinoma patients. (B) RAP 




The Bard1-deficient murine mammary carcinoma cells were isolated and derived from a 
primary mammary tumor from a Bard1flex1/flex1, Wapcre/+ Bard1 mammary epithelium-specific 
conditional knockout genetically engineered mouse model with a B6129SF1/J background.208 The 
cells were procured from the Baer laboratory (Columbia University, New York, NY, USA). Bard1-
deficient murine mammary carcinoma cells were cultured in DMEM supplemented with 10% fetal 
bovine serum (Sigma, St. Louis, MO, USA), 1% penicillin/streptomycin (Life Technologies, 




All mouse studies, experiments, and protocols were approved by The Columbia University 
Institutional Animal Care and Use Committee (IACUC) and are compliant with ethical guidelines 
and regulations from the Institute of Comparative Medicine (ICM) at Columbia University Irving 
Medical Center (CUIMC) with the IACUC-approved protocol: AAAR6450. All mice were housed 
in CUIMC’s pathogen-free barrier facility and fed on Labdiet 5053 (standard diet). Female 8- to 
9-week old B6129SF1/J background mice were purchased from Jackson laboratory (Bar Harbor, 
ME, USA). Mice were orthotopically injected with 5 x 105 Bard1-deficient murine mammary 
carcinoma cells into the left fourth mammary fat pad. Mouse body weight and tumor volume were 
measured weekly. Tumor length and width were measured using digital calipers and the tumor 
volumes were calculated using the formula: Volume (mm3) = (Width2) x (Length/2). Mouse body 
condition, as an indicator of cachexia development, was determined by routine observation of mice 
as described previously.306  
Measurement of body weight and hind-limb grip strength 
 Measurements of body weight from healthy control mice and orthotopic Bard1-deficient 
metastatic TNBC models were performed weekly using a bench-top digital balance. All body 
weight measurements were normalized to the body weight on the day of tumor cell injection (day 
0 post injection). Measurements of hind-limb grip strength were taken weekly using a grip strength 
meter (Columbus Instruments, Columbia, OH, USA). A minimum of five measurements were 
performed per mouse weekly and the mean values were calculated. The percent grip strength was 
normalized to the mean initial grip strength values (100%) on the day of tumor cell injection.   
Tissue Collection 
 Gastrocnemius, tibialis anterior, diaphragm, and heart muscles were harvested and fixed in 
4% paraformaldehyde for 24 hours at 4⁰C or snap frozen in liquid nitrogen at stored at -80⁰C for 
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histological analysis and molecular analysis, respectively. Liver and lung tissues were harvested 
and fixed in 4% paraformaldehyde for 24 hours at 4⁰C. All paraformaldehyde-fixed tissues were 
washed in PBS for an hour and stored in 70% ethanol until further histological processing and 
analysis. 
Histological analysis of metastases and muscle fibers 
 For histological analysis, paraformaldehyde-fixed paraffin-embedded gastrocnemius and 
lung tissues were sectioned at 5µm-thickness onto positive-charged slides and stained with 
hematoxylin and eosin (H&E). H&E-stained gastrocnemius and diaphragm tissue sections were 
visualized and imaged using an Eclipse Ni-U microscope (Nikon Corporation, Tokyo, Japan). 
H&E-stained liver and lung tissue sections were visualized and imaged under a DM5500B 
microscope (Leica Microsystems, Wetzlar, Germany).  
Analysis of muscle cross-sectional area 
 Random two or three fields, totaling a combined average of 250 individual muscle fibers, 
per H&E-stained paraformaldehyde-fixed paraffin-embedded 5µm-thick cross-sections of 
gastrocnemius muscles were imaged at 20x magnification using a DM5500B microscope (Leica 
Microsystems, Wetzlar, Germany). Muscle fiber cross-sectional area was quantified using the 
drawing module in ImageJ (ImageJ software, Version 1.52h, National Institutes of Health, 
Bethesda, MD, USA) to trace individual muscle fiber boundaries. Muscle fiber cross-sectional 
areas from tumor-bearing and control mice were stratified by cross-sectional area ranges of various 
sizes and the percentage of fibers in each range were calculated. The means of cross-sectional 
areas for each range were determined from replicate muscle samples.  
RT-qPCR analysis of gene expression 
122 
 
 Snap frozen gastrocnemius, tibialis anterior, diaphragm, and heart muscles were minced 
into ~1-2mm pieces and 15mg, representative of each sample, were taken from each muscle for 
total RNA extraction using Trizol (Life Technologies, Carlsbad, CA, USA). Muscle samples were 
lysed using 5mm steel beads (Qiagen, Hilden, Germany) and the TissueLyser II (Qiagen, Hilden, 
Germany) instrument. Samples were centrifuged at 18,000 x g for 5 min and the supernatant was 
isolated and processed using the RNeasy Mini Kit (Qiagen, Hilden, Germany) with DNase 
treatment while in-column, accounting to manufacturer’s instructions. The total purified RNA in 
each sample was quantified using a Nanodrop spectrophotometer (Thermo Fisher Scientific, 
Walthom, MA, USA) and 500ng of RNA was reverse transcribed into cDNA using the cDNA 
Synthesis Kit (Applied Biosystems, Thermo Fisher Scientific, Walthom, MA, USA). RT-qPCR 
was performed using 10ng of cDNA from each sample mixed with gene-specific ptimers and 
SYBR Green PCR master mix (Applied Biosystems, Thermo Fisher Scientific, Walthom, MA, 
USA). Primers for Gapdh were used as an internal control. RT-qPCR data were analyzed on an 
Applied Biosystems 7500 Real Time PCR system (Applied Biosystems, Thermo Fisher Scientific, 
Walthom, MA, USA) and the fold change in gene expression was determined using the 2-∆DDCt 
method.307 RT-qPCR primer sequences used in this study are shown in Table S1.  
Intramuscular metal ion analysis 
 15-20mg of each gastrocnemius and diaphragm muscle were sent to the Veterinary 
Diagnostic Laboratory at Michigan State University, MI, USA, for metal ion analysis. Tissues 
were dried overnight at 75⁰C, digested overnight in 10x volume relative to muscle dry weight of 
nitric acid, and diluted in a 100-fold volume of water. Inductively-coupled plasma mass 
spectrometry (ICP-MS) (Agilent, Santa Clara, CA, USA) was performed for muscle sample metal 
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ion analysis. Intramuscular metal ion concentration was determined using a four-point linear curve 
of analyte-standard response ratio.  
Muscle sample immunoblot analysis 
 15 mg of snap frozen gastrocnemius muscles from FC1242 and Pan02 experimental 
metastasis models and healthy control mice were homogenized in 250µL of lysis buffer containing 
150mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, and 0.1% SDS in 50mM Tris pH8.0 
supplemented with protease inhibitor (Roche, Mannheim, Germany) and phosphate inhibitor 
(Thermo Scientific, Waltham, MA, USA). Muscle samples were lysed using the TissueLyser II 
(Qiagen, Hilden, Germany) for two three minute cycles and supernatants were isolated after 
centrifugation at 15,000 x g for 15 min. The BCA protein assay (Pierce, Thermo Fisher Scientific, 
Carlsbad, CA, USA) was performed on supernatants to determine protein concentration. Proteins 
were run on an SDS-PAGE gel, transferred onto nitrocellulose membrane, and blocked for an hour 
with 5% non-fat milk in 25mmol/L Tris-HCl pH7.4 supplemented with 150mmol/L NaCl and 
0.1% Tween20 (TBS-T). Membranes were incubated with rabbit antibody against Phospho-
SMAD2 and SMAD2 (Cell Signaling Technologies, Beverly, MA, USA) at 1:500 dilution, 
followed by incubation with goat anti-rabbit IgG secondary antibody and HRP-conjugated donkey 
anti-goat IgG tertiary antibody (Sigma, St. Louis, MO, USA). Membranes were also incubated 
with mouse antibody against skeletal actin (Sigma, St Louis, MO, USA) at 1:5000 dilution as an 
internal control, followed by HRP-conjugated anti-mouse IgG secondary antibody (Sigma, St. 
Louis, MO, USA). Membranes were developed using the ECL substrate (Bio-rad, Hercules, CA, 







The 4T1 murine triple-negative breast cancer cell line was derived from the 410.4 cell line, 
which was isolated from a primary mammary tumor that developed spontaneously from a MMTV+ 
mouse with a BALB/c background.232,308 The 4T1 cell line was kindly provided by the Kang 
laboratory (Princeton University, Princeton, NJ, USA). The LM3 murine triple-negative breast 
cancer cell line was derived from the M3 cell line, which was isolated from a primary mammary 
tumor that developed spontaneously from a BALB/c background mouse.234 The LM3 cell line was 
kindly provided by the Urtreger laboratory (University of Buenos Aires, Buenos Aires, Argentina). 
The 4T1 and LM3 cells were cultured in RPMI-1640 and MEM, respectively, supplemented with 
10% fetal bovine serum (Sigma, St. Louis, MO, USA) and 1% penicillin/streptomycin (Life 
Technologies, Carlsbad, CA, USA). Cell lines were grown in a 37⁰C humidified incubator with 
5% CO2. 
Mouse studies 
All mouse studies, experiments, and protocols were approved by The Columbia University 
Institutional Animal Care and Use Committee (IACUC) and are compliant with ethical guidelines 
and regulations from the Institute of Comparative Medicine (ICM) at Columbia University Irving 
Medical Center (CUIMC) with the IACUC-approved protocol: AABF2565. All mice were housed 
in CUIMC’s pathogen-free barrier facility and fed on Labdiet 5053 (standard diet). Female, 6- to 
8-week old BALB/cJ (Stock No: 000651) and B cell-deficient Igh-Jtm1Cgn (Jh) mice (Model # 1147-
F) with a BALB/c background were purchased from Jackson laboratories (Bar Harbor, ME, USA) 
and Taconic Biosciences (Rensselaer, NY, USA), respectively. 4T1 and LM3 orthotopic 
metastasis models were generated by orthotopic injection of 5x105 4T1 cells or 1x106 LM3 cells 
125 
 
into the left fourth mammary fat pad of syngeneic BALB/cJ or BALB/c background mice. 4T1 
and LM3 experimental metastasis models were generated by intravenous injection 1x105 tumor 
cells into the tail vein of syngeneic BALB/cJ mice. Primary tumor growth was measured semi-
weekly by digital calipers. 4T1 orthotopic metastasis models were euthanized at either 15 days or 
3 weeks post tumor cell-implantation for early and late metastasis timepoints, respectively. LM3 
orthotopic metastasis models were euthanized at 4 weeks post tumor cell-implantation. 4T1 and 
LM3 experimental metastasis models were euthanized at 3 weeks post tumor cell-injection.  
Human Specimens 
 The Molecular Pathology Shared Resource (MPSR) Tissue Bank at the New York 
Presbyterian Hospital/Columbia University Irving Medical Center operates in compliance HIPAA 
guidelines and institutional review board (IRB)-approved protocols, and is licensed by the New 
York State Department of Health. 5µm-thick, formalin-fixed, paraffin-embedded metastatic lung 
sections from human triple-negative breast cancer patients were obtained from the MPSR Tissue 
Bank in compliance with the IRB-approved protocol: IRB-AAAR1682. The presence of triple-
negative breast cancer and lung metastasis from each patient sample was confirmed by two 
independent pathologists at the Columbia University Irving Medical Center. Limited deidentified 
patient clinical information was provided and listed in Table S3.  
 
Table S3: Molecular Pathology Shared Resource (MPSR) Tissue Bank de-identified human 
triple-negative breast cancer patient information 
Triple-negative breast 
cancer patient number 




















Table S3: Limited de-identified human triple-negative breast cancer patient information. 
Molecular Pathology Shared Resource (MPSR) Tissue Bank # SP18-9267, SP97-13426, SP04-
5220, SP14-2468, SP17-4319, SP06-21017, SP16-17328, SP14-12956, SP19-6496, SP04-11676, 
SP09-3187, SP09-14522, SP11-25325, SP13-13241, SP13-27453: triple-negative breast cancer 
patients. Tumor-infiltrating B cell density for each patient sample was determined independently 
by a pathologist as low (0, +, and ++) or high (+++ and ++++). 
 
Tissue Collection 
 Primary tumors and metastatic lungs were harvested and fixed in 4% paraformaldehyde for 
24 hours at 4⁰C, washed in PBS for an hour, and stored in 70% ethanol until further histological 
processing and analysis. 
Histological analysis of metastases and muscle fibers 
 For histological analysis, paraformaldehyde-fixed lung tissues were embedded in paraffin 
blocks and sectioned at 5µm-thickness onto positive-charged slides and stained with hematoxylin 
and eosin (H&E). The presence of lung metastases was determined through visualization of H&E-




 Paraformaldehyde-fixed, paraffin-embedded lungs from tumor-bearing mice were 
sectioned at 5µm-thickness onto positively charged glass slides. Formalin-fixed, paraffin-
embedded metastatic lung sections from human triple-negative breast cancer patients were 
obtained from the Molecular Pathology Shared Resource (MPSR) Tissue Bank at the New York 
Presbyterian/Columbia University Irving Medical Center with the institutional review board 
(IRB)-approved protocol: IRB-AAAR1682. Slides were incubated at 60⁰C for an hour and 
rehydrated using Histo-clear (National Diagnostics, Atlanta, GA, USA) and a series of ethanol 
gradients. Endogenous peroxide was blocked in 1% hydrogen peroxide for 10 min at room 
temperature. Antigen retrieval was performed using citrate buffer, pH 6.0 (Vector laboratories, 
Burlingame, CA, USA) or Tris-alkaline buffer, pH8.0 (Vector laboratories, Burlingame, CA, 
USA) a steamer apparatus for 30 min. All remaining incubation steps were performed at room 
temperature with three PBS washes between each incubation step. Endogenous avidin and biotin 
were blocked using avidin and biotin blocking reagents (Vector laboratories, Burlingame, CA, 
USA), respectively for 15 min each. Tissues were then blocked with PBS containing 3% BSA and 
10% goat or rabbit serum for 30 min and then incubated with primary antibodies (Table S4). For 
chromogenic staining, tissues were then incubated in biotinylated secondary antibodies (Table S4) 
at 1:250 dilution within blocking buffer for 30 min. The ABC and DAB kits (Vector laboratories, 
Burlingame, CA, USA) were used for signal amplification and detection, respectively, according 
to manufacturer’s instructions. Tissues were then counterstained with hematoxylin (Richard-Allan 
Scientific, Kalamazoo, MI, USA), dehydrated, and cover slides were mounted using Cytoseal XYL 
(Richard-Allan Scientific, Kalamazoo, MI, USA) for histological analysis. For immunofluorescent 
staining, slides were incubated in fluorophore-conjugated secondary antibodies (Table S4) for 30 
min in the dark. Tissue autofluorescence was quenched using the Vector TrueVIEW 
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Autofluorescence Quenching Kit (Vector Laboratories, Buringame, CA, USA) according to 
manufacturer’s instructions. Slides were mounted using Fluoro-Gel II with DAPI (Electron 
Microscopy Sciences, Hatfield, PA, USA). 
 




Manufacturer Concentration  
Rat anti-mouse B220 Biotin 
Conjugated 
BD553085 BD Biosciences, CA 1:200 
Rabbit anti-mouse S100A9 73425S Cell Signaling, MA 1:2000 
Rabbit anti-mouse PAX-5 12709S Cell Signaling, MA 1:100 
Mouse anti-human CD20 MS340-S ThermoMab, CA 1:100 
Rabbit anti-mouse / human 
Keratin-14 
905301 Biolegend, CA 1:5,000 
Rabbit anti-mouse / human 
phospho-mTOR (Ser2448) 
2976S Cell Signaling, MA 1:400 
Goat Anti-Rabbit IgG (H+L) 
Biotinylated 
BA-1000 Vector Labs, CA 1:250 
Rabbit Anti-Rat IgG (H+L) 
Biotinylated 
BA-4001 Vector Labs, CA 1:250 
Goat anti-Rabbit IgG (H+L) 
Cross-Adsorbed Secondary 




Goat anti-Rat IgG (H+L) Cross-
Adsorbed Secondary Antibody, 





Table S4: Information for primary and secondary antibodies used for immunohistochemical and 
immunofluorescent staining 
 
Analysis of immunohistochemistry-stained tissues 
 Chromogen-stained metastatic lung sections were visualized and imaged using an Eclipse 
Ni-U microscope (Nikon Corporation, Tokyo, Japan). The number of positive-stained cells and 
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the number and surface area of each lung metastasis were quantified using the counting and 
drawing modules of the ImageJ software (Version 1.53c, National Institute of Health, Bethesda, 
MD, USA), respectively. The spatial localization of metastasis-infiltrating, positive-stained B cells 
in mouse tissue were classified as invasive margin or interior based on the following criteria: 
invasive margin: within a 10µm, or 20µm, or 30µm margin from the edge of the metastasis toward 
the interior for areas with a width of under 50µm, 51-100µm, or over 100µm; interior: outside of 
the defined invasive margin toward the interior of the metastasis. The spatial localization of 
metastasis-infiltrating positive-stained B cells in human triple-negative breast cancer patient lung 
sections were classified as invasive margin or interior localization as described309 using the region-
of-interest drawing and positive cell detection modules of the Quantitative Pathology & Bioimage 
Analysis software (QuPath Version 2.0, University of Edinburgh, Edinburgh, United Kingdom). 
Only lung sections showing complete lung metastases, defined as without artefacts in the interior 
and the invasive margin and without with sections of the lung metastases cut off, from human 
triple-negative breast cancer patients were analyzed. Metastasis-infiltrating B cells located further 
within the metastasis from the defined invasive margin region are classified as interior localization. 
B cell counts were calculated as 1) the proportion of the number of invasive margin or interior 
localization B cells to total B cells (with all counts normalized to the surface area of each lung 
metastasis, and 2) the ratio of total metastasis-infiltrating B cells to the number of tumor cells in 
each lung metastasis. Cytoekratin-14- and p-mTOR-stained lung metastases from mouse models 
were analyzed as the proportion of positive-stained tumor cells to total tumor cells in each 
metastasis using the region-of-interest drawing and positive cell detection module of the 
Quantitative Pathology & Bioimage Analysis software (QuPath Version 2.0, University of 
Edinburgh, Edinburgh, United Kingdom). Tumor cells were identified by restricting the cell 
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detection parameters to large-nucleated cells and positive staining was detected by setting 
thresholds for signal intensity (low: 1+, high: 2+ and 3+). The number of lung metastases for 4T1 
orthotopic metastasis models harvested at 15 days post tumor cell-injection was calculated by the 
quantitation of the number metastases and the number of tumor cells in each metastasis from 5 
cytokeratin-14-stained lung sections taken at >20μm intervals for each mouse. Representative 
images were taken at 20x magnification using an Eclipse Ni-U microscope (Nikon Corporation, 
Tokyo, Japan). CD20-stained metastatic lungs from human triple-negative breast cancer patients 
were scored as having low (0, +, and ++) or high (+++ and ++++) numbers of tumor-infiltrating B 
cells in a blinded pathological review by an independent pathologist. p-mTOR-stained lung 
metastases from human triple-negative breast cancer patients were scored as low (0 and +) or high 
(++ and +++) expression in a blinded pathological review. Immunofluorescent-stained metastatic 
lungs were visualized and imaged using a Leica CTR5500 microscope with a Leica DFC3000 G 
camera module (Leica Microsystems, Wetzlar, Germany). Positive cells were determined using 
the counting module of the ImageJ software (Version 1.53c, National Institute of Health, Bethesda, 
MD, USA). All data is representative of a minimum of 3 independent experiments. 
Isolation of lung metastases and development of lung-metastasis-derived organoids 
Lungs with macroscopic metastatic lesions from 4T1 and LM3 orthotopic metastasis 
models were harvested, briefly washed in ice-cold HBSS, and minced with a scalpel into 1-2mm3 
pieces.310,311 Minced tissues were transferred into a 15mL tube and digested in 0.1% Collagenase 
I (Worthington Biochemical, Lakewood, NJ, USA), 0.1% Trypsin (Sigma, St. Louis, MO, USA), 
0.1% Insulin (Sigma, St. Louis, MO, USA), and 1% Penicillin/Streptomycin (Life Technologies, 
Carlsbad, CA, USA) in DMEM High Glucose medium for 30-45 min at 37oC on a shaker until 
broken into barely-visible pieces and not over-digested.310 Digested tissues were pelleted by 
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centrifugation at 1500 rpm for 10 min and the supernatant was removed. The organoid pellet was 
resuspended and washed in DMEM, then centrifuged at 1,500 rpm for 10 min and the supernatant 
was aspirated. The organoid pellet was resuspended in 4mL DMEM containing 40µL of 2000 
U/mL DNase (Sigma, St. Louis, MO, USA) and mixed for 5 min by gentle inversion of the tube 
by hand. The organoids were then subjected to 5 spin-wash cycles with DMEM. After the final 
cycle, the organoid pellet was re-suspended in 1-2mL DMEM. 
Organoid plating and passaging 
  Organoid density was calculated and re-adjusted to the desired concentration of 1000 
organoids per mL of solution.310 Briefly, a 40µL sample of resuspended organoids was pipetted 
onto a 30mm petri dish to determine the concentration of organoids in the solution.312 The volume 
of organoid solution needed to acquired the desired number of organoids was calculated and 
aliquoted into a 1.5mL microcentrifuge tube and pelleted by centrifugation at 300 x g. The 
supernatant was aspirated and resuspended in the desired amount of Matrigel (pre-thawed 
overnight in 4oC and kept on ice until use) according to the following formula calculated for plating 
onto a 12-well plate: aliquot volume = number of wells × 50 organoids ∕ concentration of organoid 
solution. 40µL of the Matrigel-suspended organoids were then plated onto each well of a 12-well 
plate. The plated organoids were incubated at 37oC for 30 min for the Matrigel to fully solidify 
and 1.5mL of medium respective of the organoid cell line (DMEM or RPMI-1640 supplemented 
with 10% Fetal Bovine Serum (Sigma, St. Louis, MO, USA) and 1% penicillin/streptomycin (Life 
Technologies, Carlsbad, CA, USA)) was added into each well. Organoid cultures were passaged 
weekly by aspirating the medium and dissociation of the Matrigel matrix by adding 1mL of ice-
cold PBS. Organoids were mechanically dissociated into smaller pieces by pipetting up and down 
using a P1000 pipette. Once the Matrigel and organoids was dissolved and broken down, 
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respectively, the organoid suspension was transferred into a 1.5mL microcentrifuge tube and spun 
down at 300 x g for 5 min at 4oC. The supernatant was removed from the tube using a P200 pipette. 
Organoids were resuspended in fresh Matrigel (volume of Matrigel added = number of wells x 40 
µL) plating onto a 12-well plate: aliquot volume = number of wells × 50 organoids ∕ concentration 
of organoid solution. 40µL of the Matrigel-suspended organoids were then plated onto each well 
of a 12-well plate. The plated organoids were incubated at 37oC for 30 min for the Matrigel to fully 
solidify and 1.5mL of medium respective of the organoid cell line (DMEM or RPMI-1640 
supplemented with 10% Fetal Bovine Serum and 1% penicillin/streptomycin (Life Technologies, 
Carlsbad, CA, USA)) was added into each well. 
Isolation of B cells by flow cytometry 
 4T1 and LM3 orthotopic metastasis models were euthanized and their lungs and blood 
were extracted according to Columbia University’s Institutional Animal Care and Use 
Committee’s approved protocol: AABF2565. Lungs were washed in ice-cold sterile HBSS and 
transferred into a sterile hood. Lungs were minced with a scalpel into 1-2mm3 pieces followed by 
transfer into a 15mL tube and digested in digestion buffer, HBSS supplemented with 2mg/mL 
collagenase I (Worthington Biochemical, Lakewood, NJ, USA), and 2 U/mL dispase II (Roche, 
Indianapolis, IN, USA), and incubated at 37°C for 30 min on a shaker. Digested lung tissues were 
pelleted by centrifugation at 500 x g for 5 min at 4°C. The supernatant was aspirated and the pellet 
was resuspended in sterile HBSS at 4°C. Blood was collected by cardiac puncture and immediately 
transferred into BD Vacutainer plastic blood collection tubes with K2EDTA (BD Biosciences, San 
Jose, CA, USA). Red blood cells were lysed with 2-3mL/lung or 1mL/100μL blood of ACK Lysis 
Buffer (Lonza, Morristown, NJ, USA) for 3 minutes and quenched by adding 8mL of sterile HBSS 
at 4°C. Cells were passed through a 70μm filter, centrifuged at 500 x g for 5 min, resuspended in 
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sterile HBSS, centrifuged again, and resuspended in FACS buffer (HBSS + 0.5% BSA) at 4°C. 
Cell concentration was calculated using a TC20 Automated Cell Counter (Bio-Rad, Hercules, CA, 
USA). The desired cell concentration was adjusted and transferred into 1.5mL microcentrifuge 
tubes and stained with fluorophore conjugated antibodies at 1:100 (Table S5) for 45 min at 4°C. B 
cells were sorted using the BD Influx cell sorter (BD Biosciences, San Jose, CA, USA). Sorted B 
cells were pelleted at 500 x g, the supernatant was aspirated, and resuspended in B cell medium: 
RPMI-1640 supplemented with 10% Fetal Bovine Serum (Sigma, St. Louis, MO, USA), 2mM L-
glutamine (Sigma, St. Louis, MO, USA), and 0.5µM 2-mercaptoethanol (Sigma, St. Louis, MO, 
USA). B cells were plated onto sterile 30mm petri dishes and incubated overnight in a 37⁰C 
humidified incubator with 5% CO2.
 
 






Rat IgG2b κ anti-
mouse CD45 
PerCP BD557235 BD Biosciences, 
CA 
Rat IgG2a κ anti-
mouse B220 
FITC BD553087 BD Biosciences, 
CA 
Rat IgG2a κ Isotype 
Control 
PE 12-4321-71 eBiosciences, CA 
Rat IgG2b κ isotype 
Control 
PE BD553989 BD Biosciences, 
CA 
 
Table S4: Information for antibodies used for flow cytometry experiments  
 
3-Dimensional co-culture of lung metastases-derived organoids and sorted B cells 
  Organoids were passaged and resuspended in ice-cold Matrigel as previously described 
(volume of Matrigel added = number of wells x 40 µL). Sorted B cells were cultured overnight 
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and the concentration was determined using a TC20 Automated Cell Counter (Bio-Rad, Hercules, 
CA, USA). The volume needed to acquire the desired number of B cells was determined using the 
formula: 1x104 B cells / well (12-well plate), and aliquoted into a 1.5mL microcentrifuge tube. 
The B cells were spun at 1,500 rpm and the supernatant was aspirated. The organoid-Matrigel 
mixture was then transferred into the B cell tube and both organoids and B cells were 
homogeneously resuspended through gentle pipetting on ice. 40µL of organoid and B cell 
suspension in Matrigel was added on each well of a 12-well plate. The plated organoids were 
incubated at 37oC for 30 min for the Matrigel to fully solidify and 1.5mL of medium respective of 
the organoid cell line (DMEM or RPMI-1640 supplemented with 10% Fetal Bovine Serum 
(Sigma, St. Louis, MO, USA) and 1% penicillin/streptomycin (Life Technologies, Carlsbad, CA, 
USA) was added into each well. Organoids were imaged at 10x magnification at 0, 48, and 96 
hours post plating using a Leica DM IL LED microscope (Leica Microsystems, Wetzlar, 
Germany). 312. Data is representative of a minimum of three independent experiments. Data is 
representative of a minimum of three independent experiments. 
Quantitation of 3-dimensional organoid invasion 
 Monoculture control and co-cultured lung metastasis-derived organoids were imaged at 
10x magnification at 0, 48, and 96 hours post plating using a Leica DM IL LED microscope (Leica 
Microsystems, Wetzlar, Germany). Organoid invasion was calculated by outlining and calculating 
the form factor of each organoid using the drawing module and shape descriptors plugin of ImageJ 
(ImageJ software, Version 1.52h, National Institutes of Health, Bethesda, MD, USA). The form 
factor formula is as follows: Form Factor = (Perimeter)2 / (4πArea). A perfect circle has a form 
factor of 1, which is the maximum area for a given perimeter, and organoids with increasing 
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irregular shapes and invasive protrusions will have increased form factors. Invasion over time is 
quantified as a measure of fold change of form factor over time.  
Transwell migration assay 
For each well used for the transwell migration assay: 5x104 tumor cells were serum-starved 
overnight in serum-low medium, RPMI-1640 supplemented with 0.2% Fetal Bovine Serum 
(Sigma, St. Louis, MO, USA) and 1% penicillin/streptomycin (Life Technologies, Carlsbad, CA, 
USA), with or without 1x104 B220+ B cells isolated from the lungs of orthotopic metastasis models 
and suspended in a Millicell PET 0.4μm-pore size membrane hanging cell culture insert (Millipore, 
Burlington, MA, USA) containing B cell medium, RPMI-1640 supplemented with 10% Fetal 
Bovine Serum (Sigma, St. Louis, MO, USA), 2mM L-glutamine (Sigma, St. Louis, MO, USA), 
and 0.5µM 2-mercaptoethanol (Sigma, St. Louis, MO, USA). After overnight co-culture, B cells 
were removed and tumor cells were labeled with 5μM Celltracker Green CMFDA dye (Life 
Technologies, Carlsbad, CA, USA) for 30 min. Tumors cells were trypsinized and resuspended in 
a 24 well-sized Corning Fluoroblok 3.0μm-pore size membrane cell culture insert (Corning 
Incorporated, Corning, NY, USA) containing serum-low medium, RPMI-1640 supplemented with 
0.2% Fetal Bovine Serum (Sigma, St. Louis, MO, USA) and 1% penicillin/streptomycin (Life 
Technologies, Carlsbad, CA, USA). The inserts were placed into wells of a 24 well plate 
containing growth medium, RPMI-1640 supplemented with 10% Fetal Bovine Serum (Sigma, St. 
Louis, MO, USA), 1% penicillin/streptomycin (Life Technologies, Carlsbad, CA, USA) and 
incubated for 5 hours at 37°C in a humidified incubator with 5% CO2 for tumor cell migration. 
After 5 hours, all media in the transwell and 24 well plate were aspirated. The transwells were 
washed in PBS and fixed in 4% paraformaldehyde for 15 min and washed twice with PBS. The 
cells on the apical side of each transwell membrane were gently scraped off and the membranes 
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were excised using a scapel and forceps and mounted basal side up onto slides using Fluoro-Gel 
II with DAPI (Electron Microscopy Sciences, Hatfield, PA, USA). The total number of tumor cells 
that had fully migrated to the basal side of each transwell membrane were visualized and imaged 
at 10x magnification using a Leica CTR5500 microscope with a Leica DFC3000 G camera module 
(Leica Microsystems, Wetzlar, Germany) using the Leica Application Suite X software (Version 
1.5.1.13187, Leica Microsystems, Wetzlar, Germany). The total number of tumor cells that had 
fully migrated to the basal side of each transwell membrane were counted using the counting 
module of ImageJ (ImageJ software, Version 1.52h, National Institutes of Health, Bethesda, MD, 
USA). Tumor cells located on the outer edges of the membrane were excluded from all counts to 
exclude artifactual edge-effects. Data is representative of a minimum of three independent 
experiments.  
p-mTOR immunoblot analysis 
5x104 tumor cells were cultured in growth medium, RPMI-1640 supplemented with 10% 
Fetal Bovine Serum (Sigma, St. Louis, MO, USA), 1% penicillin/streptomycin (Life 
Technologies, Carlsbad, CA, USA), with or without 1x104 B220+ B cells isolated from the lungs 
of orthotopic metastasis models and suspended in a Millicell PET 0.4μm-pore size membrane 
hanging cell culture insert (Millipore, Burlington, MA, USA) containing B cell medium, RPMI-
1640 supplemented with 10% Fetal Bovine Serum (Sigma, St. Louis, MO, USA), 2mM L-
glutamine (Sigma, St. Louis, MO, USA), and 0.5µM 2-mercaptoethanol (Sigma, St. Louis, MO, 
USA). After overnight co-culture, B cells were removed and tumor cells were lysed in lysis buffer 
containing 150mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, and 0.1% SDS in 50mM Tris 
pH8.0 supplemented with protease inhibitor (Roche, Mannheim, Germany) and phosphate 
inhibitor (Thermo Scientific, Waltham, MA, USA). The BCA protein assay (Pierce, Thermo Fisher 
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Scientific, Carlsbad, CA, USA) was performed on supernatants to determine protein concentration. 
Proteins were run on an SDS-PAGE gel, transferred onto nitrocellulose membrane, and blocked 
for an hour with 5% non-fat milk in 25mmol/L Tris-HCl pH7.4 supplemented with 150mmol/L 
NaCl and 0.1% Tween20 (TBS-T). Membranes were incubated with rabbit antibody against mouse 
phosphor-mTOR at Ser2448 (Cell Signaling Technologies, Beverly, MA, USA) at 1:500 dilution, 
followed by incubation with goat anti-rabbit IgG secondary antibody and HRP-conjugated donkey 
anti-goat IgG tertiary antibody (Sigma, St. Louis, MO, USA). Membranes were also incubated 
with mouse antibody against skeletal actin (Sigma, St Louis, MO, USA) at 1:5000 dilution as an 
internal control, followed by HRP-conjugated anti-mouse secondary antibody (Sigma, St. Louis, 
MO, USA). Membranes were developed using the ECL substrate (Bio-rad, Hercules, CA, USA) 
and visualized using the Bio-Rad ChemiDoc Imaging System (Rio-Rad, Heracules, CA, USA).  
Statistical analysis 
Statistical significance for comparison of organoid invasion and fold change in form factor was 
calculated using the non-parametric unpaired Mann-Whitney U test, as these data do not follow a 
normal distribution. All other statistical significance between groups were determined using the 
unpaired two-tailed Student’s t-test. All statistical analyses were calculated using the Prism 
Software (Version 9.1.0, GraphPad Software, San Diego, CA). Values are shown as either bar 
graphs (mean + standard error of the mean) or as a violin plot (median, with the violin depicting 
the maximum and minimum of the dataset, respectively). A p-value of <0.05 was considered 
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